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Abstract	  
	  
Deregulation	   of	   normal	   CDK	   activity	   can	   lead	   to	   cell	   transformation	   through	  
enhanced	   growth	   signalling.	   CDKs	   are	   therefore	   attractive	   drug	   targets	   but	   the	  
propensity	   for	   CDKs	   to	   functionally	   compensate	   as	   a	   failsafe	   mechanism	   makes	  
selecting	   the	   most	   efficient	   CDK	   to	   inhibit	   a	   difficult	   task.	   Many	   drugs	   aimed	   at	  
inhibiting	  CDK	  action	  are	  non-­‐selective,	  eliciting	  pleiotropic	  effects	  and	   therefore	  a	  
more	   selective	   approach	  may	  be	   advantageous.	  Given	   its	   dual	   importance	   in	   both	  
the	   cell	   cycle	   and	   transcription,	   CDK7	   has	   recently	   become	   the	   focus	   for	   drug	  
development.	   Previous	   work	   from	   the	   group	   has	   identified	   a	   CDK7-­‐specific	   small	  
molecule	   inhibitor,	   named	  BS181,	  which	   inhibits	   cancer	   cell	   growth	   in	   vitro	   and	   in	  
vivo	  and	  leads	  to	  cell	  cycle	  arrest	  and	  apoptosis.	  A	  second	  compound,	  named	  BS194,	  
is	  a	  selective	  inhibitor	  of	  CDK1,	  CDK2,	  CDK5	  and	  CDK9.	  	  
siRNA-­‐mediated	  knockdown	  of	  each	  component	  of	  the	  CAK	  complex	  was	  undertaken	  
in	  HCT116	  colorectal	  cancer	  cells	  and	  verified	  by	  western	  blotting	  and	  qRT-­‐PCR.	  Cell	  
cycle	  FACS	  analysis	  showed	  an	   increase	   in	  apoptosis	  when	  CDK7,	  cyclin	  H	  or	  MAT1	  
were	  knocked-­‐down.	  	  
Western	  blotting	  revealed	  a	  curious	  relationship	  between	  each	  member	  of	  the	  CAK	  
complex;	   knockdown	   of	   any	   one	   component	   of	   the	   CAK	   complex	   resulted	   in	   a	  
reduction	  in	  levels	  of	  the	  other	  components.	  As	  these	  effects	  were	  not	  observed	  at	  
the	   mRNA	   level,	   these	   findings	   are	   indicative	   of	   ubiquitin/proteasome-­‐mediated	  
degradation.	  	  
Finally,	   a	   gene	   expression	   microarray	   was	   performed	   on	   RNA	   preparations	   made	  
from	  HCT116	   cells	   treated	  with	   BS181	  or	   BS194.	   It	   is	   clear	   that	   the	   two	   inhibitors	  
elicit	   their	   effects	   in	   subtly	   different	  ways	   leading	   to	   distinct	   genes	   and	   pathways	  
being	  perturbed.	  Although	  p53	  signalling	  is	  a	  common	  theme,	  it	  appears	  that	  at	  the	  
concentrations	  used,	  the	  two	  agents	  modulate	  this	  axis	  with	  different	  kinetics.	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I	   conclude	   that,	   contrary	   to	   the	   potential	   advantages	   of	   selectively	   inhibiting	   CAK,	  
pan-­‐inhibition	   with	   an	   agent	   capable	   of	   targeting	   several	   CDKs	   may	   prove	   more	  
efficacious	  in	  cancer	  therapy.	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1 Introduction	  
	  
1.1 CDK7	  and	  the	  CDK	  Activating	  Kinase	  (CAK)	  complex	  
	  The	  gene	  encoding	  cyclin	  dependent	  kinase	  7	  (cdk7)	  is	  located	  on	  the	  long	  arm	  of	  chromosome	  5.	  It	  codes	  for	  a	  protein	  of	  40kDa	  that	  is	  ubiquitously	  expressed	  at	  all	   stages	   of	   the	   cell	   cycle	   and	   remains	   nuclear	   in	   its	   location	   (Bartkova,	  Zemanova	   et	   al.	   1996).	   Like	   other	   CDKs,	   the	   protein	   product	   of	   cdk7	   (CDK7)	  requires	   phosphorylation	   (at	   T170)	   and	   subsequent	   binding	   of	   its	   regulatory	  cyclin	   partner,	   cyclin	   H	   in	   order	   to	   become	   fully	   activated.	   Unlike	   other	   CDKs	  however,	   CDK7	   has	   a	   second	   phosphorylation	   site	   in	   its	   T-­‐loop	   region,	   S164,	  which	   is	   necessary	   for	   enhanced	   activity.	   The	   T-­‐loop,	   or	   activation	   loop,	   is	   a	  peptide	  sequence,	  present	  in	  all	  CDKs	  (fig	  1),	  which	  occludes	  the	  catalytic	  site.	  In	  CDK7,	   following	   phosphorylation	   events	   at	   the	   key	   Serine	   and	   Threonine	  residues,	   the	   T-­‐loop	   moves	   away,	   allowing	   full	   engagement	   with	   its	   binding	  partner,	   cyclin	   H	   (Russo	   A,	   et	   al.	   Nat	   Struc	   Biol	   1996).	   	   This	   double	  phosphorylation	  increases	  the	  affinity	  for	  cyclin	  H	  (Martinez,	  Afshar	  et	  al.	  1997).	  Interaction	  with	  a	  third	  protein,	  MAT1	  completes	  the	  fully	  active	  CDK	  activating	  kinase	   (CAK)	   complex.	   MAT1	   can	   substitute	   for	   T170	   phosphorylation,	   being	  sufficient	   for	   CDK7-­‐cyclin	   H	   activation	   and	   is	   necessary	   for	   stability	   of	   the	  complex	   (Devault,	  Martinez	   et	   al.	   1995).	   Studies	   show	   that	  MAT1	   also	   has	   the	  ability	  to	  switch	  substrate	  preference	  of	  the	  CAK	  complex	  (Yankulov	  and	  Bentley	  1997)	   and	   even	   determine	   G1	   exit	   during	   the	   cell	   cycle	   by	   directing	  phosphorylation	  of	   the	   retinoblastoma	   (Rb)	  protein	   (Wu,	  Chen	  et	   al.	  2001).	  By	  contrast,	  despite	  being	  capable	  of	  interacting	  with	  several	  proteins	  itself,	  cyclin	  H	  is	   not	   thought	   to	   influence	   CAK	   substrate	   specificity	   or	   its	   interaction	   with	  proteins	  intrinsic	  to	  the	  cell	  cycle.	  Interestingly,	  several	  studies	  have	  revealed	  a	  deviation	  of	  cyclin	  H	  expression	  to	  be	  associated	  with	  cancer	  and	  suggest	  it	  as	  a	  possible	  prognostic	  marker	  (Bavi,	  Abubaker	  et	  al.	  2008;	  Hongsachart,	  Huang-­‐Liu	  et	  al.	  2009;	  Romagnoli,	  Fasoli	  et	  al.	  2009)	  although	  it	  was	  not	  stipulated	  in	  these	  studies	   whether	   CDK7	   and	   MAT1	   expression	   followed	   the	   same	   pattern	   or	  whether	  this	  was	  for	  free	  cyclin	  H.	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Fig.	  1.	  T-­loop	  sequences	  of	  cell-­cycle	  CDKs.	  The	  DGF	  and	  APE	  motifs,	  in	  bold,	  are	  conserved	  throughout	  the	  family.	  Phosphorylation	  sites	  are	  shown	  in	  red,	  the	  amino	  acid	  position	  of	  which,	  are	  indicated	  by	  an	  asterisk.	  Note	  the	  two	  phosphorylation	  sites	  in	  CDK7.
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1.2 CDK7	  function	  and	  its	  contribution	  to	  cell	  fate	  
	  To	   consider	   the	   CAK	   complex	   as	   merely	   dichotomous	   is	   perhaps	   an	   unfair	  appraisal	  of	  its	  diverse	  abilities.	  In	  addition	  to	  its	  roles	  in	  cell	  cycle	  progression	  and	  promoter	  clearance	  of	  RNA	  polymerase	  II	  (RNAPII),	  it	  has	  also	  been	  shown	  to	  phosphorylate	  oestrogen	  receptor	  α	  (Chen,	  Riedl	  et	  al.	  2000;	  Chen,	  Washbrook	  et	  al.	  2002),	  as	  well	  as	  retinoic	  acid	  receptor	   (Rochette-­‐Egly,	  Adam	  et	  al.	  1997;	  Bastien,	   Adam-­‐Stitah	   et	   al.	   2000;	   Keriel,	   Stary	   et	   al.	   2002;	   Bour,	   Gaillard	   et	   al.	  2005)	  and	  p53	  (Ko,	  Shieh	  et	  al.	  1997;	  Lu,	  Fisher	  et	  al.	  1997),	  thus	  augmenting	  its	  functional	  repertoire	  to	  hormonal	  signalling	  and	  even	  apoptosis.	  The	  essence	  of	  this	  section	  will	  be	  to	   introduce	  the	  CAK	  complex	  as	  (1)	  a	  primary	  regulator	  of	  the	   cell	   cycle,	   (2)	   a	   kinase	   necessary	   for	   RNAPII	   promoter	   clearance	   and	  elongation	   and	   (3)	   an	   emerging	   contributor	   to	   signalling	   pathways	   through	  lesser-­‐documented	   interactions,	   which	   may,	   in	   some	   cases	   seem	   to	   govern	  paradoxical	  cell	  fates.	  Figure	  2	  provides	  a	  schematic	  overview	  of	  these	  functions.	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Fig.	  2.	  The	  multiple	  abilities	  of	  CAK	  The	  schematic	  depicts	  the	  role	  of	  free	  CAK	  (CDK7,	  cyclin	  H	  and	  MAT1)	  as	  the	  primary	  activator	  of	  interphase	  CDKs	  for	  cell	  cycle	  progression	  and	  together	  with	  11	  other	  proteins	  of	  the	  general	  transcription	  factor	  (TFIIH),	  as	  a	  regulator	  of	  RNA	  polymerase	  II	  activity	  and	  several	  tertiary	  pathways	  including	  hormone	  signalling.	  In	  this	  diagram,	  P	  represents	  the	  phosphorylated	  sites.
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1.2.1	  Cell	  cycle	  progression	  
	  To	   appreciate	   how	   CAK	   facilitates	   cell	   cycle	   progression,	   it	   serves	   to	  contextualise	  its	  position	  relative	  to	  the	  inner	  workings	  of	  the	  cycle	  by	  providing	  an	  overview.	  What	  follows	  is	  not	  an	  exhaustive	  review	  of	  each	  component,	  rather	  a	  summary	  of	  the	  neighbouring	  phases,	  acknowledging	  some	  of	  the	  key	  players.	  	  The	   cell	   cycle	  orchestrates	   the	  process	  by	  which	  a	   cell	  moves	   from	  quiescence	  (G0)	   to	   proliferation	   and	   possesses	   several	   cell	   cycle	   checkpoints	   that	   help	  ensure	  genetic	  fidelity	  by	  providing	  protection	  against	  DNA	  damage.	  The	  entire	  cycle	  is	  composed	  of	  DNA	  synthesis	  (S	  phase)	  and	  mitosis	  (M	  phase).	  These	  are	  separated	  by	  two	  gaps	  (G1	  and	  G2).	  Traditionally,	  G1,	  S	  and	  G2	  are	  considered	  as	  composing	   interphase,	   whilst	   mitosis	   being	   treated	   as	   quite	   a	   separate	   set	   of	  events.	  According	  to	  the	  classical	  model	  of	  the	  mammalian	  cell	  cycle,	  each	  phase	  is	  governed	  by	  specific	  CDK-­‐cyclin	  complexes	   (figure	  3),	  which	  are	   responsible	  for	  driving	  the	  events	  associated	  during	  each	  phase.	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Fig.	  3.	  The	  cell	  cycle	  A	   schematic	   representation	   of	   the	   cell	   cycle,	   illustrating	   the	   CDKs	   that	   govern	   each	  phase.	   CDKs	   are	   fully	   active	   when	   bound	   to	   their	   respective	   cyclin	   partner	   and	  phosphorylated	   in	   their	   T-­‐loop	   region.	   Rb-­‐E2F	   occupies	   the	   restriction	   point,	   beyond	  which,	   cells	   are	   committed	   to	   a	   full	   round	   of	   growth.	   The	   significance	   of	   Rb	  phosphorylation	  means	  that	  it	  can	  subsequently	  dissociate	  from	  the	  transcription	  factor	  E2F,	   allowing	   the	   transcription	   of	   factors	   necessary	   for	   continuation	   of	   the	   cell	   cycle	  beyond	   S	   phase.	   In	   this	   diagram	   P	   represents	   phosphorylated	   proteins.	  	  M,	  Mitosis;	  G1,	  Gap	  1;	  S,	  DNA	  synthesis;	  G2,	  Gap	  2.	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G1	  to	  S	  phase	  In	  the	  classical	  view,	  the	  transition	  from	  quiescence	  (G0)	  through	  G1	  to	  S	  phase	  occurs	  only	  in	  the	  presence	  of	  sufficient	  extrinsic	  growth	  factors	  and	  mitogens	  so	  that	  the	  cell	  may	  traverse	  the	  restriction	  point	  (Pardee	  1974)	  and	  embark	  on	  a	  new	  round	  of	  growth,	  independent	  of	  additional	  growth	  stimuli.	  Once	  the	  cell	  has	  passed	  the	  restriction	  point	  (see	  below),	  it	  has	  committed	  to	  completing	  a	  cycle	  irrespective	   of	   whether	   growth	   factors	   become	   limiting.	   This	   mechanism	   is	  important	   to	   ensure	   that	   cells	   can	   always	   complete	   a	   full	   cycle.	   Although	   the	  sequential	   phases	   of	   the	   cycle	   that	   follow	   the	   restriction	   point	   do	   not	   require	  growth	  factor	  stimulus,	  such	  signals	  (primarily	  of	   the	  MEK/ERK	  and	  PI3K/AKT	  pathways)	   are	   necessary	   for	   the	   induction	   and	   accumulation	   of	   regulatory	   D-­‐type	   cyclins	   (D1,	   D2	   and	   D3)	   by	   transcriptional	   activation	   and	   stabilization	  during	   early	   G1	   (Blagosklonny	   and	   Pardee	   2002)	   (Malumbres	   and	   Barbacid	  2009).	   Cyclin	   D1,	   the	   most	   ubiquitous	   and	   well	   studied	   of	   the	   three	   family	  members	  can	  partner	  with	  CDK4	  and	  6	  to	  drive	  the	  cell	  through	  G1.	  CDK4	  and	  6	  are	  constitutively	  expressed	  whilst	  D-­‐type	  cyclins	  are	  not	  expressed	  in	  quiescent	  cells	  so	  are	  therefore	  presumed	  to	  be	  the	  limiting	  factors	  for	  CDK4/6	  activation	  (Obaya	  and	  Sedivy	  2002).	  	  Activation	   of	   these	   complexes	   leads	   to	   partial	   phosphorylation	   (and	   hence	  inactivation)	  of	  the	  pocket	  proteins	  –	  RB	  (p105),	  RBL1	  (p107)	  and	  RBL2	  (p130),	  which	   allow	   the	   subsequent	   expression	   of	   cyclins	   E1	   and	   E2,	  which	   in	   return,	  bind	  to	  and	  activate	  CDK2.	  CDK2	  activity	  characterises	  the	  later	  stages	  of	  G1	  and	  S-­‐phase.	   In	   the	   case	   of	   RB,	   when	   it	   is	   partially	   phosphorylated	   in	   early	   G1,	   it	  remains	  bound	  to	  E2F	  but	  it	  still	  has	  the	  ability	  to	  transcribe	  certain	  genes	  such	  as	   cyclin	   E	   (Dickson	   and	   Schwartz	   2009).	   It	   also	   demonstrates	   a	   mutual	  dependency	   on	   cyclin	   E	   for	   further	   transcription	   of	   genes	   that	   facilitate	   DNA	  synthesis	  during	  the	  S	  phase	  (Duronio,	  Brook	  et	  al.	  1996).	  In	  late	  G1	  phase,	  cyclin	  E/A-­‐CDK2	  complexes	  contribute	  to	  the	  hyperphosphorylation	  of	  RB,	  which	  leads	  to	   full	   activation	   of	   E2F.	   A	   study	   in	   mice	   embryos	   found	   that	   this	   apparent	  positive	   feed-­‐forward	   loop	   between	   cyclin	   E1/E2	   and	   E2F	   has	   been	   shown	   to	  exclusively	   rely	   upon	  RB	   and	   not	  RB1	   or	  RB2	   (Geng,	   Yu	   et	   al.	   2001).	   Thus	  RB	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implements	   a	   more	   central	   role	   in	   the	   cell	   cycle	   than	   its’	   two	   paralogs.	  Incidentally,	   cyclin	  E	  also	  phosphorylates	  several	  S-­‐phase	  specific	  substrates	  at	  this	  stage	  such	  as	  NPAT,	  which	  has	  been	  found	  to	  accelerate	  S	  phase	  progression	  when	  over	  expressed	  (Zhao	  et	  al.	  1998).	  	  
RB	  and	  the	  importance	  of	  a	  step-­wise	  inactivation	  RB	   represents	   a	  prototypical	   tumour	   suppressor	   gene	  and	  as	   such	  became	   the	  first	   cloned	   gene	   of	   its	   type	   (Du	   and	   Pogoriler	   2006)	   and	   further	   provided	   an	  ideal	   model	   on	   which	   Knudsen	   based	   his	   two-­‐hit	   theory	   of	   carcinogenesis	  (Knudson	  1971).	  Bi-­‐allelic	  loss	  of	  RB	  in	  embryonic	  retinoblasts	  leads	  to	  a	  tumour	  of	  the	  retina,	  retinoblastoma,	  but	  since	  being	  identified	  in	  retinoblastoma,	  RB	  has	  been	  shown	  to	  be	  deregulated	  in	  virtually	  all	  cancers	  (Nevins	  2001)	  and	  this	   is	  because	   of	   the	   pivotal	   role	   it	   plays	   around	   the	   G1/S	   boundary,	   whereupon	  successful	  inactivation	  of	  RB	  leads	  to	  an	  orchestrated	  set	  of	  events	  necessary	  for	  the	  continuation	  of	  the	  cell	  cycle	  in	  both	  normal	  and	  neoplastic	  growth.	  The	   Rb	   family	   -­‐	   also	   called	   ‘pocket	   proteins’	   by	   virtue	   of	   sequence	   homology	  around	   a	   conserved	  protein-­‐binding	  pocket	   domain,	   interact	  with	   several	   viral	  and	   cellular	   proteins	   which,	   when	   bound	   to	   the	   active,	   hypophosphorylated	  protein,	   are	   inactive	   (Du	   and	   Pogoriler	   2006);	   it	   is	   therefore	   only	   when	   it	   is	  hyperphosphorylated	   in	   late	   G1,	   that	   it	   becomes	   inactivate	   and	   no	   longer	  sequesters	  its	  binding	  partners.	  	  The	  pocket	  regions	  of	  Rb	  proteins	  are	  characterised	  by	  two	  domains	  (A	  and	  B),	  which	  are	  responsible	   for	  binding	  to	  E2F	  transcription	  factors	  and	  other	  target	  proteins	  containing	  the	  LXCXE	  motif	  like	  the	  D-­‐type	  cyclins	  but	  are	  separated	  by	  a	  spacer	   regioin	   (S),	  which	  keeps	   the	   two	  binding	  domains	  spatially	   separated,	  allowing	  Rb	  family	  members	  to	  bind	  several	  target	  proteins	  at	  once	  (Lee,	  Russo	  et	  al.	  1998).	  It	  is	  of	  no	  surprise	  then	  that	  Rb	  can	  elicit	  both	  growth	  inhibitory	  and	  promoting	  signals	  depending	  on	  what	  protein	  partner	  they	  bind.	  For	  RB	  (p105),	  there	   is	   currently	  a	   list	  of	  more	   than	  100	  known	  binding	  partners	   (Morris	  and	  Dyson	   2001),	   exemplified	   by	   arguably	   the	   best	   studied	   -­‐	   the	   E2F	   gene	   family.	  This	   family	   of	   nine	   transcription	   factors	   coordinate	   a	   variety	   of	   cellular	  functions:	   DNA	   replication,	   mitosis,	   mitotic	   and	   DNA	   repair	   checkpoints,	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differentiation,	  apoptosis	  and	  autophagy	  (Polager	  and	  Ginsberg	  2008).	  It	  appears	  that	  the	  decision	  of	  whether	  to	  induce	  proliferative	  or	  apoptotic	  changes	  within	  the	  cell	  may	  largely	  be	  determined	  by	  signalling.	  For	  example,	  E2F1	  is	  thought	  to	  induce	  apoptosis	   in	   the	  presence	  of	  DNA	  damage	  signalling	  whereas	  mitogenic	  signalling	   inhibits	   this.	  There	   is	  an	  added	   level	  of	  complexity	  as	   the	  E2F	   family	  can	  be	  broadly	  split	  into	  two	  groups	  according	  to	  function:	  the	  activators	  (E2F1-­‐3a)	  and	  Repressors	  (E2F4-­‐8)	  of	  transcription,	  although	  microarray	  studies	  show	  that	  ‘activators’	  lead	  to	  the	  down-­‐regulation	  of	  just	  as	  many	  genes	  (Polager	  and	  Ginsberg	  2008).	  	  RB	  function	  may	  be	  lost	  either	  through	  mutation,	  caspase	  mediated	  degradation,	  interference	  by	  viral	  oncoproteins	  such	  as	  the	  large	  T	  antigen	  of	  polyoma	  virus	  or	   E7	   of	   human	   papilloma	   virus	   (Helt	   and	   Galloway	   2003)	   or	   through	  inactivation	  by	  gradual	  CDK	  phosphorylation.	  It	  is	  important	  to	  note	  that	  whilst	  all	   modes	   of	   RB	   inactivation	   may	   lead	   to	   cellular	   transformation,	  phosphorylation	  events	  remain	  a	  canonical	  feature	  of	  normal	  cell	  growth	  and	  it	  is	   only	   when	   the	   precursors	   of	   phosphorylation,	   namely	   CDK2,	   4	   and	   6	   are	  constitutively	  active	  is	  there	  a	  tendency	  for	  a	  given	  cell	  to	  transform.	  However	  in	  normal	  cells,	  there	  exists	  a	  distinct	  and	  coordinated	  sequence	  of	  phosphorylation	  events	   during	   G1-­‐S	   transition,	  which	  was	   first	   documented	   in	   1989	   in	   several	  reports	  (Buchkovich,	  Duffy	  et	  al.	  1989;	  Chen,	  Scully	  et	  al.	  1989).	  It	  was	  noted	  that	  RB	   was	   most	   heavily	   phosphorylated	   from	   S	   phase	   and	   in	   G0	   an	  unphosphorylated	  form	  was	  detectable.	  Although	  the	  precise	  sequence	  of	  events	  remains	  elusive,	  we	  do	  know	  that	  16	  potential	  thr/ser-­‐pro	  sites	  exist	  and	  all	  sites	  are	   phosphorylated	   before	   transition	   to	   S	   phase	   (Halaban	   2005).	   Some	   of	   the	  earliest	  attempts	  to	  pinpoint	  which	  CDKs	  are	  associated	  with	  individual	  residues	  implicated	   CDK4/cyclinD	   as	   the	   critical	   kinase,	   initiating	   phosphorylation	   of	  serine	  795	  and	  hence	  concomitant	  activation	  of	  RB	  (Connell-­‐Crowley,	  Harper	  et	  al.	   1997).	   This	   is	   at	   odds	   with	   one	   currently	   accepted	   model	   where	   initial	  CDK4/6-­‐cyclin	  D	  activity	  phosphorylates	  a	  number	  of	  residues	  during	  early-­‐mid	  G1	  only	  to	  be	  superseded	  by	  CDK2/cyclin	  E-­‐mediated	  Rb	  phosphorylation,	  which	  pushes	   the	   cell	   through	   the	   restriction	   point	   into	   S	   phase	   (Ezhevsky,	   Ho	   et	   al.	  2001).	  Here,	   CDK2/cyclinA	   is	   said	   to	   phosphorylate	   (and	   thus	   deactivate)	   E2F	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family	   proteins,	   safeguarding	   against	   constitutive	   transcription,	   which	   could	  eventually	   lead	   to	   the	   transcription	   of	   tumour	   suppressor	   genes	   such	   as	   p53	  (Halaban	  2005).	   Indeed,	   this	  model	  places	  CDK2/cyclin	  E	  as	   the	   critical	   kinase	  most	   likely	   to	   hyperphosphoylate	   Rb	   and	   as	   such	   pull	   it	   out	   of	   the	   CDK4/6	  hypophosphorylated	  (partially-­‐active)	  state.	  Despite	  this,	  cyclin	  D-­‐CDK4/6	  does	  play	   important	   roles	   in	  preparing	   the	   cell	   for	   S	   phase	   entry,	   particularly	  when	  overexpressed:	  Firstly,	  the	  LXCXE	  domain	  of	  D	  cyclins	  compete	  for	  the	  respective	  binding	  pocket	  on	  Rb	  against	  motifs	  containing	  chromatin	  remodelling	  proteins	  like	  histone	  deacetylases	   (HDACs);	  Secondly,	   they	  also	  help	   to	  activate	  cyclin	  E	  and	   CDK2	   by	   sequestering	   CDK	   inhibitors	   p21	   and	   p27;	   finally,	   they	   activate	  metabolic	  genes	  in	  G1	  necessary	  for	  cell	  growth.	  In	   addition	   to	   disruption	   of	   E2F	   transcription	   factors,	   differential	   Rb	  phosphorylation	   can	   also	   disrupt	   its	   binding	   to	   other	   proteins	   which	   bind	   to	  separate	   pockets,	   such	   as	   c-­‐Abl	   or	   LXCXE-­‐containing	   proteins	   (Knudsen	   and	  Wang	  1996;	  Zarkowska	  and	  Mittnacht	  1997).	  
Coordinated	  inactivation	  RB	  and	  RBL1	  are	  phosphorylated	  by	  cyclin	  D1-­‐CDK4/6	  whereas	  RBL2	  depends	  on	   cyclin	   D3-­‐CDK4	   phosphorylation	   and	   all	   three	   members	   can	   be	  phosphorylated	   by	   cyclin	   E-­‐CDK2	   and	   RBL2	   and	   RBL1	   are	   phosphorylated	   by	  cyclin	   A-­‐CDK2	   (Giacinti	   and	   Giordano	   2006).	   However,	   it	   is	   RB	   that	   is	   so	  intimately	   tied	   in	   to	   the	   cell	   cycle:	   it	   occupies	   an	   important	   position	   at	   the	  gateway	  to	  S	  phase,	  which	  poses	  an	  obstacle	  that	  cells	  must	  overcome	  in	  order	  progress	  past	   the	   restriction	  point.	   It	   has	  been	  determined	   that	  RB	  acts	   as	   the	  molecular	   switch	   that	   requires	   to	   be	   hyperphosphorylated	   for	   the	   restriction	  point	  to	  be	  traversed,	  by	  virtue	  of	  the	  transcriptional	  activity	  it	  actively	  represses	  in	   E2F.	   Indeed,	   in	   quiescent	   cells	   it	   is	   hypophosphorylated	   and	   becomes	  increasingly	  phosphorylated	  during	  G1	  and	  remains	  hyperphosphorylated	  until	  late	   mitosis	   (Weinberg	   1995).	   Hypophosphorylated	   Rb	   physically	   blocks	   the	  activity	  of	  E2F	  transcription	  factors	  by	  binding	  to	  the	  transactivation	  domain	  and	  the	  promoter	  region	  of	  E2F	  target	  genes	  as	  a	  complex.	  It	  may	  also	  be	  involved	  in	  recruitment	  of	  co-­‐repressor	   factors	  such	  as	  HDAC,	  polycomb	  group	  proteins	  or	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methyltransferases	   (Giacinti	   and	   Giordano	   2006).	   Both	   CDK4/6-­‐cyclinD	   and	  CDK2-­‐cyclin	  E	  phosphorylate	  the	  RB	  family	  proteins	  on	  different	  sites	  (Connell-­‐Crowley,	   Harper	   et	   al.	   1997;	   Zarkowska	   and	   Mittnacht	   1997),	   thus	   enabling	  dissociation	  of	  RB	  from	  E2F	  transcription	  factors,	  which	  are	  themselves	  involved	  in	  transcription	  of	  genes	  necessary	  for	  cell	  cycle	  progression.	  	  It	   is	  not	  yet	  fully	  understood	  how	  the	  series	  of	  phosphorylation	  events	  leads	  to	  the	  release	  of	  E2F	  however,	   the	  sequential	  phosphorylation	  of	  RB,	   first	   in	  early	  G1	  by	  cyclin	  D-­‐CDK4/6	  and	  then	  in	  the	  middle	  to	  late	  G1	  by	  cyclins	  E/A-­‐CDK2,	  is	  thought	  to	  cause	  a	  conformational	  change	  that	  inhibits	  E2F	  binding.	  Despite	  this,	  a	  recent	  study	  using	  recombinant	  RB	  and	  an	   in	  vitro	  calorimetry	  assay	  coupled	  with	   NMR	   spectroscopy	   (Burke,	   Deshong	   et	   al.	   2010),	   found	   that	  phosphorylation	  of	  Ser608/612	  causes	  an	  intramolecular	  association	  between	  the	  S	  domain	  and	   the	  pocket	  domains,	  which	  occludes	   the	  E2F	  binding	   site.	   Further,	  this	   study	   also	   suggests	   that	   phosphorylation	   of	   Thr356/373	   also	   inhibits	   E2F	  binding	  but	  crucially	  both	  of	  these	  events	  are	  required	  to	  bring	  about	  complete	  dissociation	  from	  E2F.	  Since	  each	  CDK	  probably	  has	  preferential	  target	  sites	  on	  RB,	  it	  is	  tempting	  to	  speculate	  that	  each	  may	  contribute	  differently	  to	  the	  overall	  stabilisation	   of	   RB.	   Perhaps,	   this	   may	   also	   go	   some	   way	   to	   explain	   why	  metazoans	  have	  evolved	  a	  number	  of	  cell	  cycle-­‐related	  CDKs.	  	  	  	  
S	  phase	  Once	   the	   cycle	   has	   passed	   the	   restriction	   point,	   the	   absence	   of	   mitogens	   and	  other	  growth	  factors	  are	  no	  longer	  rate	  limiting	  and	  the	  cell	  is	  “committed”	  to	  a	  full	   round	   of	   growth.	   In	   S	   phase,	   the	   synthesis	   stage,	   events	   are	   dominated	   by	  CDK2,	   partnering	   in	   early	   S	   phase	   with	   cyclin	   E	   and	   then	   later	   with	   cyclin	   A.	  Here,	   with	   E2F	   fully	   activated	   (and	   RB	   inactive),	   S-­‐phase	   components	   are	  transcribed	  (Sherr	  2000).	  The	  arival	  of	  S	  phase	  is	  accompanied	  with	  rapidly	  falling	  levels	  of	  cyclin	  D1.	  This	  is	   essential	   because	   cyclin	   D1	   represses	   DNA	   replication	   by	   binding	   to	  proliferating	   cell	   nuclear	   antigen	   (PCNA),	   which	   inhibits	   DNA	   polymerase-­‐mediated	  DNA	  synthesis.	  Cyclin	  D	   can	  also	  partner	  CDK2,	  which	   inhibits	  CDK2	  phosphorylation	  events	   since	   the	   cyclin	  D1-­‐CDK2	  complex	   is	   inactive	   (Fukami-­‐
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Kobayashi	   and	   Mitsui	   1999).	   The	   proteasomal	   degradation	   of	   cyclin	   D1	   is	  initiated	   by	   phosphorylation	   at	   Thr286	   by	   glycogen	   synthase	   kinase	   (GSK3β)	  (Diehl,	  Cheng	  et	  al.	  1998).	  Like	   cyclin	   D,	   cyclin	   E	   also	   has	   a	   short	   half-­‐life	   and	   is	   rapidly	   turned-­‐over,	  reflecting	   traceability	   between	   the	   RNA	   expression	   and	   protein	   expression.	  	  Autophosphorylation	  by	  CDK2	  at	  a	  specific	  residue,	  Thr380	  marks	  the	  protein	  for	  degradation	  via	  the	  ubiquitin-­‐proteasome	  pathway	  (Clurman,	  Sheaff	  et	  al.	  1996;	  Won	   and	   Reed	   1996).	   One	   of	   the	   key	   proteins	   thought	   to	   recognise	   this	   for	  ubiquitination	   is	   Cul-­‐3	   (Singer,	   Gurian-­‐West	   et	   al.	   1999).	   A	   similar	   study	   later	  implicated	   Fbw7,	   a	   substrate	   recognition	   subunit	   of	   a	   family	   of	   E3	   ubiquitin	  ligases,	   which	   specifically	   recognises	   phospho-­‐proteins	   (Koepp,	   Schaefer	   et	   al.	  2001;	   Strohmaier,	   Spruck	   et	   al.	   2001).	   However	   a	   later	   study	   proposed	   that	  autophosphorylation	   of	   cyclin	   E	   by	   CDK2	   was	   not	   adequate	   on	   its	   own	   to	  substantiate	  ubiquitination	  and	  it	  is	  currently	  thought	  that	  several	  sites	  need	  to	  be	  phosphorylated	  and	   that	  Thr380	  may	  also	   require	  GSK3	   for	  phosphorylation	  (Welcker,	  Singer	  et	  al.	  2003).	  Once	  the	  levels	  of	  cyclin	  E	  have	  diminished,	  S	  phase	  is	  under	  control	  of	  cyclin	  A-­‐CDK2,	  which	  governs	  the	  production	  of	  many	  proteins	  involved	  in	  DNA	  synthesis	  but	  at	  entry	  to	  S	  phase,	  cyclin	  E	  levels	  are	  at	  its	  highest	  and	  together	  with	  cyclin	  A	   help	   drive	   replication	   and	   keep	   the	   process	   restricted	   to	   once	   per	   cycle	   i.e.	  prevention	   of	   re-­‐replication	   (Woo	   and	   Poon	   2003).	   During	   DNA	   replication,	  cyclin	  E/A-­‐CDK2	  is	  involved	  in	  activating	  the	  pre-­‐replication	  complex,	  a	  complex	  of	   four	   proteins	   that	   associate	  with	   the	   origin	   recognition	   complex	   (ORC)	   that	  recognises	  replication	  initiation	  sites	  along	  DNA.	  ORC	  remains	  bound	  to	  the	  DNA	  throughout	   the	   duration	   of	   the	   cell	   cycle.	   The	   pre-­‐replication	   complex	   actually	  begins	  to	  assimilate	  during	  the	  latter	  stages	  of	  G1,	  however	  it	  is	  during	  S	  phase	  that	   it	   is	   activated.	  Firstly,	   cyclin	  E/A-­‐CDK2	  phosphorylates	   the	  pre-­‐replication	  complex	   allowing	   the	   association	   of	   a	   sixth	   essential	   protein,	   CDC45.	   This	  activation	  process	  triggers	  unwinding	  of	   the	  replication	  origin	  and	  gives	  access	  of	   the	   single	   stranded	   DNA	   to	   DNA	   polymerase	   α.	   Secondly,	   cyclin	   A-­‐CDK2	  localises	   with	   and	   phosphorylates	   DNA	   polymerase	   α	   and	   several	   other	  components	  of	  the	  replication	  machinery,	  which	  is	  essential	  for	  elongation.	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It	  has	  also	  been	  shown	  that	  cyclin	  A-­‐CDK2	  has	  the	  ability	  to	  prevent	  replication	  by	  phosphorylating	  one	  of	  the	  components	  of	  the	  pre-­‐replication	  and	  replication	  complexes,	  CDC6,	  which	  is	  concomitantly	  tagged	  for	  export	  from	  the	  nucleus	  and	  subsequently	  degraded	  by	  proteolysis.	  CDC6	  itself	  is	  transcribed	  in	  G1	  in	  an	  E2F-­‐dependent	   manor.	   Phosphorylation	   of	   free	   CDC6	   that	   is	   not	   bound	   in	   a	  replication	   complex	   on	   DNA	   may	   be	   the	   rate-­‐limiting	   step	   for	   replication	  initiation	  and	  hence	  ensure	  that	  only	  one	  round	  occurs	  per	  cell	  cycle	  (Woo	  and	  Poon	  2003).	  
The	  S-­phase	  checkpoint	  CDK2	  is	  also	  necessary	  to	  mediate	  the	  S-­‐phase	  checkpoint,	  a	  surveillance	  system	  that	  monitors	  the	  integrity	  of	  DNA	  and	  arrests	  the	  cell	  cycle	  in	  response	  to	  DNA	  damage	  such	  as	  double	  strand	  breaks	  (DSBs)	  or	  other	  lesions	  caused	  by	  ionizing	  radiation	   (IR),	   UV	   or	   stalled	   replication	   forks	   from	   chemotherapeutic	   agents.	  	  The	   nature	   of	   this	   damage	   activates	   either	   ATM	   or	   ATR,	   two	   related	   proteins,	  that	   can	   signal	   through	   CHK1/2	   to	   direct	   the	   degradation	   of	   CDC25A,	   a	  phosphatase	   that	   dephosphorylates	   Thr14/Tyr15	   on	   CDK2,	   thus	   keeping	   it	  active	   (Woo	  and	  Poon	  2003).	  Whilst	  ATM/R	  are	   similar	   and	   lead	  ultimately	   to	  the	   same	   cellular	   response	   during	   the	   S-­‐phase	   checkpoint,	   ATM	   responds	  primarily	   to	  DSBs	   caused	   by	   IR	  whilst	   ATR	   is	  more	   promiscuous	   of	   its	   stimuli	  and	   can	   respond	   to	   UV,	   alkylating	   agents	   and	   inhibition	   of	   DNA	   replication	  (Cuadrado,	  Martinez-­‐Pastor	  et	  al.	  2006;	  Stokes,	  Rush	  et	  al.	  2007).	  Moreover	  ATR	  preferentially	   targets	   CHK1	   whereas	   ATM	   has	   been	   shown	   to	   preferentially	  phosphorylate	  CHK2,	  but	  may	  also	  activate	  CHK1.	  Interestingly,	  CDK2	  inhibition	  either	   by	   siRNA	   or	   small	   molecule	   inhibitors	   has	   been	   shown	   to	   induce	   this	  checkpoint	  too	  (Zhu,	  Alvarez	  et	  al.	  2004).	  Finally,	  it	  is	  of	  note	  that	  a	  distinguishing	  feature	  of	  the	  S-­‐phase	  checkpoint	  is	  the	  distinct	   lack	   of	   p53	   involvement	   unlike	   the	   G1	   checkpoint.	   P53	   is	   a	   tumor	  suppressor,	   that	   is	   absent	   or	   deleted	   in	   more	   than	   50%	   of	   tumors	   (Hollstein,	  Sidransky	   et	   al.	   1991).	   During	   the	   G1	   checkpoint,	   p53	   is	   normally	   protected	  against	   MDM2	   mediated	   degradation	   by	   phosphorylation	   that	   is	   mediated	   by	  ATM/R	   and	   CHK1/2.	   Therefore,	   at	   the	   G1	   checkpoint,	   active	   p53	   can	   bind	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damaged	  DNA	  and	  activate	  the	  expression	  of	  several	  genes	  including	  p21cip1/waf1,	  which	  bind	   to	  CDK2,	   thus	  arresting	  G1-­‐S	   transition	   (Woo	  and	  Poon	  2003).	  The	  noticeable	  absence	  of	  p53	  is	  thus	  crucial	  for	  uninterrupted	  of	  cell	  growth.	  
G2	  and	  M	  phase	  Whilst	  the	  G2	  and	  M	  phases	  are	  characterised	  by	  the	  rise	  of	  cyclin	  A	  and	  B	  and	  CDK1	  (CDC2)	  and	  because	  of	  a	  propensity	  for	  using	  cell	  sorting	  techniques	  such	  as	  FACS,	  which	   is	  not	  discriminatory	  enough	   to	  accurately	  distinguish,	   the	   two	  phases	  are	  often	  morphed	   together,	  being	   termed	   “G2/M”	   (Rieder	  2011).	  They	  are	  however,	  biochemically	  distinct.	  Chromosomal	  condensation	  begins	  in	  early-­‐mid	  G2.	  At	  this	  point,	  condensation	  is	  still	   reversible	   and	   the	   cell	   is	   only	   committed	   to	   complete	   mitosis	   and	  subsequent	   division	   from	   late	   prophase	   of	   the	  M	  phase	   (Rieder	   2011).	   Thus	   a	  clear	   division	   between	   the	   two	   phases	   is	   blurred.	   Indeed,	   mitosis	   has	  traditionally	  been	   thought	  of	   as	   the	  beginning	  of	   chromosome	  condensation.	   It	  may	   therefore	   be	  more	   definitive	   to	   consider	   the	   adjacent	   phases	   in	   terms	   of	  their	  distinct	  checkpoints	  –	  one	  that	  operates	  at	  the	  G2/M	  boundary	  and	  another	  during	  M-­‐phase.	  I	  shall	  briefly	  describe	  the	  signalling	  cascades	  that	  characterise	  them.	  At	   the	  G2/M	  DNA	  damage	  checkpoint,	  cells	  have	  the	  chance	  to	  repair	  damaged	  DNA	  before	  entering	  mitosis	  proper	  and	  thereby	  avoiding	  cellular	  death.	  G2	  is	  a	  useful	   phase	   to	   repair	   DSBs	   due	   to	   the	   duplicated	   DNA,	   thus	   providing	   an	  opportunity	   to	   use	   sister	   chromatids	   for	   homologous	   recombination	   (Haber	  2000).	  This	  checkpoint	  operates	  via	  one	  of	  two	  available	  signalling	  cascades:	  The	  ATM/R	   or	   p38/CHFR	   pathway.	   Both	   of	   which	   act	   to	   depress	   cyclin	   A/B-­‐CDK	  activity	  and	  result	  in	  a	  transient	  block	  in	  G2	  (Rieder	  2011).	  However	  under	  some	  conditions	  there	  is	  evidence	  of	  p53	  signalling,	  giving	  a	  sustained	  blockage,	  which	  is	   independent	  of	   these	   former	  mechanisms	   (Agarwal,	  Agarwal	  et	  al.	  1995;	   Jin,	  Tong	   et	   al.	   2002)	   although	   there	   are	   also	   reports	   of	   crosstalk	   between	   these	  pathways.	  For	  instance	  ATM/R	  activation	  from	  UV/IR	  induced	  DNA	  damage	  may	  facilitate	  dissociation	  of	  MDM	  2/4	  from	  p53	  by	  phosphorylation	  (Maya,	  Balass	  et	  al.	   2001).	   This	   ATM-­‐dependency	   may	   only	   be	   true	   in	   some	   tissues	   however,	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whereas	  de	  novo	  p53	  signalling	  is	  thought	  to	  be	  representative	  of	  most	  epithelial	  cells	  (Gurley	  and	  Kemp	  2007).	  Similar	  to	  the	  intra-­‐S	  phase	  checkpoint,	  DNA	  damage	  is	  sensed	  by	  ATM/R,	  which	  responds	   by	   signalling	   through	   CHK1,	   which	   inactivate	   CDC25	   by	  phosphorylation.	  Since	  CDC25	  phosphatase	  normally	  acts	  to	  keep	  key	  inhibitory	  residues	   of	   CDK1	   dephosphorylated	   and	   thus	   active,	   this	   results	   in	   preventing	  entry	  into	  mitosis	  (Boutros,	  Lobjois	  et	  al.	  2007;	  Rieder	  2011).	  	  The	  p38/CHFR	  pathway	  represents	  an	  alternative	   that	  operates	   in	   response	   to	  cellular	   stresses	   that	   do	   not	   cause	   DNA	   damage.	   Assaults	   from	   osmotic	   shock,	  histone	   deacetylase	   inhibitors	   and	   certain	   Topoisomerase	   II	   inhibitors	   delay	  progression	   without	   inducing	   ATM/R	   signalling	   (Mikhailov,	   Shinohara	   et	   al.	  2005).	   Also,	   p38	   constitutes	   a	   bona	   fide	   checkpoint	   operating	   at	   the	   G2/M	  transition	  because	  stress-­‐activated	  mitotic	  delay	  can	  be	  overridden	  by	  inhibiting	  p38	   (Hartwell	   and	  Weinert	   1989).	   However	   both	   pathways	   achieve	   the	   same	  end:	  that	  is	  to	  depress	  CDK	  activity.	  Interestingly,	  p38	  appears	  to	  act	  principally	  by	   inhibiting	   cyclin	   A-­‐CDK2	   whereas	   CHFR,	   in	   response	   to	   microtubule	  disassembly	  indirectly	  inhibits	  cyclin	  B-­‐CDK1.	  Both	  cascades	  lead	  to	  inactivation	  of	  CDC25,	  just	  like	  ATM	  does	  (Mikhailov,	  Shinohara	  et	  al.	  2005).	  G2	  arrest	  can	  be	  overridden	  by	  an	   important	  mitotic	  kinase,	  polo-­‐like	  kinase	  1	  (PLK1).	   Constitutively	   active	   PLK1	   has	   shown	   to	   override	   the	   inhibition	   of	  centrosome	   separation	   following	   DNA	   damage	   (Zhang,	   Fletcher	   et	   al.	   2005).	  Moreover,	  it	  has	  also	  been	  shown	  to	  phosphorylate	  Cdc25	  and	  activate	  it	  as	  well	  as	   directly	   phosphorylate	   the	   CDK1	   inhibitor	   WEE1	   (van	   Vugt	   and	   Medema	  2005).	  The	  spindle	  assembly	  checkpoint	  (SAC)	  represents	  a	  further	  level	  of	  control	  for	  the	  mitotic	  cell.	  This	  mechanism	  delays	  the	  onset	  of	  sister	  chromatid	  separation	  at	  anaphase	  when	  kinetochores	  are	  not	  attached	  to	  microtubules	  radiating	  from	  the	   spindle	   poles,	   allowing	   time	   for	   reattachment	   and	   thus	   avoiding	   unequal	  separation	  of	  sister	  chromatids	  resulting	   in	  aneuploid	  progeny	  (Musacchio	  and	  Salmon	  2007;	  Rieder	  2011).	  Under	  normal	  circumstances,	  mitosis	  proceeds	  into	  anaphase	   by	   the	   ubiquitination	   and	   subsequent	   degradation	   of	   securing	   and	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cyclin	   B,	   which	   is	   normally	   stable	   until	   the	   end	   of	   metaphase	   (Rieder	   2011).	  Securin	  is	  a	  stoichiometric	  inhibitor	  of	  seperase,	  a	  protease	  shown	  to	  cleave	  the	  protein	   complex	   holding	   sister	   chromatids	   together	   and	   cyclin	   B	   presence	   is	  necessary	   for	   CDK1	   activity,	   which	   promotes	   the	   mitotic	   exit	   (Musacchio	   and	  Salmon	  2007).	  	  Central	   to	   this	   is	   the	   cyclosome	  or	  Anaphase	  Promoting	  Complex	   (APC),	   an	  E3	  ubiquitin	  ligase	  assemblage.	  This	  requires	  to	  be	  activated	  by	  Cdc20,	  degradation	  of	  which	  has	  shown	  to	  represent	  a	  critical	  control	  mechanism	  in	  response	  to	  the	  SAC	   (Tang,	   Shu	   et	   al.	   2004;	   Ge,	   Skaar	   et	   al.	   2009).	   Unattached	   kinetochores	  recruit	   a	   number	  of	   proteins	   such	   as	  Mad1,	  Mad2,	   Cenp-­‐E	   and	  BubR1	   that	   are	  involved	  in	  sequestering	  Cdc20.	  Their	  recruitment	  may	  be	  initiated	  by	  Aurora	  B	  (Vigneron,	   Prieto	   et	   al.	   2004).	   The	   precise	   mechanism	   remains	   unknown	   but	  some	   observations	   suggest	   that	   Mad	   1	   binds	   to	   and	   converts	   Mad2	   to	   a	  conformation	   that	   interacts	   with	   Cdc20	   to	   inhibit	   its	   association	   with	   the	  cyclosome	   (Peters	   2002;	   Mapelli	   and	   Musacchio	   2007).	   There	   are	   also	  suggestions	   that	   cyclin	   B-­‐CDK1	   may	   phosphorylate	   Cdc20	   and	   inactivate	   it	   in	  
vitro	   (Yudkovsky,	   Shteinberg	   et	   al.	   2000;	   D'Angiolella,	   Mari	   et	   al.	   2003).	  However,	   a	   recent	   report	   implicates	   CDK1	   activity	   in	   the	   continuation	   of	   SAC-­‐imposed	  arrest	   through	   the	   re-­‐establishment	  of	  kinetochore	  bi-­‐orientation	  and	  regulating	   the	   transcription	   of	   Cdc20	   (Liang,	   Lim	   et	   al.	   2011).	   It	   could	   be	   that	  CDK1	  maintains	  Cdc20	  inactivation	  during	  the	  early	  phases	  of	  mitosis	  but	  during	  the	  onset	  of	  anaphase,	  becomes	  involved	  in	  the	  active	  promotion	  of	  mitotic	  exit.	  	  Kinetochore	  attachment	  defects	  must	  be	  corrected.	  This	   is	  achieved	   in	  part,	  by	  another	   important	   kinase,	   Aurora	  B.	   Aurora	  B	   inhibition	   by	   a	   selective	  Aurora	  kinase	   inhibitor	   and	   siRNA	   showed	   that	   proper	   chromosome	   alignment,	  segregation	  and	  cytokinesis	  fail	  and	  that	  cells	  frequently	  showed	  a	  high	  degree	  of	  merotelic	   attachment	   of	   chromatids	   and	   enter	   anaphase	   with	   no	   arrest	  (Ditchfield,	  Johnson	  et	  al.	  2003).	  Recently,	  some	  evidence	  has	  shed	  light	  on	  how	  Aurora	   B	   achieves	   the	   plasticity	   to	   correct	   unequal	   kinetochore	   attachment	  (Welburn,	   Vleugel	   et	   al.	   2010):	   Aurora	   B	   phosphorylates	   three	   distinct	   sites	  within	  the	  KMN	  network,	   the	  core	  microtubiule-­‐binding	  site	  of	   the	  kinetochore	  and	   the	   major	   substrate	   of	   Aurora	   B	   (Cheeseman,	   Chappie	   et	   al.	   2006),	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compromising	   microtubule	   binding	   and	   lead	   to	   detachment	   of	   kinetochores.	  Chromosome	  alignment	  then	  has	  a	  chance	  to	  be	  realigned	  during	  the	  SAC,	  which	  is	  activated	  unattached	  kinetochores	  (Musacchio	  and	  Salmon	  2007).	  
The	  involvement	  of	  CAK	  CAK	  is	  responsible	  for	  activating	  CDKs	  involved	  in	  the	  cell	  cycle.	  In	  fact,	  evidence	  from	   siRNA	  mediated	   knockdown	   and	   chemical	   genetics	   adds	   credence	   to	   the	  notion	   that	   it	   is	   the	   only	   true	   CDK	   activating	   kinase	   in	  metazoans	   (Wohlbold,	  Larochelle	  et	  al.	  2006;	  Larochelle,	  Merrick	  et	  al.	  2007).	  This	  has	  been	  a	  point	  of	  contention	   amongst	   some	   groups	   and	   for	   reasons	   that	   seem	   to	   be	   largely	  attributed	   to	   the	  evolutionary	  origins	  of	  CAK,	   the	   functional	  differences	  of	  CAK	  between	   yeast	   and	   metazoans	   and	   the	   fact	   that	   in	   some	   instances,	   despite	  depletion	  of	  CDK7	  either	  by	   siRNA	   (Wohlbold,	   Larochelle	   et	   al.	   2006)	  or	  using	  temperature	   sensitive	  mutants	   in	  Drosophila	  melanogaster	   (Larochelle,	   Pandur	  et	   al.	   1998)	   and	   c.	   elegans	   (Wallenfang	   and	   Seydoux	   2002)	   CDK2	  phosphorylation	  and	  its	  in	  vitro	  activity	  is	  still	  not	  fully	  sequestered.	  It	  has	  been	  suggested	   that	  perhaps	  another,	  as	  yet	  unidentified	  CAK	  could	  exist.	  Moreover,	  an	  earlier	  report	  (Leclerc,	  Raisin	  et	  al.	  2000),	  showed	  that	  a	  dominant	  negative	  CDK7	   mutant	   did	   not	   affect	   mitotic	   divisions	   in	   Drosophila	   embryos.	   It	   is	  possible	   that	   techniques	   used	   to	   deplete	   CDK7	   in	   earlier	   studies	   using	   siRNA,	  immunodepletion	   or	   the	   engineering	   of	   temperature	   sensitive	   mutants	   left	  residual	  CDK7	  activity.	  One	  recent	   report	  of	  a	  novel	  protein	  p42,	  with	  putative	  CAK	  activity,	  identified	  using	  a	  BLAST	  search	  of	  yeast	  CAK	  orthologs	  in	  the	  fruit	  fly	  genome	  (Liu,	  Wu	  et	  al.	  2004)	  was	  later	  proved	  not	  to	  have	  any	  intrinsic	  CDK	  activating	  activity	  (Wohlbold,	  Larochelle	  et	  al.	  2006).	  It	  has	  since	  been	  suggested	  (Abbas	  and	  Dutta	  2006)	  that	  the	  conflicting	  data	  could	  be	  due	  to	  differences	   in	  cell	  type	  used	  or	  that	  the	  reduction	  in	  CDK2	  phosphorylation	  may	  be	  secondary	  to	   the	   growth	   arrest	   caused	   when	   p42	   was	   constitutively	   knocked	   down.	   In	  another	   paper	   by	   the	   same	   group	   (Abbas,	   Jha	   et	   al.	   2007),	   it	   was	   shown	   that	  CDK2	  has	  the	  ability	  to	  autophosphorylate,	  although	  this	  evidence	  must	  be	  taken	  with	   an	   element	   of	   caution	   since	   they	   used	   bacterial	   recombinant	   CDK2	   and	  subsequently	   used	   in	   vitro	   systems	   to	   evoke	   autophosphorylation	   (and	  measured	  its	  activity	  indirectly	  by	  monitoring	  histone	  H1	  phosphorylation).	  Such	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systems	  do	  not	  reflect	  the	  cellular	  environment	  adequately	  and	  whilst	  there	  may	  be	  circumstantial	  evidence	  that	  CDK2	  can	  be	  phosphorylated	  either	  by	   itself	  or	  perhaps	   other	   kinases,	   the	   evidence	   overwhelmingly	   favours	   CAK	   as	   the	  principal	  kinase	  –	  at	  least	  for	  CDK1	  and	  2.	  Also,	  a	  chimeric	  study	  (Garrett,	  Barton	  et	  al.	  2001),	  which	  transplanted	  the	  T-­‐loop	  regions	  of	  CDK7	  to	  the	  body	  of	  CDK2	  illustrated	   that	   that	   the	   resulting	  CDK2-­‐7	  hybrid	  was	  unable	   to	   activate	   native	  CDK2	  but	  could	  activate	  CDK7,	  suggesting	  that	  autophosphorylation	  was	  unable	  to	   take	   place	   and	   could	   probably	   be	   attributed	   to	   architectural	   features	   (see	  figure	   1	   for	   the	   sequence	   of	   the	   CDK7	   T-­‐loop	   region).	   More	   recently,	   a	   novel	  technique	   utilizing	   chemical	   genetics	   and	   subsequent	   homologous	   gene	  replacement	   of	   an	   analogue	   sensitive	   (AS)	   CDK7	   (Larochelle,	   Merrick	   et	   al.	  2007),	   unequivocally	   demonstrated	   that	   selective	   inhibition	   of	   CDK7	   in	   the	  human	  colorectal	  cancer	  HCT116	  cell	  line	  during	  G1	  and	  S/G2	  prevents	  S	  phase	  and	   mitotic	   entry	   respectively	   as	   well	   as	   curtailing	   CDK2	   and	   CDK1	  	  phosphorylation.	   This	   chemical	   genetics	   approach	   has	   an	   advantage	   over	  temperature	   sensitivity	   or	   RNA	   interference-­‐mediated	   knockdown	   as	   it	   allows	  one	   to	  distinguish	  between	   the	   catalytic	   and	   structural	   functions	  of	   kinases:	   in	  short,	  if	  an	  AS	  CDK	  is	  inhibited	  by	  a	  bulky	  ATP	  analogue,	  such	  as	  1-­‐NM-­‐PP1,	  it	  can	  still	   form	   complexes	   with	   its	   cognate	   cyclin	   partner	   as	   well	   as	   other	   natural	  substrates	   or	   inhibitors,	   meaning	   that	   the	   catalytic	   action	   is	   prohibited	   only	   -­‐	  thus	  providing	  a	  more	  natural	  physiological	  environment	  in	  which	  the	  resulting	  phenoptype	   may	   be	   studied.	   Interestingly,	   this	   study	   also	   elucidated	   an	  unexpected	   new	   mode	   by	   which	   CDK7	   disruption	   leads	   to	   a	   block	   on	   CDK1	  activation	  through	  inhibition	  of	  binding	  to	  its	  cyclin	  partner,	  cyclin	  B,	  therefore	  demonstrating	  that	  with	  CDK1,	  the	  two	  obligate	  activation	  steps	  (cyclin	  binding	  and	   subsequent	   phosphorylation)	   are	   both	   hindererd	   when	   CDK7	   activity	   is	  inhibited.	  Whether	  this	  coordinated	  activation	  is	  restricted	  to	  CDK1	  has	  yet	  to	  be	  determined.	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Physical	  interactions	  between	  CDK7	  and	  other	  CDKs	  With	   regard	   to	   the	   specificity	   and	   physical	   interactions	   of	   CDK7	   with	   other	  CDK’s,	   chimeras	   between	   the	   activation	   segments	   of	   CDK7	   and	   CDK2	   revealed	  that	   substrate	   recognition	   was	   likely	   to	   be	   determined	   by	   protein	   sequences	  distal	  to	  the	  activation	  segment	  (Garrett,	  Barton	  et	  al.	  2001).	  This	  has	  also	  been	  suggested	   by	   Larochelle	   et	   al	   (Larochelle,	   Batliner	   et	   al.	   2006).	   A	  more	   recent	  study	   (Lolli	   and	   Johnson	   2007)	   illustrates	   that	   by	   combining	   C-­‐terminal	  mutagenesis,	   mass	   spectrometry	   and	   3-­‐D	   imaging,	   recognition	   is	   by	   virtue	   of	  several	   weak	   interacting	   regions	   ensuring	   specificity	   and	   orientating	   the	  proteins	  so	  that	  activation	  segments	  are	  proximal	  to	  the	  catalytic	  site	  of	  the	  other	  CDK.	  This	  also	  illustrates	  how	  they	  can	  phosphorylate	  one	  another.	  That	  said,	  a	  mutagenesis	   study	  of	   the	  CDK4	  active	  site	  gives	  evidence	   that	  phosphorylation	  does	   rely	   on	   the	   integrity	   of	   this	   sequence	   (Bockstaele,	   Bisteau	   et	   al.	   2009).	  However,	   this	  study	   fails	   to	  address	   the	   fact	   that	  mutation	  of	  a	   residue	   in	  such	  close	   proximity	   to	   the	   phosphoacceptor	   site	   may	   alter	   the	   architecture	   of	   the	  activation	  loop	  enough	  to	  favour	  phosphorylation	  by	  alternative	  means.	  Evidence	   of	   a	   step-­‐wise	   activation	   of	   CDKs	   (cyclin	   binding	   followed	   by	  phosphorylation)	   was	   first	   unequivocally	   demonstrated	   in	   a	   cell-­‐free	   system	  whereby	   recombinant	   CDC2	   and	   CDK2	  were	   found	   to	   be	   activated	   in	   an	   ATP-­‐dependent	  manner	  following	  the	  addition	  of	  crude	  cell	  extracts	  (Desai,	  Gu	  et	  al.	  1992).	  The	  Thr-­‐172	  residue	   in	  CDK4	  (and	  Thr-­‐177	   in	   its	   functional	  homologue	  CDK6),	   which	   are	   analogous	   to	   the	   phospho-­‐sites	   in	   CDC2	   and	   CDK2,	   was	  hypothesised	   and	   subsequently	   proven	   to	   be	   phosphorylated	   in	   insect	   cells	   in	  
vivo	  (Kato,	  Matsuoka	  et	  al.	  1994).	  As	  demonstrated	  in	  previous	  studies,	  this	  one	  also	  observed	   that	   the	  CDK	  and	  cyclin	  sub-­‐units	   first	   form	  an	   inactive	  complex	  that	   is	   later	   activated	   by	   phosphorylation	   on	   the	   critical	   residue.	  However	   the	  question	   of	   whether	   the	   CAK	   that	   activates	   CDK4	   is	   the	   same	   complex	   that	  activated	  CDC2/CDK2	   remained	  unanswered	   for	   some	   time.	   Initial	   attempts	   to	  phosphorylate	   CDK4	   with	   CDC/K2	   CAK	   were	   unsuccessful	   using	   xenopus	  recombinant	   protein	   (Kato,	  Matsuoka	   et	   al.	   1994)	   but	   later	   experiments	   using	  mouse	   CAK	   (which	   shows	   86%	   sequence	   identity	   to	   xenopus	   CAK	   and	   95%	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identity	  with	  human	  CAK)	  illustrated	  capability	  of	  acting	  as	  a	  bona	  fide	  CAK	  for	  CDC/K2	  and	  CDK4/6	  (Matsuoka,	  Kato	  et	  al.	  1994).	  Interestingly,	  it	  was	  the	  observation	  that	  the	  amino	  acid	  sequence	  adjacent	  to	  the	  critical	   residues	   in	   CDK4	   (Thr-­‐172-­‐Pro-­‐Val-­‐Val),	   which	   is	   different	   to	   that	  flanking	  the	  CDC/K2	  critical	  residues	  (Thr-­‐161/160-­‐His-­‐Glu-­‐Val),	  that	  served	  as	  the	   lynchpin	   for	   suspecting	   activation	   might	   be	   mediated	   by	   a	   different	   CAK.	  Additionally,	   there	   is	   also	   dissimilarity	   in	   this	   sequence	   to	   CDK6	   at	   the	   +1	  position	   (Thr-­‐177-­‐Ser-­‐Val)	   which	   may	   explain	   previous	   observations	   that	  mammalian	  CAK	  has	  a	  higher	  affinity	  for	  CDK6	  over	  CDK4	  in	  vitro	  (Kaldis,	  Russo	  et	   al.	   1998;	   Bockstaele,	   Kooken	   et	   al.	   2006;	   Bockstaele,	   Bisteau	   et	   al.	   2009).	  	  Despite	  this,	  one	  early	  study	  showed	  that	  CDK4	  could	  be	  activated	  by	  CAK	  from	  HeLa	  cell	  extracts	  (Kaldis,	  Russo	  et	  al.	  1998),	  suggesting	  that	  the	  cellular	  milieu	  contains	   other	   factors	   assisting	   its	   phosphorylation.	   Two	   further	   studies	  (Bockstaele,	  Kooken	  et	  al.	  2006;	  Bockstaele,	  Bisteau	  et	  al.	  2009)	  augmented	  this	  by	   showing	   a	   clear	   difference	   between	   in	   vitro	   and	   in	   vivo	   CAK	   activity:	   CDK6	  was	   a	   better	   substrate	   for	  mammalian	   CAK	   than	   CDK4	   as	   it	  was	  more	   readily	  phosphorylated	  (at	  Thr-­‐177)	  under	   low	  Mg-­‐ATP	  concentrations,	  as	  determined	  by	  in	  vitro	  experiments.	  Under	  these	  conditions	  it	  was	  also	  found	  that,	  similar	  to	  CDK2,	   CDK6	   could	   be	   phosphorylated	   without	   prior	   cyclin	   binding	   whereas	  CDK4	  has	  an	  absolute	  requirement	  for	  binding	  with	  a	  D-­‐type	  cyclin,	  which	  is	  at	  odds	  with	  a	  previous	  finding	  (Kaldis,	  Russo	  et	  al.	  1998).	  However,	  in	  vivo	  studies	  showed	   that	   CDK4	   was	   more	   readily	   activated	   than	   CDK6	   in	   five	   cell	   lines	  (Bockstaele,	  Bisteau	  et	  al.	  2009).	  It	  was	  suggested	  that	  the	  sequence	  of	  the	  T-­‐loop	  activation	   region	   immediately	   abutting	   the	   critical	   residue	   was	   key	   to	   this	  difference	  and	  in	  vivo	  mutation	  studies	  of	  the	  proline	  in	  the	  +1	  position	  to	  CDK4	  Thr-­‐172	   to	   either	   serine	   or	   histidine	   lead	   to	   a	   concomitant	   abolition	   of	  phosphorylation.	   Moreover,	   they	   found	   that	   mutating	   the	   serine	   in	   the	   +1	  position	  of	  CDK6	  Thr-­‐177	  to	  proline	  increased	  activity,	  suggesting	  that	  a	  proline-­‐directed	   kinase	   may	   be	   implicated	   in	   directing	   phosphorylation	   of	   CDK4.	   Not	  only	   does	   this	   question	   the	   validity	   of	   CDK7/cyclin	   H/MAT1	   being	   the	   only	  human	  CAK	  but	   it	  also	  suggests	   that	  CDK4	  and	  CDK6	  are	  activated	  by	  different	  mechanisms	   and	   appears	   to	   place	   CDK4	   as	   the	   critical	   G1-­‐S	   phase	   kinase.	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Echoing	   this,	   it	   was	   also	   noted	   that	   whereas	   cyclin	   D3	   regularly	   induced	  subsequent	  phosphroylation	  of	  CDK4	  at	  Thr-­‐172,	  it	  only	  weakly	  associated	  with	  CDK6	  in	  the	  five	  cell	  lines	  tested.	  	  	  
Evidence	  for	  a	  CDK	  substrate	  dichotomy	  All	  this	  may	  indicate	  that	  CDK7	  is	  to	  some	  degree	  dispensable	  for	  the	  early	  part	  of	   the	   cell	   cycle.	   Indeed	   not	   only	   does	   the	   mode	   of	   activation	   appear	   to	   be	  different	   for	   CDK4	   (sequence-­‐dependent	   rather	   than	   structurally-­‐dependent),	  CDK4	  has	  been	  shown	  not	   to	  phosphorylate	  CDK7	  (Garrett,	  Barton	  et	  al.	  2001)	  unlike	  CDC/K2,	  which	  has	  been	  proposed	  to	  be	  part	  of	  a	  positive	  feedback	  loop	  (Garrett,	  Barton	  et	  al.	  2001;	  Lolli	  2010).	  Therefore	  one	  could	  reasonably	  expect	  CDK4	   to	   take	  part	   in	  a	   similar	   feedback	  mechanism	   if	   it	   really	  was	  a	  bona	   fide	  CAK	   substrate.	   Further,	   CDK4	   is	   structurally	   distinct	   from	   other	   CDK-­‐cyclin	  complexes	  (Day,	  Cleasby	  et	  al.	  2009;	  Takaki,	  Echalier	  et	  al.	  2009),	  and	  also	  shows	  a	   requirement	   for	   CIP/KIP/INK	   CDK	   inhibitors	   such	   as	   p21	   or	   p27	   to	   bind	   to	  CDK4	   for	   phosphorylation	   of	   Thr-­‐172	   (Bockstaele,	   Kooken	   et	   al.	   2006;	   Takaki,	  Echalier	  et	  al.	  2009).	  This	  requirement	   is	  quite	  unlike	  any	  other	  cell	  cycle	  CDK.	  Moreover,	   unlike	   CDK4,	   CDK6	   has	   been	   shown	   to	   be	   phosphorylated	   without	  canonical	   cyclin	   binding,	   again,	   just	   like	   CDC/K2	   (Bockstaele,	   Kooken	   et	   al.	  2006).	  	  CDK6	  itself	  is	  interesting	  because	  it	  shows	  only	  modest	  activity	  in	  the	  early	  part	  of	   the	   cell	   cycle	   (Mahony,	   Parry	   et	   al.	   1998;	   Bockstaele,	   Bisteau	   et	   al.	   2009),	  illustrating	  a	  more	  submissive	  role	  compared	  to	  CDK4	  however,	   it	  does	  appear	  to	  be	  activated	  by	  CAK	  (Bockstaele,	  Bisteau	  et	  al.	  2009)	  albeit	   to	  a	   far	   reduced	  extent	  than	  CDC/K2.	  The	  reasons	  for	  this	  are	  as	  yet	  unknown	  but	  whether	  CDK6	  activity	  is	  limited	  by	  its	  own	  structure,	  the	  sequence	  motif	  in	  its	  T-­‐loop	  region	  or	  determined	  by	  other	  cellular	  factors	  such	  as	  CIP/KIP	  family	  members,	  it	  is	  clear	  that	  initiation	  of	  CDK4	  activity	  is	  tightly	  regulated	  and	  this	  makes	  sense	  given	  its	  position	  at	  the	  interface	  of	  mitogenic	  signalling	  and	  Rb	  inactivation,	  especially	  if	  one	  considers	  the	  constitutive	  expression	  and	  activity	  of	  CDK7-­‐CAK	  (Ray,	  James	  et	  al.	  2009).	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CDK7	   is	   also	   phosphorylated	   itself,	   although	   this	   is	   not	   necessary	   for	   its	   CAK	  activity	  as	  MAT1	  can	  substitute	  for	  this	  (Devault,	  Martinez	  et	  al.	  1995;	  Fisher,	  Jin	  et	   al.	   1995).	   It	   differs	   from	   other	   CDKs	   in	   that	   aside	   from	   phosphorylation	   at	  Thr170	  (Fisher,	  Jin	  et	  al.	  1995;	  Martinez,	  Afshar	  et	  al.	  1997),	  it	  possesses	  a	  second	  site	  at	  Ser164,	  which	  can	  enhance	  its	  activity	  and	  cyclin	  binding	  (Martinez,	  Afshar	  et	  al.	  1997).	  Analysis	  of	   the	  crystal	  structure	  of	  CDK7	  proposed	  that	   this	  site	   is	  contained	  within	  a	  consensus	  motif	  that	  is	  recognised	  by	  CDK2	  (Lolli,	  Lowe	  et	  al.	  2004).	   The	   fact	   that	   both	   CDK2/cyclinA	   and	   CDK1/cyclinB	   can	   phosphorylate	  CDK7	   (Garrett,	   Barton	   et	   al.	   2001)	   suggests	   a	   positive	   feedback	   loop.	  Additionally,	   there	   have	   been	   recent	   suggestions	   that	   CDK7	  may	   also	   become	  activated	  by	  PKC-­‐ι	  	  both	  in	  vitro	  and	  in	  vivo	  in	  glioma	  cells	  (Desai,	  Gu	  et	  al.	  1992).	  
1.2.2	  Activation	  of	  RNA	  polymerase	  II	  and	  initiation	  of	  transcription	  
	  CAK	  also	  plays	  a	  critical	  part	   in	  transcription	  initiation	  and	  promoter	  clearance	  of	  RNAPII	  when	  it	  is	  associated	  with	  other	  proteins	  of	  the	  general	  transcription	  factor	   TFIIH	   complex.	   A	   link	   was	   proposed	   between	   CAK	   that	   phosphorylates	  CDKs	  and	  phosphorylation	  of	  the	  C	  terminal	  domain	  (CTD),	  the	  largest	  subunit	  of	  RNAPII,	   when	   chromatography	   was	   used	   to	   purify	   the	   TFIIH	   complex	  (Shiekhattar,	  Mermelstein	  et	  al.	  1995).	  Together	  with	  seven	  other	  subunits	  of	  the	  so-­‐called	   core	   (Coin,	   De	   Santis	   et	   al.	   2006),	   CAK	   completes	   the	   functional	  complex	  so	  it	  can	  phosphorylate	  serine	  5	  in	  the	  heptapeptide	  repeat	  YSPTSPS	  in	  the	  C-­‐terminal	  domain	  of	  RNAPII,	  which	  features	  52	  repeats	  of	  the	  heptapeptide	  in	   mammals	   (Shiekhattar,	   Mermelstein	   et	   al.	   1995).	   However,	   CDK9	   also	   has	  Ser5	   phosphorylation	   potential	   (Eissenberg,	   Shilatifard	   et	   al.	   2007),	   albeit	  secondary	   to	   Ser	   2,	   its	   primary	   target	   site	   (Meinhart,	   Kamenski	   et	   al.	   2005;	  Shapiro	   2006).	   Antagonists	   directed	   towards	   CDK9	   attenuate	   Ser5	  phosphorylation	   providing	   evidence	   for	   this	   redundancy	   (Gomes,	   Bjerke	   et	   al.	  2006).	  TFIIH	  was	  also	  found	  to	  be	  involved	  in	  DNA	  repair,	  specifically	  nucleotide	  excision	   repair	   (NER),	  which	   assists	   in	   the	   removal	   of	   a	   range	   of	   DNA	   lesions	  (Schaeffer,	   Roy	   et	   al.	   1993).	   Intriguingly,	   these	   two	   processes	   are	   tightly	  regulated	  as	  separate	  phenomena,	  marked	  by	  dissociation	  of	  CAK	  from	  the	  core	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complex	   for	   NER	   and	   subsequent	   re-­‐association	   for	   establishment	   of	  transcription	  (Coin,	  Oksenych	  et	  al.	  2008).	  During	   transcription	   progression,	   several	   coordinated	   phosphorylation	   events	  are	  required	  and	  involve	  CDK7,	  8	  and	  9	  and	  some	  evidence	  even	  suggests	  CDK11	  is	  involved	  with	  pre-­‐mRNA	  splicing	  patterns	  (Hu,	  Mayeda	  et	  al.	  2003).	  In	  general,	  Ser5	   phosphorylation	   appears	   closely	   associated	   with	   promoter	   regions	   at	  initiation;	   it	   is	   thought	   to	   recruit	   capping	   enzymes	   whereas	   Ser2	  phosphorylation	   occurs	   distal	   to	   the	   promoter	   and	   recruits	   binding	   of	   3’-­‐processing	   enzymes	   within	   the	   coding	   regions	   (Komarnitsky,	   Cho	   et	   al.	   2000;	  Meinhart,	   Kamenski	   et	   al.	   2005).	   Ser5	   phosphorylation	   by	   TFIIH	   helps	   in	  promoter	  clearance	  and	   transcription	  progression	   from	  the	  pre-­‐initiation	  stage	  (Lolli	   and	   Johnson	   2005),	   followed	   by	   CDK9	   activity	   at	   the	   start	   of	   elongation	  (Saunders,	  Core	  et	  al.	  2006).	  Ser7	  has	  also	  been	  shown	  to	  be	  phosphorylated	  for	  expression	  of	  small	  nuclear	  RNAs	  (snRNA)	  (Egloff,	  O'Reilly	  et	  al.	  2007)	  and	   for	  promoter	   pausing	   events	   during	   early	   events	   (Akhtar,	   Heidemann	   et	   al.	   2009;	  Glover-­‐Cutter,	  Larochelle	  et	  al.	  2009),	  proposed	  to	  be	  critical	  for	  transcription	  of	  several	  genes.	  Conversely,	  CDK8	  phosphorylation	   is	  associated	  with	   repression	  either	   directly	   through	   premature	   phosphorylation	   of	   the	   CTD,	   or	   indirectly	  through	   by	   phosphorylating	   cyclin	   H,	   which	   prevents	   CAK	   activity	   (Meinhart,	  Kamenski	  et	  al.	  2005).	  The	  status	  of	  the	  CTD	  phosphorylation	  fluctuates	  during	  transcription	  and	  each	  change	  appears	  necessary	  for	  the	  recruitment	  of	  different	  regulatory	   complexes.	   However,	   knowledge	   about	   the	   timings	   and	   catalysis	   of	  each	  event	  and	  what	  it	  means	  for	  transcription	  still	  appears	  to	  be	  in	  its	  infancy.	  	  Inhibiting	   critical	   phosphorylation	   events	   of	   the	   CTD,	   unsurprisingly,	   has	  profound	   effects	   on	   transcription.	   The	   drug	   flavopiridol,	   a	   pan-­‐CDK	   inhibitor	  (Vermeulen,	   Van	   Bockstaele	   et	   al.	   2003)	   with	   a	   particularly	   high	   affinity	   for	  CDK9	   and	   to	   some	   extent	   CDK7	   (Shapiro	   2006),	   has	   a	   notable	   effect	   on	   those	  mRNAs	  with	  short	  half	  lives	  because	  under	  paucity	  of	  transcription	  initiation	  and	  elongation,	   rapid	  degradation	  of	   these	   transcripts	   leads	   to	  a	  substantial	  overall	  reduction	  (Shapiro	  2006).	  Microarray	  analysis	  of	  cells	   treated	  with	   flavopiridol	  shows	   a	   concurrent	   reduction	   in	   labile	  mRNAs	   in	   a	   dosage	  dependent	  manner	  such	   as	   those	   encoding	   antiapoptotic	   proteins	   of	   the	   BCL-­‐2	   (shorter	   than	   3	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hours)	  and	  IAP	  (Inhibitor	  of	  Apoptosis)	  families,	  as	  well	  as	  cell	  cycle	  regulators	  (Lam,	  Pickeral	  et	  al.	  2001).	  In	  agreement	  with	  this	  observation,	  work	  undertaken	  in	  our	  group	  recently	  illustrated	  similar	  reductions	  of	  XIAP	  and	  BCL-­‐xL	  (but	  not	  BCL-­‐2)	   when	  MCF-­‐7	   breast	   cancer	   cells	   were	   treated	  with	   the	   selective	   CDK7	  inhibitor	  BS181	   (Ali,	  Heathcote	  et	  al.	  2009).	  Additionally,	   these	  data	  also	   show	  that	  inhibition	  of	  transcription	  induces	  p53-­‐mediated	  apoptosis.	  Furthermore,	  a	  separate	   study	   with	   another	   CDK7	   inhibitor,	   xylocydine	   exhibits	   similar	   p53	  induction	   in	   the	   human	   hepatocellular	   carcinoma	   cell	   line	   HepG2	   and	   also	  illustrates	   a	   protein	   expression	   profile	   comparable	   to	   the	   studies	   undertaken	  with	  BS181	  (Cho,	  Lee	  et	  al.	  2009).	  	  	  As	   to	   the	  regulation	  of	  CTD	  activating	  CDK	  complexes,	  we	  know	  that	  CDK1	  can	  inhibit	  TFIIH	  activity	  by	  phosphorylating	  both	  CDK7	  and	  p62	  of	  the	  core	  complex	  (Long,	   Leresche	   et	   al.	   1998).	   This	   is	   in	   agreement	  with	   a	  marked	   reduction	   in	  transcription	   during	  mitosis	   (Long,	   Leresche	   et	   al.	   1998)	   and	   also	   proves	   that	  cell	   cycle	  events	  and	   transcription	  are	   spatially	   separated.	  Paradoxically,	   it	   can	  also	  be	  activated	  by	  CDK1	  and	  CDK2	  as	  previously	  discussed	  (Garrett,	  Barton	  et	  al.	  2001).	  For	  CDK9	  (P-­‐TEFb)	  however,	  it	  is	  unclear	  whether	  a	  bona	  fide	  activator	  actually	  exists	   in	  humans.	  Despite	   the	  yeast	  orthologue	  of	  CDK7	  possessing	  the	  ability	  to	  phosphorylate	  (and	  activate)	  CDK9,	  no	  such	  mechanism	  has	  as	  yet	  been	  reported	   in	   mammals	   (Fisher	   2005).	   Finding	   the	   mechanism(s)	   that	   lead	   to	  CDK9	   activation	   in	   humans	   could	   prove	   an	   important	   step	   for	   future	  therapeutics.	  
1.2.3	  Other	  CDK7	  interactions	  CDK7	  phosphorylates	  several	  members	  of	  the	  nuclear	  receptor	  superfamily	  and	  contributes	   to	   their	   function	   by	   doing	   so.	   Phosphorylation	   of	   the	   peroxisome	  proliferator-­‐activated	   receptors	   (PPARs)	  by	  TFIIH	  has	  been	   shown	   to	  promote	  their	  activities	  (Compe,	  Drane	  et	  al.	  2005)	  and	  conversely	  acts	  as	  a	  road	  block	  to	  PPAR-­‐mediated	  adipogenesis	  (Helenius,	  Yang	  et	  al.	  2008).	  Obscure	  though	  they	  are,	   both	   observations	   coincide	   with	   phosphorylation	   of	   Ser	   112	   of	   PPARγ2,	  although	  the	  latter	  (Helenius	  et	  al.	  2008)	  point-­‐out	  that	  the	  former	  study	  (Compe	  et	   al.	   2005)	   reduced	   CDK7	   phosphorylation	   indirectly	   by	  mutation	   of	   the	   XPD	  subunit	  of	  TFIIH.	  This,	  they	  say,	  could	  elicit	  secondary	  responses	  in	  tissues	  other	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than	   adipose	   and	   as	   such	   argue	   that	   it	   is	   ambiguous	   as	   to	   whether	   CDK7-­‐mediated	   phosphorylation	   at	   Ser	   112	   is	   solely	   responsible	   for	   adipogenesis.	  Moreover,	  they	  also	  show	  a	  reduction	  of	  endogenous	  MAT1	  and	  CDK7	  in	  normal	  adipose	  tissue	  and	  demonstrate,	  through	  knockdown	  of	  MAT1	  (and	  concomitant	  loss	  of	  CDK7),	  a	  marked	  reduction	  in	  adipogenic	  potential.	  The	   retinoic	   acid	   receptor	   (RAR)	   is	   posphorylated	   by	   TFIIH	   and	   free	   CAK	  (although	  more	  efficiently	  by	  TFIIH)	  at	  Ser	  77	  and	  Ser	  79	  in	  RARγ1	  and	  Ser	  66	  and	   Ser	   68	   in	   RARγ2	   in	   AF1	   of	   the	   A/B	   domain	  within	   the	   N-­‐terminal	   region	  (Rochette-­‐Egly,	   Adam	   et	   al.	   1997;	   Bastien,	   Adam-­‐Stitah	   et	   al.	   2000).	  Furthermore,	   this	   occurs	   in	   a	   ligand-­‐independent	   manner	   and	   gene	   reporter	  assays	  reveal	   that	   this	  also	  modulates	   its	  gene	   transcription	  potential	   (Bastien,	  Adam-­‐Stitah	   et	   al.	   2000).	   Interaction	   of	   RAR	   is	   thought	   to	   be	   with	   the	   core	  subunits	   of	   TFIIH	   excluding	   p62	   (Bastien,	   Adam-­‐Stitah	   et	   al.	   2000).	   Active	  phosphorylation	  in	  AF1	  is	  thought	  to	  be	  directed	  through	  the	  binding	  of	  cyclin	  H	  to	  AF2	  (Bour,	  Gaillard	  et	  al.	  2005).	  In	  contrast	  to	  RAR,	  phosphorylation	  of	  ERα	  at	  Ser	  118,	  another	  nuclear	  receptor,	  is	   completed	   in	   a	   ligand-­‐dependent	  manner,	   although	   similarities	   exist	   in	   that	  the	   presence	   of	   an	   AF2	  within	   the	   ligand	   binding	   domain	   (LBD)	   is	   needed	   for	  coordinated	   phosphoryation	   (Chen,	   Riedl	   et	   al.	   2000).	   Specifically,	   this	   relies	  upon	   integrity	   of	   helix	   12	   of	   the	   LBD/AF2	   binding	   to	   XPD	   and	   unlike	   RAR,	   is	  mediated	   by	   interaction	   with	   p62	   and	   XPD,	   mutation	   of	   which	   leads	   to	   a	  decrease	   in	   Ser	   118	   phosporylation	   (Chen,	   Riedl	   et	   al.	   2000).	   It	   has	   also	   been	  shown	  that	  Ser	  118	  phosphorylation	  can	  occur	   in	  a	   ligand-­‐independent	   fashion	  but	  this	  is	  controlled	  by	  MAPK	  (Chen,	  Washbrook	  et	  al.	  2002).	  There	  have	  also	  been	  documented	  interactions	  of	  TFIIH	  with	  other	  transcription	  activators:	   for	   example	   E2F-­‐1	   interacts	   with	   TFIIH	   through	   the	   p62	   subunit	  (phosphorylation	   of	   which	   causes	   degradation	   during	   S	   phase),	   Octamer	  transcription	  factors	  through	  MAT1	  (Inamoto,	  Segil	  et	  al.	  1997)	  and	  Ets1,	  whose	  targets	  include	  other	  transcription	  factors	  such	  as	  AP-­‐1,	  NF-­‐КB	  and	  PAX,	  as	  well	  the	  vitamin	  D	  receptor	  (VDR)	  (Vandel	  and	  Kouzarides	  1999;	  Li,	  Pei	  et	  al.	  2000;	  Drane,	  Compe	  et	  al.	  2004).	  It	  is	  interesting	  to	  note	  that	  with	  the	  latter	  example,	  it	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has	   been	   proposed	   that	   because	   VDR	   lacks	   a	   functional	   AF1	   domain,	   Ets1	   can	  substitute	   for	   this	   by	   activating	  VDR	   subsequent	   to	   phosphorylation,	   therefore	  providing	   an	   indirect	   link	   from	   TFIIH	   to	   the	   VDR	   and	   its	   signalling	   pathway	  (Drane,	  Compe	  et	  al.	  2004).	  One	   other	   transcriptional	   regulator	   that	   should	   not	   be	   omitted	   from	   this	  overview	   is	   p53,	   because	   of	   its	   pivotal	   role	   in	  maintaining	   the	   integrity	   of	   cell	  growth,	  (for	  a	  recent	  review	  see	  (Menendez,	  Inga	  et	  al.	  2009)).	  Two	  independent	  reports	  in	  1997	  (Ko,	  Shieh	  et	  al.	  1997;	  Lu,	  Fisher	  et	  al.	  1997)	  implicated	  p53	  as	  a	  new	  substrate	  for	  TFIIH.	  Both	  reports	  draw	  on	  earlier	  studies	  (Xiao,	  Pearson	  et	  al.	   1994;	  Wang,	   Yeh	   et	   al.	   1995;	   Leveillard,	  Andera	   et	   al.	   1996)	   that	   show	  p53	  binding	   to	   XPB,	   XPD	   and	   p62	   of	   the	   core	   TFIIH	   and	   used	   these	   findings	   to	  investigate	  whether	  CDK7	  could	  use	  p53	  as	  a	  substrate.	  Both	  groups	  went	  on	  to	  show	  this	  was	  the	  case	  and	  indicate	  MAT1	  as	  a	  critical	  stabilising	  or	  enhancing	  factor	  for	  sequence-­‐specific	  phosphorylation	  of	  p53	  and	  as	  such	  propose	  a	  model	  which	  couples	  p53	  activation	  with	  DNA	  repair.	  In	  yet	  a	  further	  twist	  to	  the	  story,	  another	  group	  published	  data	  soon	  after,	  showing	  that	  p53	  can	  in	  fact	  bind	  cyclin	  H	  both	  in	  vivo	  and	  in	  vitro	  and	  abrogate	  CAK	  phosphorylation	  of	  cell	  cycle	  CDK’s	  and	  the	  CTD	  of	  RNAPII	  (Schneider,	  Montenarh	  et	  al.	  1998).	  This	  report	  showed	  only	   weak	   phosphorylation	   of	   WT	   p53	   and	   did	   not	   link	   p53	   phosphorylation	  with	  its	  activation.	  	  
1.3	  CDKs	  and	  cancer	  CDK	  activity	  is	  increased	  in	  proliferative	  disorders	  owing	  to	  the	  frequent	  overexpression	  of	  their	  positive	  regulators	  and	  frequent	  inactivation	  of	  endogenous	  inhibitors	  like	  members	  of	  the	  INK4	  family	  (additionally,	  see	  section	  1.4	  for	  a	  summary	  of	  endogenous	  CDK	  inhibitors).	  Abnormal	  CDK	  activity	  has	  also	  been	  reported	  in	  viral	  infections,	  neurodegenerative	  disorders	  such	  as	  Alzheimer’s	  and	  Parkinson’s	  disease,	  ischemia	  and	  traumatic	  brain	  injury.	  In	  this	  section,	  I	  introduce	  the	  studies	  that	  support	  a	  correlation	  between	  aberrant	  CDK	  activity	  and	  cancer	  and	  then	  focus	  on	  CDK7,	  considering	  its	  potential	  as	  a	  therapeutic	  target	  and	  address	  some	  of	  the	  concerns	  and	  caveats	  associated	  with	  this.	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1.3.1	  Association	  of	  CDKs	  with	  specific	  cancers	  
	  Although	   CDKs	   are	   rarely	   mutated	   in	   cancer	   themselves,	   several	   studies	   have	  shown	   some	   association.	   CDK4	   amplification	   has	   been	   shown	   in	   sporadic	   and	  familial	  melanoma,	   glioma,	   osteosarcoma	  and	   cancers	  of	   the	  breast	   and	  uterus	  for	   instance	   (Ortega,	   Malumbres	   et	   al.	   2002;	   Vermeulen,	   Van	   Bockstaele	   et	   al.	  2003).	  In	  familial	  melanoma,	  a	  germline	  mutation	  in	  the	  p16INK4A	  binding	  domain	  in	   100%	  of	   patients	   tested,	   rendered	   it	   resistant	   to	   physiological	   inhibition	   by	  the	  p16	  (Zuo,	  Weger	  et	  al.	  1996).	  Furthermore,	  another	  study	  (Smalley,	  Xiao	  et	  al.	  2009)	   identified	   that	   in	  a	   substantial	   group	  of	   sporadic	  melanomas	   that	  did	  not	   harbour	   the	   commonly	   mutated	   BRAF	   or	   NRAS	   oncogenes,	   CDK4	   was	  overexpressed.	   Chromosomal	   translocations	   and	   gene	   amplification	   of	   CDK6	  have	   also	   been	   associated	   with	   tumour	   development	   including	   lymphomas,	  squamous	   cell	   carcinoma	   and	   glioma	   (Ortega,	   Malumbres	   et	   al.	   2002;	   Wang,	  Zheng	   et	   al.	   2012)	   and	   recently	   in	   bladder	   cancer,	   where	   it	   was	   proposed	   to	  serve	  as	  a	  biomarker	  (Wang,	  Zheng	  et	  al.	  2012).	  	  Given	  the	  optimal	  position	  that	  CDK4/6	  occupies	  in	  the	  cell	  cycle,	  the	  RB	  signal	  axis	   it	   operates	   within	   and	   its	   association	   with	   cyclin	   D1,	   it	   is	   perhaps	  unsurprising	   that	   activating	  mutations	   are	   associated	  with	   such	   a	   spectrum	   of	  cancers.	   Indeed,	   aberrant	   cyclin	   D1	   overexpression	   is	   well	   documented	   B-­‐cell	  malignancies,	   breast,	   esophageal,	   bladder,	   lung	   and	   squamous	   cell	   carcinomas	  (Vermeulen,	  Van	  Bockstaele	  et	  al.	  2003).	  However,	  CDK1	  and	  2	  have	  also	  been	  shown	   to	   be	   over	   expressed	   in	   a	   subset	   of	   colon	   cancers	   and	   CDK5,	   which	   is	  associated	  with	  metastases	  in	  pancreatic	  cancer	  (Feldmann,	  Mishra	  et	  al.	  2010),	  was	   shown	   to	   be	   amplified	   and	   overexpressed	   in	   pancreatic	   cancer	   and	  migration	  and	   invasion	  was	   inhibited	  by	  roscovitine	  treatment	   in	  vitro	  (Eggers,	  Grandgenett	  et	  al.	  2011).	  CDK7	   expression	   is	   not	   thought	   to	   deviate	   significantly	   between	   tumour	   cells	  and	  normal	  cells	  although	   in	  one	  study	   (Ying	  Z	  et	  al	  2009)	  a	  potential	  positive	  correlation	   was	   found	   between	   cyclinH/CDK7	   expression	   and	   ovarian	   cancer	  staging.	  This	  example	  aside,	  evidence	  for	  CDK7	  being	  directly	  correlated	  is	  scant,	  however,	  its	  pivotal	  position	  at	  the	  confluence	  of	  two	  major	  cellular	  growth	  and	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survival	  processes,	  makes	  it	  a	  potential	  anti-­‐cancer	  target	  and	  as	  such	  warrants	  further	  investigation.	  
	  
1.3.2	  CDK7	  function	  in	  cancer	  
	  Normal	  function	  of	  CDK7,	  as	  we	  have	  seen	  constitutes	  the	  kinase	  portion	  of	  free	  CAK	  and	  TFIIH	  to	  orchestrate	  events	  in	  the	  cell	  cycle	  and	  in	  RNAPII	  transcription	  as	  well	  as	  activate/repress	  several	  other	   targets	   such	  as	  nuclear	   receptors	  and	  other	  transcription	  factors.	  However	  the	  implications	  of	  these	  cellular	  processes	  very	  much	  depend	  on	   the	   integrity	  of	   other	   signalling	   cascades	   and	   regulatory	  signals.	  Given	  the	  central	  roles	  CDK7	  has	  in	  maintaining	  cell	  growth,	  it	  could	  be	  seen	  as	  a	  double-­‐edged	  sword.	  It	   is	   important	  to	  note	  that	  CDKs	  themselves	  are	  infrequently	  mutated	  and	  that	  deregulation	  of	  CDK	  activity	  normally	   arises	   through	   cyclin	  over-­‐expression	  or	  silencing	   of	   endogenous	   CDK	   inhibitors	   (CKIs)	   through	  mutation	   or	   epigenetic	  mechanisms	  (Malumbres	  and	  Barbacid	  2001).	  This	  can	  lead	  to	  uncontrolled	  cell	  growth.	   For	   example,	   constitutive	   expression	   of	   cyclin	   D	   through	   aberrant	  mitogenic	   induction	   can	   lead	   to	   the	   cell	   cycle	   permanently	   cycling	   through	  activation	   of	   CDKs	   4	   and	   6,	   and	   subsequently	   CDK2/cyclinE.	   Indeed	   many	  cancers	  have	  elevated	  levels	  of	  cyclin	  D1	  (Bartkova,	  Lukas	  et	  al.	  1995;	  Bartkova,	  Lukas	  et	  al.	  1996).	  CDK7	  is	  different	  in	  this	  respect	  because	  it	  is	  not	  induced	  by	  this	   signalling	   cascade	   in	   the	   same	   way	   that	   classical	   cell	   cycle	   CDKs	   are	   and	  cyclin	  H	  or	  MAT1	  don’t	  appear	  to	  oscillate	  during	  the	  cell	  cycle	  (Fisher	  2005).	  In	  fact	  the	  mRNA	  levels	  of	  CDK7	  appear	  constant	  (Levedakou,	  He	  et	  al.	  1994)	  and	  the	  protein	  is	  stable	  for	  more	  than	  16hrs	  in	  Xenopus	  (Brown,	  Jones	  et	  al.	  1994).	  Instead,	  its	  enhanced	  activity	  is	  regulated,	  as	  we	  have	  already	  seen,	  indirectly	  by	  cyclins	   via	   phosphorylation	   by	   CDK2	   or	   CDK1	   and	   endogenous	   CKIs	  (Senderowicz	  2003;	  Lolli	  and	  Johnson	  2005).	  T-­‐loop	  phosphorylation	  and	  MAT1	  association	   both	   stabilise	   the	   complex	   and	   increase	   its	   specificity	   (Larochelle,	  Chen	   et	   al.	   2001).	   Thus	   CAK	   activity	   remains	   constant	   whilst	   cells	   are	   cycling	  (Lolli	  and	  Johnson	  2005)	  and	  data	  suggests	  this	  to	  be	  the	  case	  even	  in	  a	  quiescent	  state	   (Bartkova,	   Zemanova	   et	   al.	   1996).	   CDK7,	   though	   not	   implicated	   in	   cell	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transformation	   or	   cancer	   growth	   per	   se,	   was	   shown	   to	   be	   slightly	   elevated	   in	  cancer	   cells	  when	   compared	   to	  normal	   cells	   (Bartkova,	   Zemanova	  et	   al.	   1996).	  One	  might	  expect	  such	  modest	  increments	  as	  a	  consequence	  of	  up-­‐regulation	  of	  cell	  cycle	  intrinsic	  CDKs,	  particularly	  CDK1/2.	  	  The	   ubiquity	   of	   CDK7	   presence	   and	   activity	   and	   its	   role	   in	   the	   cell	   cycle	   and	  transcription	  makes	  it	  an	  ideal	  drug	  target.	  In	  principle,	  it	  could	  be	  a	  better	  target	  than	  intrinsic	  cell	  cycle	  CDKs	  because	  of	  the	  functional	  redundancy	  they	  seem	  to	  possess	  (Malumbres,	  Pevarello	  et	  al.	  2008).	  For	  example,	  cells	  without	  CDK2	  can	  still	   cycle	   (Sherr	   and	   Roberts	   2004)	   and	   CDK2	   null	   mice	   are	   viable	   (Berthet,	  Aleem	  et	  al.	  2003).	  Conversely,	  mice	   lacking	  MAT1	  are	  unable	   to	  enter	  S	  phase	  and	   have	   defective	   RNAPII	   activity	   (Rossi,	   Londesborough	   et	   al.	   2001),	  highlighting	  the	  critical	  need	  for	  CAK	  activity.	  In	  ER-­‐positive	  breast	  cancer,	  it	  is	  a	  particularly	  attractive	   target	  given	   its	   ability	   to	  activate	  ERα	   (Chen,	  Riedl	   et	   al.	  2000;	   Chen,	   Washbrook	   et	   al.	   2002).	   Two	   recent	   studies	   show	   how	   selective	  inhibition	  of	  CDK7	  (Ali,	  Heathcote	  et	  al.	  2009)	  and	  CDK7	  and	  CDK9	  (Cho,	  Lee	  et	  al.	   2009)	   lead	   to	   apoptosis	   and	   inhibition	   of	   tumour	   xenograft	   growth,	  illustrating	  the	  potential	  of	  CDK7	  inhibition	  in	  cancer	  therapy.	  However,	   the	   inhibition	   of	   CDK7	  may	   carry	   risks	   too;	   its	   ubiquity	   and	  mutual	  dependence	   for	   both	   cancerous	   and	   normal	   cells	   could	   make	   inhibition	   toxic,	  thereby	   underlining	   the	   importance	   for	   creating	   highly	   specific	   drugs,	   so	   that	  minimal	   concentrations	   can	   be	   used.	   Another	   consideration	   is	   that	   some	  of	   its	  targets	  are	  also	  pro-­‐apoptotic	  such	  as	  p53	  (Ko,	  Shieh	  et	  al.	  1997;	  Lu,	  Fisher	  et	  al.	  1997).	  In	  addition,	  if	  TFIIH/CAK	  turns	  out	  to	  be	  indispensible	  for	  the	  recruitment	  of	   p53	   for	   NER	   then	   this	   could	   pose	   a	   problem	   if	   CDK7	   becomes	   a	   target	   for	  anticancer	  therapy.	  	  	  	  	  
1.4	  CDK	  inhibitors	  
	  CDK	   inhibitors	   (CKIs)	   keep	   the	   cell	   cycle	   in	   check	   and	   fall	   into	   two	   categories	  based	   on	   the	   CDK	   they	   inhibit.	   The	   INK4	   class,	  which	   inhibit	   CDK4	   and	   CDK6,	  typified	  by	  p16INK4a	  and	  p15INK4b	  bind	  exclusively	  to	  CDK4/6,	  whereas	  the	  more	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promiscuous	  CIP/KIP	   inhibitors,	   such	  as	  p21cip1	   and	  p27kip1,	  bind	   to	  cyclin	  D,	  E	  and	  A-­‐dependent	  CDKs	  (Sherr	  and	  Roberts	  1999).	  	  CKIs	  block	  activation	  of	  CDKs	  by	  causing	  conformational	  changes	  rendering	  their	  activation	  site	  inaccessible	  to	  CAK,	  or	  by	  preventing	  the	  obligate	  binding	  of	  their	  regulaory	   cyclin	   (Lolli	   and	   Johnson	   2005).	   For	   INK4	   type	   CKIs,	   repression	  commences	   by	   binding	   to	   the	   putative	   cyclin	   D	   binding	   site	   on	   CDK4/6	   and	  blocking	   their	   interaction;	   CIP/KIP	   CKIs	   on	   the	   other	   hand	   bind	   to	   preformed	  CDK/cyclin	  complexes	  (Obaya	  and	  Sedivy	  2002).	  Regulation	  of	  CKIs,	  which	  are	  at	  high	  levels	  in	  quiescent	  cells,	  is	  abrogated	  by	  the	  onset	   of	   cell	   cycle	   entry	   through	   mitotic	   stimulation.	   In	   the	   same	   way	   that	  CDK4/6/cyclin	   D	   initiate	   phosphorylation	   of	   the	   RB	   proteins	   during	   G1	   entry,	  equally	   as	   important	   is	   its	   sequestration	   of	   the	   CDK2/cyclin	   E	   inhibitor	   p27,	  which	   allows	   the	   complex	   to	   finish	   phosphorylation	   (Obaya	   and	   Sedivy	   2002).	  Interestingly,	  this	  mechanism	  is	  proposed	  to	  be	  enhanced	  by	  the	  proto-­‐oncogene	  c-­‐MYC	   (Perez-­‐Roger,	   Kim	   et	   al.	   1999).	   Therefore	   inactivation	   of	   CKIs	   either	  through	   attenuation	   by	   endogenous	   proteins,	   aberrant	   methylation	   (Merlo,	  Herman	   et	   al.	   1995),	   viral	   inactivation	   (Bulavin,	   Tararova	   et	   al.	   1999)	   or	  increased	   degradation	   by	   the	   ubiquitin/proteasome	   pathway	   can	   lead	   to	   cell	  transformation.	  	  
1.5	  Synthetic	  inhibitors	  
	  In	   an	   effort	   to	   synthesise	   small	  molecule	   CDK	   inhibitors,	   two	  major	   categories	  have	   been	   developed:	   direct	   inhibitors,	   which	   can	   be	   considered	   as	   ATP	  analogues	  are	  directed	  at	  the	  ATP	  binding	  site	  and	  are	  exemplified	  by	  drugs	  such	  as	   flavopiridol	  or	  roscovitine.	   In	  contrast,	   indirect	   inhibitors	  affect	  CDK	  activity	  by	  acting	  on	  upstream	  targets.	  Of	   the	   former	  group,	  one	  can	   further	  categorise	  them	  based	  on	  whether	  they	  target	  cell	  cycle	  or	  transcriptional	  CDKs.	  Cell	  cycle	  specific	   inhibitors	   typically	   target	   CDK4/6,	   for	   example	   PD0332991,	   which	   is	  specific	  for	  CDK4/	  cyclin	  D1	  and	  CDK6/cyclin	  D2,	  causes	  G1	  arrest	  and	  reduction	  of	  RB	  phosphorylation	  at	  Ser	  780	  and	  Ser	  795,	  consistent	  with	  CDK4	  inhibition	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(Toogood,	   Harvey	   et	   al.	   2005)	   and	   also	   shows	   tumour	   regression	   in	   xenograft	  models	   (Fry,	  Harvey	  et	  al.	  2004).	  Another	  drug,	  olomoucine	  specifically	   targets	  CDK2	  and	  leads	  to	  G1	  arrest	  (Alessi,	  Quarta	  et	  al.	  1998).	  Most	  pertinent	  to	  the	  present	  research	  are	  transcriptional	  CDK	  inhibitors,	  which	  primarily	   target	   CDK7	   and	   CDK9.	   The	   action	   of	   drugs	   such	   as	   flavopiridol	   or	  roscovitine	  lead	  to	  cellular	  changes	  that	  indicate	  a	  subsequent	  down-­‐regulation	  of	   transcriptional	   activity,	   as	   well	   as	   cell-­‐cycle	   disruption.	   These	   are	   potent	  inhibitors	  of	  cancer	  cell	  growth	  and	  as	  such	  have	  been	  tested	  in	  several	  phase	  1	  and	   phase	   2	   clinical	   trials	   either	   on	   their	   own	   or	   in	   combination	   with	  chemotherapeutics	   (Benson,	   White	   et	   al.	   2006;	   El-­‐Rayes,	   Gadgeel	   et	   al.	   2006;	  Fornier,	   Rathkopf	   et	   al.	   2007;	   Carvajal,	   Tse	   et	   al.	   2009).	   Flavopiridol,	   the	   first	  CDK	   inhibitor	   to	   enter	   clinical	   trials,	   has	   been	   involved	   in	   over	   50	   trials.	  However,	  results	  so	  far	  have	  been	  mixed.	  	  Flavopiridol	   differs	   from	   roscovitine	   in	   that	   it	   is	  more	   selective	   for	   CDK9	   than	  any	  other	  inhibitor	  and	  as	  a	  consequence	  it	  primarily	  inhibits	  transcription,	  such	  that	   mRNAs	   of	   anti-­‐apoptotic	   proteins	   and	   some	   transcription	   factors	   that	  display	  short	  half-­‐lives	  are	  quickly	  degraded	  (Shapiro	  2006).	  Roscovitine	  on	  the	  other	  hand	  shows	  selective	  inhibition	  of	  CDK2	  and	  CDK7	  and	  CDK9,	  with	  cellular	  changes	   reflecting	   this	   (Shapiro	   2006).	   In	   addition,	   roscovitine	   exhibits	  pleiotropic	   effects	   causing	  apoptosis	   through	  p53	  and	  NF-­‐кB	   (Dey,	  Wong	  et	   al.	  2008;	   Wesierska-­‐Gadek,	   Hajek	   et	   al.	   2008),	   as	   well	   as	   activating	   the	   MAPK	  pathway	  (Whittaker,	  Walton	  et	  al.	  2004).	  It	  is	  serendipitous	  that	  these	  off-­‐target	  effects	  also	  attenuate	  proliferation.	  	  It	   is	  convenient	   to	  consider	  synthetic	   inhibitors	  by	   their	  scope	  of	  action:	  Broad	  range	   (targeting	   several	   CDKs)	   and	   selective	   inhibitors	   and	   traditionally,	   the	  various	   chemical	   nuances	   of	   compound	   structure	   have	   been	   described	   in	   this	  context.	  However	  I	  will	  attempt	  to	  describe	  several	  compounds	   in	  an	  historical	  context	   as	   to	   remain	   in	   keeping	  with	   the	   chronology	   of	   inhibitor	   development	  and	  the	  treatment	  landscape	  in	  which	  they	  currently	  reside.	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1.5.1	  Flavopiridol	  
	  The	   first	   generation	   of	   CDK	   inhibitors	   are	   typified	   by	   flavopiridol	   and	  roscovitine,	  which	  have	  a	  broad	  spectrum	  of	  activity.	  Flavopiridol	  was	   the	   first	  compound	   to	   be	   entered	   into	   clinical	   trials,	   based	   on	   the	   efficacy	   of	   its	   pre-­‐clinical	  data.	  As	  such,	  the	  observations	  have	  given	  us	  some	  insight	  into	  its	  mode	  of	  action.	  Flavopiridol	   is	   a	   plant-­‐based	   flavanoid	   derived	   from	   an	   alkaloid	   isolated	   from	  
Dysoxylum	   binectariferum,	   a	   plant	   indigenous	   to	   India	   identified	   for	   its	   anti-­‐inflammatory	   properties	   (Naik	   et	   al	   1988)	   and	   attracted	   subsequent	   interest	  because	  of	   its	  reported	  anti-­‐tumourgenic	  properties	  (Kaur,	  Stetler-­‐Stevenson	  et	  al.	  1992).	  Flavopiridol	  works	  by	  competitively	  inhibiting	  ATP	  binding	  to	  the	  CDK	  active	  sight,	  which	  was	  initially	  reported	  for	  CDKs	  2	  and	  4	  (Carlson,	  Dubay	  et	  al.	  1996;	   De	   Azevedo,	   Mueller-­‐Dieckmann	   et	   al.	   1996)	   and	   CDK1	   (Losiewicz,	  Carlson	  et	  al.	  1994)	  but	  was	  later	  confirmed	  also	  to	  occlude	  ATP	  from	  the	  active	  site	   of	   CDK9	   (Filgueira	  W	  et	   al.	   2002)	   although	   this	   is	   not	   thought	   to	   be	   in	   an	  ATP-­‐dependent	   manner	   since	   kinetically,	   inhibition	   of	   CDK9	   best	   fits	   an	  uncompetitive	  model	   (Chao,	   Fujinaga	   et	   al.	   2000).	   This	  may,	   in	   part	   be	   due	   to	  how	  tightly	  the	  inhibitor	  is	  able	  to	  bind	  to	  the	  active	  site	  of	  CDK9	  (Chao	  and	  Price	  2001).	  It	  is	  now	  generally	  accepted	  that	  it	  inhibits	  CDKs	  1,	  2	  and	  4/6	  at	  ≤	  100nm	  in	  the	  following	  IC50	  ranges:	  CDK	  1	  (30-­‐400nm),	  2	  (100nm),	  4/6	  (20-­‐60nm)	  and	  CDK7	   (100-­‐300nm)	   (Sedlacek	  2001)	   and	   is	  most	  potent	   against	  CDK9	   (~3nm)	  (Chao,	  Fujinaga	  et	  al.	  2000).	  A	  comparison	  between	  flavopiridol	  and	  another	  CDK	  inhibitor	   SNS-­‐032	   echoed	   these	   IC50	   ranges	   and	   highlighted	   the	   selectivity	   of	  flavopiridol	  for	  CDK9	  (Hawtin	  E	  et	  al.	  2007).	  Its	  recognised	  potential	  as	  an	  anti-­‐cancer	  agent	  in	  pre-­‐clinical	  studies	  meant	  that	  flavopiridol	   became	   the	   first	   intentional	   CDK	   inhibitor	   to	   enter	   clinical	   trials	  (Senderowicz,	  Headlee	  et	  al.	  1998).	  Laboratory	  studies	   indicate	   it	  has	  a	  host	  of	  desirable	  cellular	  effects	  consistent	  with	  the	  CDKs	  it	  inhibits:	  positive	  regulation	  of	   apoptosis,	   cell	   growth	   cessation,	   a	   reduction	   of	   labile	  mRNAs	   such	   as	   cyclin	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D1,	  anti-­‐angiogenic	  properties,	  cell	  cycle	  blockage	  at	  G1/S	  and	  G2/M	  boundaries	  and	  only	  moderate	  side	  effects	  in	  early	  human	  studies	  (Senderowicz,	  Headlee	  et	  al.	  1998;	  Senderowicz,	  Reid	  et	  al.	  1999).	  However,	  further	  laboratory	  and	  clinical	  studies	  better	  defined	   its	  mode	  action	  and	  highlighted	   its	   therapeutic	  potential	  as	  well	  as	  its	  shortcomings.	  	  Despite	  encouraging	  pre-­‐clinical	  data	  and	  early	  clinical	   tolerability,	   flavopiridol	  has	  had	  mixed	  success	  in	  clinical	  trials	  and	  is	  as	  much	  to	  do	  with	  histology	  as	  it	  is	  with	   dose	   schedule	   choice.	   For	   instance,	   early	   clinical	   trials	   delivering	  continuous	  intravenous	  infusions	  (CIVI),	  which	  lead	  to	  nM	  serum	  concentrations	  of	  the	  drug,	  prompted	  the	  development	  of	  bolus	  infusions,	  which	  are	  thought	  to	  be	   more	   effective	   in	   maintaining	   higher	   plasma	   levels	   (Shapiro	   2004).	   The	  inability	   of	   CIVI	   scheduling	   to	   maintain	   apoptosis-­‐inducing	   concentrations	   is	  thought	  to	  be	  due	  to	  increased	  plasma	  protein	  binding	  (Byrd,	  Lin	  et	  al.	  2007)	  and	  studies	   confirming	   this	   (Shapiro,	   Supko	   et	   al.	   2001)	   facilitated	   a	  move	   toward	  shorter	   drug	   infusions.	   There	   has	   also	   been	   a	   trend	   in	   combining	   flavopiridol	  with	   other	   chemotherapeutic	   agents	   in	   recent	   years,	   making	   way	   for	   novel	  regimens	  usually	   including	  a	  30	  minute	  or	  1	  hour	  bolus	  delivery	   followed	  by	  a	  longer	   continuous	   infusion	   of	   flavopiridol	   (Lin,	   Ruppert	   et	   al.	   2009;	   Rathkopf,	  Dickson	  et	  al.	  2009;	  Blum,	  Phelps	  et	  al.	  2010;	  Dickson,	  Shah	  et	  al.	  2010;	  Holkova,	  Perkins	  et	  al.	  2011;	  Karp,	  Smith	  et	  al.	  2011).	   In	  haematological	  malignancies	  at	  least,	  flavopiridol	  has	  had	  substantial	  success	  (Byrd,	  Lin	  et	  al.	  2007;	  Lin,	  Ruppert	  et	  al.	  2009;	  Holkova,	  Perkins	  et	  al.	  2011;	  Karp,	  Smith	  et	  al.	  2011)	  but	  only	  limited	  success	   in	   solid	   tumours,	   although	   bolus	   infusion	   in	   a	  mixed	   regimen	  has	   also	  had	   limited	   success	   in	   advanced	   solid	   tumours	   (Rathkopf,	  Dickson	   et	   al.	   2009;	  Dickson,	   Shah	   et	   al.	   2010).	   Of	   note,	   this	   style	   of	   combined	   therapy	   achieved	  complete	  responses	  in	  a	  phase	  I	  trial	  in	  patients	  with	  recurrent/refractory	  B	  cell	  neoplasms	   (Holkova,	  Perkins	   et	   al.	   2011)	   complete	   remission	   in	   some	  patients	  with	  acute	  leukemias	  (Karp,	  Smith	  et	  al.	  2011)	  and	  a	  53%	  overall	  response	  in	  a	  phase	   II	   study	   of	   patients	   with	   CLL	   (Lin,	   Ruppert	   et	   al.	   2009).	   Dose	   limiting	  toxicities	   in	   most	   phase	   I	   studies	   tend	   to	   be	   leukopenia,	   lymphopenia,	  neutropenia	  and	  fatigue.	  The	  relative	  success	  seen	  in	  tumours	  of	  hematopoietic	  origin	  may	  largely	  be	  due	  to	  their	  dependency	  on	  labile	  transcripts	  for	  survival.	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Cells	   of	   hematopoietic	   origin	  were	   shown	   to	   be	  more	   sensitive	   to	   flavopiridol-­‐induced	  apoptosis	  without	  cell-­‐cycle	  arrest	  or	  p53	  induction	  (Parker,	  Kaur	  et	  al.	  1998).	   Since	   these	   cells	   are	   not	   actively	   cycling,	   apoptosis	   is	   thought	   to	   be	  mediated	   through	   CDK9	   inhibition	   which	   accounts	   for	   the	   loss	   of	   short-­‐lived	  transcripts	  such	  as	  cyclin	  D1	  and	  MCL-­‐1	  that	  confer	  a	  survival	  advantage	  (Chen,	  Keating	  et	  al.	  2005),	  whereas	  in	  actively	  cycling	  solid	  tumour	  cell	  lines	  it	  leads	  to	  cell	   cycle	   arrest	   at	   G1	   and	   G2	   phases	   –	   consistent	   with	   the	   CDKs	   it	   inhibits	  (Shapiro	  2004),	  thus	  leading	  to	  cytostatic	  growth	  arrest.	  Much	  of	  this	  knowledge	  has	   proved	   to	   be	   the	   rationale	   behind	   some	   of	   the	   combined	   regimens	   with	  chemotherapeutics	  able	  to	  impose	  S	  phase	  delay	  such	  as	  cisplatin	  or	  gemcitibine	  since	  it	  was	  observed	  that	  cells	  in	  the	  S	  phase	  are	  more	  sensitive	  to	  flavopiridol	  (Matranga	   and	   Shapiro	   2002).	   Apoptosis	   is	   then	   thought	   to	   proceed	   through	  perturbation	  of	  the	  RB-­‐E2F	  axis	  (Shapiro	  2004).	  	  	  In	   solid	   tumour	   cell	   lines,	   where	   flavopiridol	   is	   thought	   to	   work	   through	   cell	  cycle	  arrest,	  apoptosis	  is	  widely	  acknowledged	  to	  be	  p53	  independent	  (Shapiro	  et	   al	   1999).	   However,	   there	   is	   evidence	   of	   flavopiridol	   working	   in	   a	   p53-­‐dependent	  manner	  which	  was	  shown	  in	  the	  isogenic	  HCT116	  pair	  following	  the	  TOPO	  poison	  CPT-­‐11	  treatment	  (Ambrosini	  et	  al	  2008)	  following	  a	  phase	  I	  report	  in	  solid	  tumours	  (Shah	  Clin	  Canc	  Res	  2005).	  Moreover,	  other	  studies	  suggests	  a	  critical	   dose	   exists,	   above	  which	   p53	   status	   becomes	   the	  main	   determinant	   of	  apoptosis	  (Blagsklonny	  et	  al	  2002;	  Demidenko	  2004).	  	  	  
1.5.2	  Roscovitine	  
	  Roscovitine	   is	   a	   purine	   analogue	   and	   together	   with	   olomoucine,	   purvalanol	   A	  and	  B	  as	  well	  as	  several	  other	  purine	  analogues,	  comprise	  a	  group	  of	  relatively	  specific	   CDK	   inhibitors.	   The	   development	   of	   this	   group	   was	   based	   largely	   on	  natural	   plant	   hormones	   such	   as	   dimethylaminopurine,	   which	   was	   initially	  identified	  for	  anti-­‐CDK1	  activity	  although	  was	  non-­‐specific	  in	  this	  regard	  (Meijer	  and	   Pondaven	   1988).	   Subsequent	   screening	   efforts	   found	   that	   olomoucine,	   a	  chemically	  synthesised	  cytokinin	  analogue	  was	  highly	  specific	  for	  CDK1,	  2	  and	  5	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and	   inhibited	   cell	   proliferation	   in	   tumour	   cells	   (Crews	   and	   Shotwell	   2003;	  Vermeulen,	   Van	   Bockstaele	   et	   al.	   2003)	   however,	   larger	   screens	   of	   cytokinin	  analogues	   revealed	   roscovitine	   had	   a	   much	   more	   potent	   inhibition	   for	   CDK1	  (Vermeulen,	  Van	  Bockstaele	  et	  al.	  2003).	  Roscovitine	  was	  shown	  to	  be	  a	  selective	  inhibitor	   of	   CDKs	   1,	   2	   and	   5	   (IC50	   <1µM)	   as	   well	   as	   having	   some	   selectivity	  towards	   erk1	   and	   2	   (IC50	   <50µM)	   but	   inhibits	   CDK4/6	   at	   a	   concentration	  >100µM	   (Meijer	   et	   al	   1997).	   Nowadays,	   it	   is	   widely	   acknowledged	   that	  roscovitine	  works	  by	  exerting	   its	  effects	   specifically	  on	  CDK2-­‐cyclin	  E/A,	  CDK7	  and	  CDK9	  and	  acts	  at	  the	  G1/S	  checkpoint	  of	  the	  cell	  cycle.	  	  Currently,	   roscovitine	   is	   undergoing	   phase	   I	   trials	   in	   combination	   with	   other	  drugs	   for	   solid	   tumours	   (NCT01333423	  and	  NCT00999401)	  and	  has	  also	  been	  examined	   in	   a	   phase	   II	   trial	   for	   non	   small	   cell	   lung	   cancer	   although	   this	   was	  subsequently	   terminated	   (NCT00372073).	   When	   administered	   in	   combination	  with	   gemcitabine	   and	   cisplatin,	   roscovitine	   lead	   to	   six	  partial	   responses,	   seven	  stable	  disease	  and	  one	  progressive	  disease	  amongst	  14	  patients	  of	   the	  phase	   II	  trial	  (Siegel-­‐Lakhai	  et	  al	  2005).	  The	  combination	  of	  these	  drugs	  is	  thought	  to	  act	  dually	   at	   the	   G1/S	   phase	   checkpoint	   (roscovitine)	   and	   during	   S	   phase	  (gemcitabine	   and	   cisplatin).	   Moreover,	   separate	   data	   also	   suggests	   it	   may	   be	  efficacious	   in	  myleloma	   through	   down-­‐regulation	   of	  MCL-­‐1	   (Raje,	   Kumar	   et	   al.	  2005).	  	  
1.5.3	  Other	  CDK	  inhibitors	  currently	  in	  clinical	  trials	  
	  The	  majority	  of	  other	  compounds	  are	  in	  phase	  I	  clinical	  trials	  for	  advanced	  and	  refractory	   solid	   tumours	   and	  myeloid	   tumours	   (Lapenna	   and	   Giordano	   2009).	  Some	  of	  these	  have	  been	  used	  extensively	  in	  pre-­‐clinical	  investigations	  and	  show	  substantial	  anti-­‐tumour	  activity,	  with	  high	  selectivity	  against	  several	  CDKs.	  Most	  notably,	   SNS-­‐032	   (Sunesis),	   which	   inhibits	   CDK2,	   7	   and	   9	   and	   potentiates	  apoptosis	   in	   CLL	   through	   reduction	   of	   MCL-­‐1	   and	   XIAP	   (Chen,	   Wierda	   et	   al.	  2009)	   has	   been	   studies	   in	   phase	   I	   trials	   of	   advanced	  B-­‐lymphoid	  malignancies	  (NCT00446342)	   and	   solid	   tumours	   (NCT00292864)	   although	   phase	   I	   results	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suggested	  limited	  activity	  in	  patients	  with	  advanced	  CLL	  and	  MM	  (Tong,	  Chen	  et	  al.	  2010).	  R547	  (Hoffmann-­‐La	  Roche),	  an	   inhibitor	  of	  CDK1,	  2,	  4	  and	  7	  has	  also	  been	  investigated	  in	  phase	  I	  trials	  for	  advanced	  solid	  tumours	  (NCT00400296).	  This	   compound	  also	   showed	  promising	  anti-­‐tumour	  activity	   in	  a	  variety	  of	   cell	  lines	  by	  causing	  a	  block	  in	  G1	  and	  G2	  and	  induction	  of	  apoptosis	  and	  importantly,	  this	  was	  independent	  of	  multidrug	  resistance	  and	  p53	  status	  (DePinto,	  Chu	  et	  al.	  2006).	  The	  phase	  I	  study	  reported	  good	  tolerability	  to	  exposures	  of	  pre-­‐clinical	  efficiency	   concentrations	   and	   the	  pharmacodynamic	  marker	  used	   in	   this	   study	  (pRB)	  was	  decreased	  in	  response	  to	  treatment	  (Diab	  S	  et	  al.	  2007).	  	  Few	  compounds	  have	  been	  taken	  through	  to	  phase	  II	  trials	  but	  E7070/indisulam	  (Eisai),	  PD-­‐0332991	   (Pfizer)	  and	  SCH-­‐727965	   (Schering-­‐Plough)	  are	   three	   that	  have	   been	   studied	   in	   this	   context.	   In	   combination	   with	   bortezomib	   and	  dexamethasone	   PD-­‐0332991,	   a	   selective	   inhibitor	   of	   CDK4/6	   was	   tested	   in	  patients	  with	  MM	  (NCT00555906),	  with	  and	  without	  letrozole	  in	  advanced	  ER+	  breast	   cancer	   and	   as	   monotherapy	   in	   advanced	   (stage	   IV)	   NSCLC	  (NCT01291017),	   a	   range	   of	   solid	   tumours	   (NCT01037790),	   Rb+	   glioblastoma,	  recurrent	   ovarian	   cancer	   (NCT015436743)	   and	   in	   HCC	   (NCT01356628).	   The	  majority	   of	   these	   phase	   II	   trials	   continue	   but	   preclinical	   results	   suggest	  favourable	  effects	  in	  human	  xenograft	  mouse	  models,	  where	  in	  Rb+	  cells	  it	  lead	  to	   G1	   arrest	   (Fry,	   Harvey	   et	   al.	   2004).	   Another	   preclinical	   suggests	   selective	  effectiveness	   in	   ER+	   breast	   cancer	   cells	   (Finn,	   Dering	   et	   al.	   2009),	   thus	  potentially	  offering	  a	  patient	  stratification	  approach	  in	  future	  clinical	  trials.	  	  E7070	   (indisulam)	   has	   been	   assessed	   in	   phase	   II	   trials	   as	   monotherapy	   in	  patients	   with	   melanoma	   stage	   IV	   (NCT00014625),	   metastatic	   breast	   cancer	  (NCT00080197),	   RCC	   (NCT00059735),	   gastric	   cancer	   (NCT00165594)	   and	   in	  combination	   with	   irinotecan	   (NCT00165867)	   and	   capecitabine	  (NCT001165854)	   for	  metastatic	   colorectal	   cancer	   and	   in	   for	  metastatic	   breast	  cancer	  (NCT00165880).	  Although	  E7070	  appears	  to	  be	  well	  tolerated	  by	  patients	  (Haddad,	   Weinstein	   et	   al.	   2004;	   Smyth,	   Aamdal	   et	   al.	   2005),	   clinical	   benefits	  appear	   sparse	   although	  post-­‐treatment	  modulation	  of	  Rb	  phosphorylation	  was	  observed	  (Haddad,	  Weinstein	  et	  al.	  2004).	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1.5.4	  Experimental	  CDK	  inhibitors	  
	  Several	  other	  experimental	  drug	  classes	   such	  as	   the	  paullones	  and	   indolinones	  show	  substantial	  anti-­‐CDK	  activity	  but	  have	   thus	   far	  not	  been	   tested	   in	  clinical	  trials.	  Kenpaullone	  was	  discovered	   in	  a	  NCI	  screen	  for	  compounds	  with	  similar	  action	   to	   flavopiridol	  and	  was	  shown	   to	  be	  potently	   selective	  of	  CDK1	  but	  also	  inhibits	   CDK2	   (Zaharevitz,	   Gussio	   et	   al.	   1999).	   	   Indirubin,	   which	   was	   first	  identified	  as	  the	  active	  ingredient	  from	  the	  indigo	  plant	  and	  routinely	  used	  as	  a	  Chinese	   herbal	   remedy	   was	   used	   to	   treat	   CML.	   Along	   with	   its	   synthetic	  analogues,	  it	  has	  been	  shown	  to	  inhibit	  CDK1,	  2,	  4	  and	  5	  (Hoessel,	  Leclerc	  et	  al.	  1999)	   and	   be	   effective	   in	   several	   cancer	   cell	   lines	   including	   colon	   carnicoma	  (Lane,	   Yu	   et	   al.	   2001)	   and	   more	   recently	   glioblastoma,	   where	   it	   blocked	  migration	  and	  angiogenesis	  (Williams,	  Nowicki	  et	  al.	  2011).	  	  
1.5.5	  In-­‐house	  CDK	  inhibitors	  In	  collaboration	  with	  the	  Department	  of	  Chemistry,	  Imperial	  College	  London,	  we	  have	  developed	  a	  panel	  of	  purine	  analogues	  capable	  of	   inhibiting	  several	  CDKs	  (see	  sections	  2.2.14	  and	  2.2.15	  for	  details	  of	  the	  in	  silico	  and	  synthetic	  chemistry	  methods).	   Briefly,	   there	   were	   identified	   following	   in	   silico	   screening	   using	  computer	  aided	  drug	  design	  (CADD),	  in	  which	  roscovitine	  was	  fitted	  to	  the	  CDK2	  and	  CDK7	   structures,	   allowing	   the	   identification	  of	   roscovitine	  moieties	  whose	  alteration	  might	  enhance	  CDK7	  selectivity.	  	  Previously,	  we	   have	   shown	   that	   the	   novel	   small	  molecule	   inhibitor	   BS181	   (fig	  4A)	   is	   selective	   for	  CDK7	  at	   sub-­‐µM	   concentration	   (Ali,	  Heathcote	   et	   al.	   2009).	  This	  potently	  inhibits	  CDK7	  in	  vitro	  (IC50	  =	  21	  nM)	  and	  is	  highly	  selective,	  hence,	  CDK2	  (IC50	  =	  750	  nM)	  was	  inhibited	  35	  times	  less	  potently	  than	  CDK7	  and	  other	  CDKs	  were	   inhibited	  at	  considerably	  higher	   IC50	  values.	  This	  was	  confirmed	  by	  the	   finding	   that	   in	   vivo,	   RNAPII	   CTD	   Ser	   5	   phosphorylation	   was	   more	   greatly	  inhibited	  than	  Ser	  2	  phosphorylation.	   In	  this	  experiment,	  BS181	  was	  compared	  to	  roscovitine,	  which	   illustrated	  a	  higher	  affinity	   for	  CDK9	  inhibition,	  as	   judged	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by	   a	   greater	   decrease	   of	   RNAPII	   CTD	   Ser2	   phosphorylation.	   Additionally,	   cell-­‐cycle	  disruption	  was	  manifested	  in	  RB	  hypophosphorylation.	  	  Our	  screening	  efforts	  have	  yielded	  a	  series	  of	  compounds,	  identified	  in	  the	  same	  way	  including	  another	  interesting	  compound,	  BS194	  (Fig	  4B).	  Whilst	  BS194	  only	  moderately	   inhibited	  CDK7	  (IC50	  =	  250	  nM),	   it	  potently	   inhibits	  CDK2	  (IC50	  =	  3	  nM),	   CDK1	   (IC50	   =	   250	   nM)	   and	   CDK9	   (IC50	   =	   90	   nM)	   (Heathcote,	   Patel	   et	   al.	  2010).	  Moreover,	  BS194	  potently	  inhibited	  the	  growth	  of	  all	  60	  cancer	  cell	  lines	  in	  the	  National	  Cancer	  Institute’s	  panel	  of	  cancer	  cell	  lines.	  Unlike	  BS181,	  which	  stimulates	  apoptosis,	  BS194	  largely	  promotes	  cell	  cycle	  arrest.	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Fig.	  4.	  Chemical	  structure	  of	  in-­house	  CDK	  inhibitors	  BS181	  (A)	  and	  BS194	  (B)	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1.5.6	  Broad-­‐spectrum	  and	  selective	  inhibition	  
	  Alternatively,	  one	  may	  class	  synthetic	  CDK	  inhibitors	  according	  to	  their	  range	  of	  inhibition;	  whilst	  some	  work	  on	  a	  broad	  range	  of	  CDKs,	  others	  are	  selective	  and	  thus	  could	  prove	  indispensible	  in	  the	  clinical	  setting.	  To	  this	  end,	  two	  questions	  that	  need	  to	  be	  addressed	  are	  which	  CDK	  (or	  range	  of	  CDKs)	  represent	  the	  best	  target(s)	  and	  should	  we	  be	  targeting	  several	  with	  a	  pan-­‐inhibitor	  or	  remain	  more	  selective?	  	  Presumably,	   answers	  will	   vary	   according	   to	   the	   individual.	  A	   recent	   review	  on	  the	  subject	  suggests	  that	  due	  to	  the	  lack	  of	  prognostic	  and	  predictive	  biomarkers	  that	  associate	  with	  CDK	  inhibition,	  it	  would	  be	  a	  difficult	  task	  to	  treat	  patients	  in	  this	  way	  and	  as	  such,	  more	  emphasis	  needs	  to	  be	  placed	  on	   learning	  about	   the	  biology	   of	   CDK	   inhibition	   in	   pre-­‐clinical	   models	   (Cicenas	   and	   Valius	   2011).	  However,	  based	  on	  our	  knowledge	  of	  the	  cell	  cycle	  and	  associated	  disease	  states,	  we	  can	  postulate	  that	  being	  selective	  may	  offer	  some	  advantages.	  Since	  CDKs	  operate	  at	  different	  points	  of	  the	  cell	  cycle	  and	  are	  not	  all	  universally	  required	  during	  development	  by	   all	   tissue	   types,	   some	   tumour	   types	   are	  more	  sensitive	   to	   blockade	   of	   CDKs	   than	   others.	   As	   reviewed	   by	   Malumbres	   and	  Barbacid	   (Malumbres	   and	   Barbacid	   2009)	   some	   tumour	   cells	   require	   specific	  CDKs	  for	  proliferation	  and	  the	  use	  of	  mouse	  models	  demonstrate	  that	  different	  CDKs	   are	   required	   at	   different	   stages	   of	   development,	   suggesting	   that	  susceptibility	   of	   tumour	   cells	   to	   CDK	   inhibitors	   may	   be	   defined	   by	   their	  developmental	   origin.	   For	   instance	   colon	   cancer	   cell	   lines	   have	   been	   shown	   to	  proliferate	   in	   the	  absence	  of	  CDK2	  but	   inhibition	  of	  CDK2	   in	  glioblastamas	  and	  osteosarcomas	  prevent	   their	  proliferation	  and	  similarly,	  CDK4	  does	  not	  appear	  to	  be	  essential	  to	  mammary	  gland	  development	  in	  mice	  and	  mice	  lacking	  cyclin	  D1	  (and	  thus	  unable	  to	  activate	  CDK4)	  appear	  to	  be	  resistant	  to	  breast	  tumours	  induced	  by	  ERBB2	  (Malumbres	  and	  Barbacid	  2009).	  Moreover,	   it	  has	  also	  been	  observed	   that	   much	   depends	   on	   the	   nature	   of	   the	   oncogenic	   mutation,	   for	  instance,	   the	   same	   mice	   that	   lack	   cyclin	   D1,	   are	   not	   resistant	   to	   tumour	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development	   induced	   by	   MYC	   or	   WNT1	   (Malumbres	   and	   Barbacid	   2009).	   In	  short,	   the	   sensitivity	   appears	   to	   depend	   on	   both	   the	   cellular	   context	   and	  mutations	   behind	   tumour	   growth	   and	   this	   may	   explain	   the	   relatively	   modest	  activity	  of	  CDK	  inhibitors	  used	  in	  clinical	  trials	  to	  this	  point.	  	  	  There	  is	  a	  genuine	  paucity	  of	  compelling	  evidence	  to	  conclude	  whether	  a	  broad	  range	   or	   more	   selective	   inhibitor	   offers	   a	   better	   approach.	   A	   multi-­‐targeted	  inhibitor	   might	   be	   preferred	   to	   combat	   the	   phenomenon	   of	   compensatory	  activity	  seemingly	  exhibited	  by	  interphase	  CDKs	  and	  this	  has	  certainly	  been	  the	  principle	   behind	   the	   design	   of	   some	   inhibitors	   (Zhang,	   Lundgren	   et	   al.	   2008).	  Moreover,	   it	   has	   been	   argued	   that	   pan-­‐inhibitors	   target	   multiple	   pathways,	  which	   are	   often	   deregulated	   in	   cancer	   cells:	   cell	   cycle,	   transcription,	   p53	  response	  and	  apoptosis,	  which	  may	  also	  reduce	  the	  risk	  of	  multidrug	  resistance	  (Węsierska-­‐Gądek,	  Maurer	  et	  al.	  2011).	  This	  approach	  is	  particularly	   important	  when	  considering	  the	  heterogenous	  nature	  of	  most	  tumours.	  Selective	  inhibitors	  may	   be	   better	   for	   treating	   conditions	   where	   one	   kinase	   is	   deregulated	   and	  indeed	  may	   prevent	   healthy	   cells	   being	   damaged	   and	   onset	   of	   unwanted	   side-­‐effects	  and	  they	  also	  have	  the	  advantage	  of	  being	  easier	   to	  monitor	   in	   terms	  of	  pharmacodynamic	  profiles.	  However,	  as	  described	  above,	   in	  the	  case	  of	  specific	  CDK	  inhibitors,	  both	  the	  cellular	  context	  and	  mutations	  driving	  oncogenesis	  may	  need	   to	   be	   known	   in	   order	   to	   stratify	   patients	   successfully	   to	   this	   type	   of	  treatment.	   To	   this	   end,	   molecular	   profiling	   using	   genomic	   technologies	   will	  surely	  prove	  essential.	  Inhibiting	   transcriptional	  CDKs	   (CDK7,	  8	  and	  9)	  may	  augment	   the	  apoptosis	   in	  tumour	  cells	  of	  hematopoietic	  origin,	  since	  their	  survival	  depends	  on	  continuous	  expression	  of	   anti-­‐apoptotic	  proteins	   such	   as	  XIAP	  or	  MCL-­‐1.	   Indeed,	   the	  most	  successful	   trials	   to	   date	   have	   been	   in	   such	   neoplasias,	   as	   reviewed	   previously.	  This,	   along	  with	   the	  dual	   activity	   that	  CDK7	  has	   in	   activating	   interphase	  CDKs,	  provides	   the	   rationale	   behind	   therapeutically	   targeting	   it	   and	   in	   one	   sense,	   is	  tantamount	  to	  using	  broad-­‐spectrum	  inhibitors	  as	  multiple	  pathways	  are	  being	  targeted.	   To	   date,	   no	   inhibitor	   has	   been	   developed	   that	   specifically	   and	  selectively	   inhibits	  CDK7;	   thus	   there	   is	  much	  anticipation	   in	   characterising	   the	  resulting	  phenotype.	  It	  is	  believed	  that	  RNAPII	  activity	  is	  constitutively	  active	  in	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some	  cancer	  cells	   (Pallis,	  Burrows	  et	  al.	  2013),	   adding	   further	   reason	   to	   target	  CDK7.	  However,	  there	  is	  some	  evidence	  to	  suggest	  that	  pan-­‐CDK	  inhibitors	  that	  do	  not	  have	  selectivity	  against	  the	  CTD	  phosphorylating	  CDKs,	  may	  improve	  the	  tolerability	   of	   these	   agents	   (Kobayashi,	   Takahashi-­‐Suzuki	   et	   al.	   2011);	  neutropenia	  appears	  to	  be	  a	  major	  dose	  limiting	  toxicity	  in	  Phase	  I	  studies	  with	  flavopiridol	  and	  it	  was	  shown	  that	  a	  pan-­‐inhibitor	  with	  activity	  against	  CDK7	  and	  9	   suppressed	   CTD	   phosphorylation	   in	   resting	   lymphocytes	   and	   reduced	  white	  cells	   in	   mice	   within	   8	   hours	   of	   administration	   suggesting	   that	   an	   inhibitor	  without	  activity	  against	  these	  might	  improve	  tolerability.	  
1.6	  Aims	  of	  the	  project	  
	  The	  aim	  of	  this	  exploratory	  project	  will	  be	  to	  help	  delineate	  two	  questions:	  1. Is	  CDK7	  a	  valid	  anti-­‐cancer	  target?	  2. Does	  selective	  CDK	  inhibition	  or	  pan-­‐inhibition	  offer	  the	  best	  therapeutic	  option?	  Currently,	  both	  questions	  generate	  intense	  debate	  and	  the	  selectivity	  question	  is	  an	   important	   question	   to	   address	   so	   that	   we	   can	   establish	   the	   most	   effective	  clinical	   trial	   design	   to	   test	   these	   agents.	   It	   is	   critical	   to	   determine	   effective	  treatment	  protocols	  for	  their	  potential	  use	  in	  the	  clinic.	  	  	  	  Work	   performed	   in	   our	   laboratory	   has	   identified	   two	   lead	   compounds,	   BS181	  and	   BS194,	   both	   of	   which	   are	   potent	   CDK	   inhibitors.	   However,	   preliminary	  studies	  have	  highlighted	  that	  their	  probable	  mode	  of	  action	  differs	  with	  respect	  to	   the	   type	   of	   cell	   death	   they	   potentiate,	   which	   is	   most	   probably	   mediated	  through	   their	   distinct	   inhibitory	   profiles.	   Using	   the	   selective	   CDK7	   inhibitor	  BS181	  and	  the	  pan-­‐CDK	  inhibitor	  BS194,	  I	  plan	  to	  perform	  the	  following	  studies	  to	  help	  answer	  our	  two	  questions:	  1. Functional	  studies	  in	  a	  cancer	  cell	  line	  to	  examine	  the	  importance	  of	  CDK7	  for	  cancer	  cell	  growth	  and	  survival;	  these	  studies	  will	  be	  centred	  around	  an	  siRNA	  approach	  and	  will	  make	  use	  primarily	  of	  HCT116	  cells,	  a	  colon	  cancer	  cell	  line	  and	  ideal	  model	  to	  analyse	  cell-­‐cycle	  effects	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2. Direct	   comparison	  of	  BS181	  and	  BS194	  by	  way	  of	   treatment	  of	  HCT116	  cells	   and	   the	   subsequent	   analysis	   of	   gene	  expression	  profiles	   to	   gain	   an	  appreciation	  of	  the	  molecular	  mechanisms	  behind	  their	  mode	  of	  action	  Thus	  my	   first	   hypothesis	   is	   that	   knockdown	   of	   CDK7	   by	   siRNA	   and	   inhibition	  with	   specific	   inhibitors	   will	   produce	   the	   same	   cellular	   phenotype,	   since	   both	  methods	  should	  prevent	  CDK7-­‐mediated	  phosphorylation.	  	  My	  second	  hypothesis	  is	  that	  inhibition	  of	  CDK7	  by	  our	  experimental	  inhibitors	  will	  lead	  to	  global	  gene	  down-­‐regulation.	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2	  Materials	  and	  Methods	  
2.1	  Materials	  
2.1.1	  General	  reagents	  and	  chemicals	  Taq	  polymerase,	  Random	  hexamer	  primers,	  dNTP’s	  and	  DNA	  size	  markers	  were	  obtained	  from	  Fermentas	  (Sunderland,	  UK).	  	  RNA	  preparation	  kits	  were	  obtained	  from	  Qiagen	   (West	   Sussex,	  UK).	   General	   chemicals	  were	   obtained	   from	  Sigma-­‐Aldrich	   (North	   Dorset,	   UK).	   All	   solutions	   were	   made	   by	   dissolving	   reagent	   in	  distilled,	   de-­‐ionised	   water	   (ddH2O)	   and	   then	   autoclaved	   and	   kept	   at	   room	  temperature	  unless	  otherwise	  stated.	  
2.1.2	  General	  stock	  solutions	  10x	  PBS	  (phosphate	  buffered	  saline)	  (1L)	   80g	  NaCl;	  2g	  KCl;	  14.5g	  Na2HPO4;	  2g	  KH2PO4.	  Store	  at	  40C.	  Western	  Blot	  resolving	  gel	  buffer	  (1L)	   750ml	  2M	  Tris-­‐HCL	  (pH	  8.8);	  4g	  SDS;	  250ml	  ddH2O	  Western	  Blot	  stacking	  gel	  buffer	  (1L)	   500ml	  1M	  Tris-­‐HCL	  (pH	  6.8);	  4g	  SDS;	  500ml	  ddH2O	  10%	  APS	   1g	  APS	  powder	  (stored	  at	  40C);	  10ml	  ddH2O.	  Aliquoted	  to	  500µl	  and	  stored	  at	  -­‐200C	  10x	  Western	  Blot	  running	  buffer	  (1L)	   30.3g	  Tris-­‐base;	  144g	  Glycine;	  10g	  SDS;	  ddH2O	  to	  1L.	  	  Adjust	  to	  pH8.3	  10x	  Western	  Blot	  transfer	  buffer	  (1L)	   30.3g	  Tris-­‐base;	  144g	  Glycine.	  Water	  to	  1L.	  1x	  Western	  Blot	  transfer	  buffer	  (1L)	   100ml	  10x	  stock	  (above);	  200ml	  Methanol;	  Water	  to	  1L.	  10%	  Tween-­‐20	   5ml	  Tween20;	  45ml	  PBS.	  	  Antibody	  blocking	  solution	  (5%)	   15g	  chosen	  blocking	  reagent	  (dried	  powdered	  milk	  or	  BSA	  (bovine	  serum	  albumin));	  PBS-­‐Tween20	  (0.1%)	  to	  300ml.	  	  Western	  Blot	  washing	  solution	  (0.1%	  Tween20-­‐PBS)	   500ml	  1x	  PBS;	  5ml	  10%	  Tween20.	  
	  
Table	  2.1:	  General	  stock	  solutions	  and	  their	  composition	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2.1.3	  Sundries	  Cell	  culture	  flasks,	  cell	  culture	  plates,	  multi-­‐well	  plates,	  15ml	  and	  50ml	  screw-­‐top	  polypropylene	   tubes	   and	   cell	   scrapers	   were	   obtained	   from	   Corning	   (Fisher	  Scientific,	   Loughborough,	   UK).	   1.5ml	   snap-­‐cap	   microfuge	   tubes	   were	   obtained	  from	  Plastibrand	  (Sigma)	  1.5	  ml	  screw-­‐cap	  tubes	  and	  2ml	  cryogenic	  vials	  were	  obtained	   from	   Corning	   (Fisher	   Scientific).	   PCR	   tubes	   were	   obtained	   from	  Anachem	  Ltd.	  (Surrey,	  UK).	  Stripette	  serological	  pipette	  tips	  and	  10,	  30,	  200	  and	  1000µl	   volume	   pipette	   tips	  were	   supplied	   by	   Corning	   (Fisher	   Scientific).	   3mm	  Whatman	  	  filter	  paper	  was	  obtained	  from	  Whatman	  International	  Ltd	  (Kent,	  UK).	  
2.1.4	  Cell	  culture	  reagents	  Cells	  were	  kept	  at	  370C	  in	  a	  humidified	  incubator	  containing	  5%	  CO2.	  All	  media	  (DMEM,	   RPMI-­‐1640	   and	  McCoy’s	   5A	  modified),	   0.02%	  NA-­‐EDTA	   solution,	   10x	  trypsin	   and	   penicillin/streptomycin/L-­‐glutamine	   (PSG)	   were	   obtained	   from	  Sigma-­‐Aldrich	   (UK).	   Fetal	   Calf	   Serum	   (FCS)	   was	   supplied	   by	   First	   Link	  (Birmingham,	  UK).	  
2.1.5	  Cell	  lines	  Unless	   otherwise	   stated,	   the	   following	   cell	   lines	  were	   obtained	   from	  American	  Type	  Culture	  Collection	  (ATCC).	  
Cell	  Type	  and	  culture	  media	   Notes	  MCF-­‐7	  (DMEM)	   	  HCT-­‐116	  (RPMI	  1640)	   	  HCT-­‐116	  p53	  -­‐/-­‐	  and	  parent	  (RPMI	  1640)	   	  HCT-­‐116	  a/s	  mutant	  and	  parent	  (McCoy’s	  5A)	   HCT-­‐116	   cell	   line	   with	   WT	   CDK7	  alleles	  being	  replaced	  with	  mutant,	  analogue	   sensitive	   alleles	   via	  homologous	   recombination.	   From	  Prof.	   R.	   Fisher,	  Mount	   Sinai	   School	  of	  Medicine,	  New	  York.	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MCF7	  MX	  (DMEM)	   Over	   expresses	   BCRP	   (ABCG2).	  MCF-­‐7	  is	  the	  parental	  line.	  	  Cell	  line	  from	   Dr	   Ernesto	   Yague,	   Imperial	  College	  NCI-­‐ADR	  (DMEM)	   Over	   expresses	   MDR1/PgP	  (ABCB1).	  Originally	  thought	  to	  be	  a	  breast	   cell	   line	   until	   1998.	   It	   has	  since	   been	   shown	   to	   be	   derived	  from	  parental	  OVCAR-­‐8	  ovarian	  cell	  line.	   Cell	   line	   maintained	   in	   full	  media	  with	  2µM	  Doxorubicin.	  From	  Dr	  Ernesto	  Yague,	  Imperial	  College.	  PhaMDR1	  (DMEM)	   Murine	   cell	   line	   derived	   from	   3T3	  cells	   over	   expressing	   MDR1/PgP	  (ABCB1).	   From	   Dr	   Ernesto	   Yague,	  Imperial	  College.	  3T3	  (DMEM)	   Murine	   parent	   line	   of	   PhaMDR1.	  From	   Dr	   Ernesto	   Yague,	   Imperial	  College.	  
	  
Table	  2.2:	  Cell	  lines	  used	  for	  experimental	  purposes	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2.1.6	  RT-­‐PCR	  primers	  
2.1.6.1	  TaqMan	  primers	  
	  The	   following	   table	   lists	   the	   TaqMan	   probes	   along	   with	   their	   assay/catalogue	  number.	  All	  TaqMan	  probes	  were	  purchased	  from	  Applied	  Biosystems	  (Cheshire,	  UK).	  
Gene	  name	   Assay	  code	  ABCB1	   HS00184500	  ABCG2	   HE01053790	  ABCC1	   00219905	  CDK7	   00387062	  Cyclin	  H	   00236923	  MAT1	   00159207	  CDK1	   00277039	  CDK2	   01548894	  CDK9	   00172036	  MCL1	   00172036	  GAPDH	   99999905	  
	  
Table	  2.3:	  TaqMan	  primers	  with	  catalogue/assay	  codes	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2.1.6.2	  SYBR	  Green	  primers	  
	  The	  following	  table	  lists	  the	  gene	  names	  of	  all	  SYBR	  Green	  primers.	  Each	  primer	  was	   custom	   designed	   by	   PrimerDesign	   UK	   (Southampton,	   UK)	   and	   therefore	  does	  not	   have	   a	   unique	   catalogue	  number.	   In	   each	   case,	   the	   sequence	  detailed	  first	  is	  the	  sense	  primer	  and	  the	  sequence	  underneath	  is	  the	  antisense.	  
Genes	  used	  for	  microarray	  validation	  Gene	  name	   Sequence	  
BHLHB2	   acgctccgctagtgcagaca	  cccaagtctcctgatgtcaag	  BTG2	   aatcttcaccccacttcctcta	  caaaattgagcagtttagaaaatcca	  CYR61	   gtgaaagcactaacaaacct	  ggcttcctttctacaatgagtc	  DCLRE1A	   ctgcccaaagcaccgggact	  ctgacaacctgcatttccaag	  DDIT3	   taccaagtgtacaagtcactctc	  acctttccttttgtctactccaa	  DDIT4	   gtgaaagcactaacacctaagag	  ccgatcataaaaacaagatacaaaac	  EXO1	   ccccctttaaacttagactttacga	  ctctttttgttagtaggtccatttac	  IER3	   gctccttttggcatagggaa	  tacgcctggtgtttctttgtg	  IGFBP3	   actctctaggggatcctgct	  tctgttgttggtgctgcttta	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JAG1	   gaggagttccctgggcttct	  gtaaaggactcgccgttgac	  JUN	   gtagttccctactcaggctt	  ggtacctctttcggagaatcctct	  JUNB	   gtagttccctactcaccccttct	  ggagtttgtagtctgttagagag	  KLF10	   agacgtcggggagagagagc	  gatactgggctcttttcttcct	  KLF4	   tggagtgtccttattgctaa	  gcacctgaaccccaaagtc	  KLF6	   aggtagcaggcactggcata	  ctggaggcaactgggtagg	  MAPK6	   tacttcctatgaagacatcag	  gcaccaagtcttccgtattaatg	  MED20	   acgggaatacagcggagacaac	  aaagatgtcagaaggagatttcaa	  MED24	   ggagcgcgcagtggccccgg	  ctccttcagcagctccttaatc	  MED27	   gccatcagacccagctccca	  agcccactgttatgaagaggat	  MYC	   gcattgtgtatactgagattgc	  aagagttccgtagctgttcaag	  MKX3-­‐1	   ggactgtagagctccttttg	  ctctgtgaaaatccaatacctctt	  NOTCH1	   agacgtcgaccagaggtcgc	  ggcagtgtctttccccaga	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RGS2	   tggtattaagtcgttgcctt	  tgatgcccacctgaagggactcca	  SRA1	   ccagctccctaagtgatgga	  tgtgatctagccaggttgact	  TAF4	   acggggaataaagcggagcctc	  ttttacatttcttcacgttttccatag	  WEE1	   cttgaagcatgtgaaagcactca	  atcatcttcgtctccttcttcag	  
	  
















	   66	  
Other	  genes	  Gene	  name	   Sequence	  BCL2	   cagtccctcgtgagagagaa	  gtaaatgccatggtttattgca	  	  BCL2L1	   gagtttgaagaaggcatcca	  atccttttggaccataggtac	  	  CDK2	   ataatcgaagactgcatgaa	  gtaccctgggtatgctgcattatt	  	  CDK4	   gcacttctgatgggtgtgaa	  tgtcctgaaatagagaccacattcg	  	  CDK6	   ctgatcacatatattgactt	  agccttttagcctttggaatggc	  	  CDK7	   gagcacccatcccataaagc	  Ccctggtgaaatgacctaccatg	  	  CDK9	   ctcagtatttatgattgaag	  gtaatgtgccgtgaaatgcccac	  	  Cyclin	  H	   caataataccttgtaagttg	  tgacctgtggtagcttttcgca	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  MAT1	   tagacgctgtcagtaaccca	  tgattttcgccagaagttgatc	  	  MCL1	   tgctcggaattaaaggcttc	  tgattgttgcgcaaacgaccaag	  	  XIAP	   ggtcattggaatccacgttt	  gctcccaagcttacaattggcat	  	  
	  
Table	   2.5:	   SYBR	   green	   primers	   (gene	   names)	   used	   following	   siRNA	   and	   drug	  
treatment	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House-­‐keeping	  genes	  Gene	  name	   Sequence	  
18S	  rRNA	   gcttgtgaaactgaacacaa	  gtgggcatctggattttagcc	  	  
ACTB	   ggtctgtcagatgacaagaa	  gtccctaacagtggtggtacggt	  	  
B2M	   gcacaggagacagaacgtct	  agtttcatggaaatcattgacc	  	  
CYC1	   ctgaggctgacacatgttaa	  tgtggcaaacatgacttagctgg	  	  
GAPDH	   gtccttggacacttgtctga	  acggttgccacatgttgacact	  	  
UBC	   attcggatcattatctgtat	  gccatggtgcacctcctagatt	  	  	  
Table	  2.6:	  List	  of	  house-­keeping	  genes	  used	  for	  SYBR	  Green	  assays	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2.1.7	  Antibodies	  Antibodies	  were	  purchased	  from	  Abcam	  (Cambridge,	  UK),	  Cell	  Signaling	  (Boston,	  USA)	   and	   Bethyl	   Laboratories	   (Texas,	   USA).	   Below	   is	   a	   list	   of	   antibodies	   used,	  their	  catalogue	  number	  and	  manufacturer.	  
Antibody	  name	   Catalogue	  number	   Manufacturer	  CDC1	   9116	   Cell	  Sig	  BTG2	   Ab85051	   Abcam	  CJUN	   Ab31419	   Abcam	  CMYC	   Ab39688	   Abcam	  CDC1	  (phospho)	   Ab47329	   Abcam	  CDK2	   Ab2363	   Abcam	  CDK2	  (Phospho)	   AP3067A	   Abgent	  CDK4	   2906	   Cell	  sig	  CDK6	   3136	   Cell	  sig	  CDK7	   Ab9516	   Abcam	  CDK9	   2316	   Cell	  sig	  Cyclin	  A	   4656	   Cell	  sig	  Cylin	  B1	   4135	   Cell	  sig	  Cyclin	  D1	   Ab24249	   Abcam	  Cylin	  D1	   Ab16663	   Abcam	  Cyclin	  E	   4129	   Cell	  sig	  Cyclin	  H	   Ab54903	   Abcam	  DDIT4	   Ab63059	   Abcam	  ERα	   Ab9269	   Abcam	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ERα	  (phospho	  S118)	   In-­‐house	   	  
JAGGED1	   Ab1771	   Abcam	  JUNB	   Ab90565	   Abcam	  KLF10	   Ab60929	   Abcam	  KLF6	   Ab87554	   Abcam	  MAT1	   SC6234	   Santa	  Cruz	  MCL1	   Ab31948	   Abcam	  NOTCH1	   Ab27526	   Abcam	  Rb	   9309	   Cell	  sig	  Rb	  (phospho	  S780)	   9307	   Cell	  sig	  Rb	  (phospho	  S795)	   Ab47474	   Abcam	  Rb	  (phospho	  (S807)	   9308	   Cell	  sig	  Rb	  (phospho	  (T821)	   Ab4787	   Abcam	  RNAPOLII	   Ab817	   Abcam	  RNAPOLII	   A300-­‐653A	   Bethyl	  RNAPOLII	  (phospho	  S2)	   Ab5095	   Abcam	  RNAPOLII	  (phospho	  S2)	   A300-­‐654A	   Bethyl	  RNAPOLII	  (phospho	  S5)	   Ab5131	   Abcam	  RNAPOLII	  (phospho	  S5)	   A300-­‐655A	   Bethyl	  XIAP	   Ab28151	   Abcam	  	  
Table	  2.7:	  Primary	  antibodies,	  catalogue	  number	  and	  manufacturer	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2.1.8	  siRNAs	  
	  All	   siRNAs	   were	   Thermo	   Scientific	   Dharmacon	   ON-­‐TARGET	   plus	   and	   were	  purchased	  from	  Fisher	  (UK).	  Below,	  are	  details	  of	  catalogue	  numbers	  and	  target	  sequences	  of	  individual	  deconvoluted	  siRNAs.	  
	  siRNA	   Catalogue	  ID	   Target	  sequence	  CDK7	  SMART	  pool	   L-­‐003241-­‐00	   	  CDK7	   J-­‐003241-­‐09	   CAUACAAGGUUAUUCUUA	  CDK7	   J-­‐003241-­‐10	   AAACUGUGAUCUAGAGGAU	  CDK7	   J-­‐003241-­‐11	   CAACAUUGGAUCCUACAUA	  CDK7	   J-­‐003241-­‐12	   GAUGACUCUUCAAGGAUUA	  Non-­‐targetting	  pool*1	   D-­‐001206-­‐13	   	  Non-­‐targetting	  pool*2	   D-­‐001206-­‐14	   	  Non-­‐targetting	  pool	  plus	   D-­‐001810-­‐10	   	  MAT1	  SMART	  pool	   L-­‐003281-­‐00	   	  Cyclin	  H	  SMART	  pool	   L-­‐003218-­‐00	   	  
	  
Table	  2.8:	  siRNA	  name,	  catalogue	  number	  and	  target	  sequence	  where	  appropriate	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2.2	  Methods	  
2.2.1	  Cell	  culture	  
	  Cell	  lines	  used	  and	  the	  preferred	  media	  in	  which	  they	  were	  grown	  in	  are	  detailed	  above	   in	   table	   2.2.	   	   All	   cell	   lines	  were	  maintained	   in	   the	   appropriate	  medium,	  supplemented	  with	  10%	  FCS,	   together	  with	   a	   solution	  of	   penicillin	   (100U/ml),	  streptomycin	   (100mg/ml)	   and	   L-­‐glutamine	   (3mM)	   (P/S/G)	   at	   370C	   in	   a	  humidified	   atmosphere	   gassed	  with	  5%	  CO2.	   Cell	   cultures	  were	   grown	   to	  75%	  confluency,	  at	  which	  point	  the	  adherent	  layer	  of	  cells	  were	  passaged	  by	  washing	  briefly	  with	  PBS	  to	  remove	  debris	  and	  then	  with	  a	  trypsin	  solution	  (1x	  trypsin	  on	  0.02%EDTA)	  to	  mechanically	  detach	  the	  cells	  from	  the	  substratum.	  The	  trypsin	  solution	  was	   left	   on	   the	   cells	   for	   3-­‐4	  minutes	   at	   370C.	   The	   addition	   of	   culture	  media	   prevented	   any	   further	   enzymatic	   action	   and	   cells	   were	   subsequently	  passaged	  into	  new	  culture	  flasks	  at	  a	  ratio	  of	  1:4.	  	  	  Cells	   were	   frozen	   at	   regular	   intervals	   to	   maintain	   stocks.	   For	   freezing,	  approximately	   5	   x	   106	   cells	   were	   trypsinised	   (as	   above)	   and	   centrifuged	   at	  15,350	   x	   g	   for	   3	   minutes	   to	   form	   a	   visible	   pellet	   of	   cells.	   Supernatant	   was	  decanted	  and	  the	  pellet	  of	  cells	  re-­‐suspended	  in	  1.5ml	  of	  freezing	  mix	  (90%	  FCS;	  10%	  DMSO).	  The	  suspension	  was	  then	  transferred	  to	  2.5ml	  cryovials	  and	  placed	  at	  -­‐800C	  overnight	  and	  stored	  in	  liquid	  nitrogen.	  	  When	  frozen	  stocks	  were	  required,	  the	  cells	  were	  thawed	  at	  370C	  in	  a	  water	  bath	  before	   being	   added	   to	   25ml	   culture	   media	   and	   subsequently	   centrifuged	   at	  15,350	  x	  g	  for	  3	  minutes.	  Supernatant	  was	  decanted	  and	  cells	  were	  re-­‐suspended	  in	  5ml	  of	  fresh	  media	  and	  transferred	  to	  a	  T25	  tissue	  culture	  flask.	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2.2.2	  RNA	  extraction	  and	  preparation	  
	  Cells	  were	  plated	  at	  a	  density	  determined	  by	  the	  size	  of	  cell-­‐culture	  vessel	  being	  used	  and	  type	  of	  experiment	  being	  undertaken.	  Details	  of	  seeding	  density	  can	  be	  found	   under	   the	   specific	   experimental	   heading	   in	   this	   chapter,	   however	   cells	  were	  generally	  left	  to	  adhere	  to	  the	  vessel	  for	  48	  hours	  prior	  to	  experimentation.	  	  Plated	  cells	  were	  rinsed	  gently	  with	  approximately	  5ml	   ice	  cold	  PBS	  to	  remove	  dead	   cells	   and	   residual	  media.	   RNA	  was	   extracted	   using	   the	   QIAshredder	   and	  RNEasy	  spin	  column	  kit	  (Qiagen).	  For	  10cm	  plates,	  650µl	  of	  RLT	  buffer	  was	  added	  to	  the	  centre	  of	  the	  plate,	  which	  was	   subsequently	   scraped	   with	   a	   non-­‐pyrogenic	   cell	   scraper	   (Corning).	   The	  lysate	   was	   added	   to	   a	   purple	   QIAShredder	   spin	   column	   and	   centrifuged	   for	   2	  minutes	   at	  15,350	  x	   g.	   700µl	   of	   70%	  ethanol	  was	   added	   to	   the	   follow	   through	  and	   transferred	   to	   a	   newly	   labelled	   pink	   RNeasy	   mini	   spin	   column.	   This	   was	  spun	   for	   30	   seconds	   and	   the	   follow-­‐through	   discarded.	   350µl	   buffer	   RWI	  was	  added	  and	  spun	  again	  for	  an	  additional	  30	  seconds	  before	  discarding	  the	  follow	  through.	  10µl	  DNAase	  I	  stock	  solution	  was	  added	  to	  70µl	  of	  RDD	  buffer	  for	  each	  sample	   so	   that	   a	   final	   volume	   of	   80µl	   was	   distributed	   equally	   between	   the	  samples.	   These	   were	   left	   at	   room	   temperature	   for	   15	   minutes	   after	   which,	   a	  further	   350µl	   RWI	   buffer	   was	   added	   and	   spun	   at	   15,350	   x	   g	   for	   30	   seconds	  before	   discarding	   the	   follow-­‐through.	   Two	   500µl	   volumes	   of	   buffer	   RPE	  were	  then	  sequentially	  added	  and	  spun	  for	  2	  minutes	  at	  15,350	  x	  g	  in	  order	  remove	  all	  ethanol	  contained	  in	  the	  buffer	  composition.	  Each	  time,	  the	  follow-­‐through	  was	  discarded.	  Finally,	  the	  spin	  column	  was	  removed	  from	  its	  2ml	  collection	  tube	  and	  placed	  into	  a	  new	  1.5ml	  tube.	  50µl	  of	  RNAase-­‐free	  water	  was	  pipetted	  onto	  the	  centre	  of	  the	  white	  membrane	  and	  left	  for	  15	  minutes	  at	  room	  temperature.	  This	  was	  finally	  spun	  for	  1	  minute	  at	  15,350	  x	  g	  to	  elute	  the	  RNA.	  The	   RNA	   concentration	   was	   measured	   using	   a	   NanoDrop	   spectrophotometer	  (Thermo	  Scientific)	  and	  the	  quality	  checked	  by	  agarose	  gel	  electrophoresis	  on	  a	  1.5%	  gel.	  RNA	  was	  stored	  at	  -­‐800C.	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2.2.3	  cDNA	  synthesis	  Reverse	  transcription	  of	  RNA	  was	  carried	  out	  using	  the	  following	  reagents	  in	  the	  specified	  composition	  for	  each	  sample:	  
• 4µl	  5X	  RT	  buffer	  (Fermentas)	  
• 2µl	  10mM	  dNTPs	  stock	  (Fermentas)	  
• 1µl	  random	  hexamer	  primers	  (200ng/µl)	  (Fermentas)	  
• 1µl	  Revertaid	  M-­‐MuLV	  Reverse	  Transcriptase	  (200u/µl)	  (Fermentas)	  
• 2µg	  total	  RNA	  diluted	  to	  final	  volume	  of	  12µl	  in	  nuclease-­‐free	  water	  A	  mater	  mix	  was	  made	  with	  the	  buffer,	  dNTPs,	  and	  random	  hexamer	  primers	  in	  a	  1.5ml	  microfuge	  tube	  and	  left	  on	  ice	  whilst	  the	  necessary	  volumes	  of	  RNA	  were	  pipetted	   along	   with	   the	   respective	   volumes	   of	   water	   into	   0.8ml	   PCR	   tubes	  (Thermo	   Scietific)	   to	   make	   the	   final	   12µl	   volume.	   Reverse	   Transcriptase	   was	  added	  to	  the	  master	  mix,	  briefly	  mixed	  with	  a	  pipette	  and	  8µl	  added	  to	  each	  tube.	  The	  reaction	  was	  exposed	  to	  the	  following	  cycling	  conditions	  in	  a	  GeneAmp	  9700	  PCR	  machine	  (Applied	  Biosystems,	  UK):	  
• 370C	  1hour	  
• 650C	  10	  minutes	  
• 40C	  ∞	  The	  reaction	  (20µl)	  was	  diluted	  in	  180µl	  nuclease-­‐free	  water	  for	  a	  1/10	  dilution	  and	  stored	  at	  -­‐200C.	  	  
2.2.4	  Real-­‐Time	  (quantitative)	  RT-­‐PCR	  
	  Real-­‐time	  PCR	  was	  performed	  on	   the	  ABI	   7900HT	  Fast	  Real-­‐Time	  PCR	  System	  (Applied	   Biosystems,	   UK)	   in	   a	   96	   well	   format.	   The	   reactions	   were	   set-­‐up	   in	  MicroAmp	   Fast	   Optical	   96-­‐well	   plates	   (Applied	   Biosystems)	   in	   triplicate.	  Absolute	   quantification	   was	   chosen	   to	   measure	   gene	   expression	   and	   gene	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expression	  was	  quantified	  using	  the	  2(-­‐Delta	  Delta	  C(T))	  method.	  An	  endogenous	  house-­‐keeping	  gene	  was	  used	  for	  relative	  quantification	  of	  gene	  expression.	  The	  reactions	  were	  as	  follows:	  
• 2µl	  cDNA	  
• 10µl	  Real	  Time	  Master	  Mix	  
• 7µl	  nuclease-­‐free	  H2O	  
• 1µl	  sequence	  specific	  primer	  Cycling	   conditions	   and	   primer	   type	   differed	   depending	   on	   what	   detection	  method	  was	  used.	  Both	  SYBRGreen	  and	  TaqMan	  methods	  were	  used	  to	  detect	  gene	  expression.	  Primer	  names	  and	   their	  primer	  codes	  are	   indicated	   in	   tables	  above.	  	  
2.2.4.1	  SYBRGreen	  detection	  
	  Samples	   were	   prepared	   as	   detailed	   above.	   For	   SYBR	   Green	   detection,	   SYBR	  Green	  Master	  Mix	   (Applied	  Biosystems)	  was	   used.	   The	   primers	   used	   for	   SYBR	  Green	  detection	  were	  custom	  designed	  by	  Primerdesign	  and	  are	  listed	  in	  tables	  above.	  	  Cycling	  conditions	  for	  SYBRGreen	  detection	  were	  as	  follows:	  
• Denaturing	  950C	  10	  minutes	  (x1)	  
• Annealing	  950C	  15	  seconds	  (x40)	  
• Extension	  600C	  1minute	  (x40)	  	  
2.2.4.2	  TaqMan	  detection	  
	  Samples	  were	  prepared	  as	  detailed	  above.	  TaqMan	  primers	  and	  Master	  Mix	  were	  both	   purchased	   from	   Applied	   Biosystems.	   The	   primers	   are	   listed	   in	   the	   table	  above.	  The	  cycle	  conditions	  were	  as	  follows:	  
• Stage	  1	  950C	  20	  seconds	  (x1)	  
• Stage	  2	  950C	  3	  seconds	  (x40)	  
• Stage	  3	  600C	  30	  seconds	  (x40)	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2.2.5	  Protein	  extraction	  
	  Cells	  were	  lysed	  and	  collected	  in	  RIPA	  buffer	  (Sigma),	  which	  was	  prepared	  in	  the	  following	  way:	  10ml	   of	   RIPA	   buffer	  was	   decanted	   into	   a	   50ml	   falcon	   tube	   (Corning)	   and	   one	  tablet	   each	   of	   Complete	   Protease	   Inhibitor	   Cocktail	   and	  PhosSTOP	  Phophotase	  Inhibitor	  Cocktail	   (Roche	  Applied	  Sciences,	  UK)	  was	  added.	  The	  buffer/cocktail	  mixture	   was	   vortexed	   for	   approximately	   1	   minute	   or	   until	   the	   tablets	   were	  dissolved.	  Cells	  were	  typically	  grown	  on	  10cm	  cell-­‐culture	  dishes	  and	  were	  washed	  twice	  with	  ice-­‐cold	  PBS	  to	  thoroughly	  remove	  cell	  debris	  and	  any	  trace	  of	  media.	  500µl	  of	  the	  prepared	  RIPA	  buffer	  was	  added	  to	  the	  plates	  and	  cells	  were	  scraped.	  The	  lysate	   was	   transferred	   to	   1.5ml	   microfuge	   tubes	   (Sigma),	   vortexed	   for	   10	  seconds	   and	   returned	   to	   ice	   for	   10	  minutes.	   This	   process	  was	   repeated	  before	  the	  samples	  were	  spun	  in	  a	  bench-­‐top	  centrifuge	  for	  5	  minutes	  at	  15,350	  x	  g.	  The	  supernatant	   was	   transferred	   to	   a	   new	   tube	   and	   the	   cell	   pellet	   discarded.	   Cell	  lysates	  were	  stored	  at	  -­‐800C.	  
	  
2.2.6	  Protein	  Quantification	  
	  Protein	  concentration	  was	  measured	  by	  using	  the	  BCA	  protein	  assay	  reagent	  kit	  (Pierce	  protein	  research	  products,	  Thermo	  Scientific).	  Briefly,	  the	  assay	  couples	  the	  reduction	  of	  CU2+	  ions	  to	  CU1+	  ions	  by	  protein	  (known	  as	  the	  biuret	  reaction)	  to	   the	   sensitive	   colourimetric	   detection	   of	   CU1+	   ions	   by	   the	   presence	   of	  bicinchoninic	  acid	  (BCA).	  In	   this	  method,	   protein	   lysates	  were	   thawed	   on	   ice.	   Kit	   reagent	  A	   (an	   alkaline	  buffer)	   was	  mixed	   with	   kit	   reagent	   B	   (BCA)	   in	   a	   ratio	   of	   1:50.	   Enough	   of	   the	  mixture	   was	   made	   to	   allow	   for	   1ml	   for	   each	   sample	   plus	   an	   additional	   five	  samples	  for	  a	  standard	  curve.	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Once	  the	  protein	  lysate	  samples	  were	  thawed,	  5µl	  was	  added	  to	  45µl	  of	  distilled	  water	  in	  a	  1.5ml	  microfuge	  tube	  to	  give	  a	  total	  volume	  of	  50µl.	  To	  this,	  1ml	  of	  the	  reaction	  mixture	  was	  added.	  The	  same	  process	  was	  repeated	  for	  five	  dilutions	  of	  a	  1mg/ml	  stock	  of	  Bovine	  serum	  albumin	  (BSA):	  0,	  5,	  10,	  20	  and	  30	  µg	  in	  a	  total	  volume	  of	  50µl.	  Once	  prepared,	   the	  samples	  were	   incubated	   in	  a	  water	  bath	  at	  370C	   for	   30	   minutes.	   The	   preparations	   were	   then	   transferred	   to	   disposable	  plastic	   cuvettes	   (Corning)	   and	   read	   on	   a	   spectrophotometer	   at	   563nm.	   A	  standard	  curve	  was	  generated	  from	  the	  five	  BSA	  dilutions	  and	  used	  to	  determine	  the	  total	  protein	  concentration	  of	  the	  samples.	  
	  
2.2.7	  Protein	  analysis	  
2.2.7.1	  SDS	  PAGE	  
	  All	   protein	   gels	   were	   run	   using	   mini	   vertical	   gel	   electrophoresis	   tanks.	  Polyacrylamide	   gels	  were	  made	  either	   at	   10%	  or	  8%	  concentration	  depending	  upon	  the	  size	  of	  the	  protein	  to	  be	  investigated.	  The	  running	  apparatus	  was	  filled	  with	  1x	  running	  buffer	  (see	  Materials	  section).	  The	  composition	  of	  the	  gels	  was	  as	  follows:	  




	  8ml	  	  
	  8ml	   	  8ml	   	  	  2.5ml	  
30%	  stock	  acrylamide	   8.5ml	   10.5ml	   16ml	   1.5ml	  
ddH2O	   15.3ml	   13.5ml	   8ml	   6ml	  
10%APS	   250µl	   200µl	   120µl	   50µl	  
TEMED	   62.5µl	   50µl	   16µl	   20µl	  
	  
Table	  2.9:	  Composition	  of	  polyacrylamide	  gels	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2.2.7.2	  Sample	  preparation	  




Wet	  Transfer	  The	   gel	   was	   blotted	   onto	   Hybond	   ECL	   nitrocellulose	   membrane	   (Amersham	  Biosciences,	  UK)	  which	  was	  sandwiched	  between	  3mm	  Whatman	  filter	  paper	  for	  1.5hrs	   at	   100V	   in	   1x	   electrotransfer	   buffer	   (see	  Materials).	   Successful	   transfer	  was	   indicated	   by	   complete	   transfer	   of	   the	   coloured	   molecular	   marker	   to	   the	  nitrocellulose	  membrane.	  The	  membrane	  was	  then	  transferred	  into	  a	  10cm	  dish	  with	  approximately	  10ml	  of	   blocking	   solution	   (see	   Materials)	   for	   1hr	   at	   room	   temperature	   on	   a	   rotary	  shaker.	  The	  membrane	  was	   incubated	  with	  the	  appropriate	  antibody	  diluted	   in	  the	   same	   blocking	   solution	   from	   the	   previous	   step	   either	   for	   1.5hrs	   at	   room	  temperature	  or	  at	  40C	  overnight	  on	  a	  rotary	  shaker.	  The	  blot	  was	  then	  washed	  3x	  for	   five	   minutes	   with	   PBS	   containing	   0.1%	   Tween20	   (see	   Materials)	   and	  incubated	   with	   a	   species-­‐specific	   secondary	   antibody.	   For	   chemiluminescent	  detection,	  secondary	  goat	  antibodies	  conjugated	  with	  HRP	  (Dako,	  UK)	  were	  used.	  For	   fluorescent	   detection,	   IRDye	   800CW	   (green)	   and	   680LT	   (red)	   species-­‐specific	   goat	   secondary	   antibodies	   (LI-­‐COR,	   UK)	   were	   used.	   In	   both	   cases	   the	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membrane	  was	  incubated	  for	  1.5hrs	  at	  room	  temperature	  before	  being	  washed	  as	  in	  the	  previous	  step.	  
	  
Dry	  transfer	  via	  the	  iBLOT	  system	  (Invitrogen,	  UK)	  Gels	   were	   transferred	   according	   to	   the	   manufacturer’s	   instructions.	   Briefly,	  polyacrylamide	   gels	   were	   trimmed	   to	   size	   and	   placed	   onto	   the	   nitrocellulose	  anode	   stack,	   followed	   by	   filter	   paper	   pre-­‐soaked	   in	   ddH2O	   and	   finally	   by	   the	  cathode	  stack.	  Each	  layer	  of	  the	  sandwich	  was	  rolled	  flat	  to	  exclude	  air	  bubbles.	  Finally	   the	  sponge	  was	   inserted	   into	   the	   lid	  of	   the	   Iblot	   transfer	  apparatus	  and	  closed.	  A	  red	  LED	  indicated	  when	  a	  complete	  circuit	  was	  made	  and	  the	  transfer	  process	   could	   then	   be	   started.	   Complete	   transfer	   routinely	   took	   7	   minutes.	  Following	   successful	   transfer	   the	   membranes	   were	   cut	   to	   size	   using	   a	   sterile	  scalpel	   and	   incubated	   in	   the	   appropriate	   blocking	   buffer	   and	   subsequent	  antibodies.	  
	  
2.2.7.4	  Protein	  detection	  and	  quantification	  
	  
Chemiluminescent	  detection	  Bands	  were	  visualised	  using	  SuperSignal	  West	  Pico	  Chemiluminescent	  Substrate	  kit	   (Thermo	   Scientific,	   UK).	   The	   signal	  was	   detected	   by	   autoradiography	   using	  Amersham	  Hyperfilm	  ECL	  X-­‐ray	  film	  (GE	  Healthcare,	  UK).	  Films	  were	  developed	  with	  a	  Konica	  SRX-­‐101A	  X-­‐ray	  developer.	  Bands	  were	  scanned	  in	  and	  saved	  as	  a	  TIFF	   file,	  which	  was	   then	  quantified	  using	   the	   freely	  available	   ImageJ	   software	  (http://rsbweb.nih.gov/ij/)	  in	  8-­‐bit	  grayscale.	  All	  bands	  were	  made	  relative	  to	  β-­‐actin.	  
Fluorescent	  detection	  Membranes	  probed	  with	  fluorescent	  secondary	  anti-­‐bodies	  were	  scanned	  on	  the	  Odyssey	  Infrared	  Imaging	  System	  scanner	  (LI-­‐COR)	  and	  bands	  quantified	  using	  the	   associated	   9201-­‐500	   Odyssey	   Software	   (LI-­‐COR).	   Again,	   relative	  quantification	  completed	  using	  β-­‐actin	  as	  a	  reference.	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2.2.8	  Sulphorhodamine	  B	  (SRB)	  assay	  
	  The	   SRB	   assay	   was	   used	   to	   measure	   growth	   of	   cells	   following	   drug	   or	   siRNA	  treatment.	  The	  remainder	  of	  this	  section	  has	  details	  the	  steps	  taken	  to	  monitor	  growth	  after	  drug	   treatment	  only.	  For	  growth	   following	  siRNA	  treatment,	   refer	  to	  the	  siRNA	  protocol.	  Cells	   were	   seeded	   in	   96	   well	   cell	   culture	   plates	   (Corning)	   in	   full	   media	   at	   a	  density	   of	   3x103/well	   in	   a	   total	   volume	  of	   100µl/well	   and	   left	   for	   48	   hours	   to	  adhere.	  All	  drugs	  were	  diluted	  in	  DMSO	  and	  added	  to	  full	  media	  in	  15ml	  sterile	  plastic	   screw	   cap	   tubes	   (Corning)	   and	   serially	   diluted	   from	   a	   400µM	   starting	  dilution.	  Cells	  were	  then	  treated	  in	  replicates	  of	  five	  by	  a	  19-­‐fold	  serial	  dilution	  of	  drugs	  ranging	  from	  400µM	  to	  0.6nM.	  The	  drug	  treatment	  was	  also	  accompanied	  by	   a	   DMSO	   control.	   The	   treatment	   and	   control	  were	   administered	   by	   a	  multi-­‐channel	  200µl	  pipette	  (Gilson)	  and	  100µl	  was	  added	  directly	  to	  the	  wells	  already	  containing	   100µl	   media,	   so	   that	   the	   final	   drug	   concentration	   was	   half	   of	   the	  starting	   concentration.	   Therefore,	   the	   final	   serial	   concentration	   ranged	   from	  200µM	  –	  0.3nM.	  Each	  drug	  treatment	  series	  was	  arranged	  over	  two	  plates.	  	  Media	  was	  replaced	  every	  three	  days	  over	  the	  duration	  of	  the	  time	  course.	  Cells	  were	   fixed	   at	   daily	   intervals	   by	   the	   addition	   of	   100µl	   cold	   40%	   trichloroacetic	  acid	  (TCA)	  to	  each	  well.	  Plates	  were	  left	  for	  1hr	  at	  room	  temperature	  and	  gently	  washed	   five	   times	   with	   ddH2O.	   Then,	   100µl	   of	   0.4%	   (w/v)	   SRB	   (in	   1%	   acetic	  acid)	  was	   added	   to	   the	  wells	   and	   left	   for	   1hr	   at	   room	   temperature.	   The	  plates	  were	  then	  gently	  washed	  with	  1%	  acetic	  acid	  five	  times	  and	  left	  to	  dry	  overnight.	  The	   remaining	  SRB	  dye	  was	   solubilised	  by	  adding	  100µl	  of	  10mM	  Tris-­‐base	   to	  each	   well	   and	   shaking	   the	   plates	   at	   room	   temperature	   for	   30	   minutes	   on	   a	  bench-­‐top	   plate	   shaker.	   Absorbance	   of	   the	   solubilised	   SRB	   dye	   was	   read	   at	  400nm	  on	  a	  Tecan	  infinite	  200	  pro	  Microplate	  Reader	  (Tecan,	  UK).	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2.2.9	  Generation	  of	  drug	  resistant	  cell-­‐lines	  
	  HCT116	   cells	   were	   grown	   in	   full	   media	   (RPMI)	   and	   maintained	   in	   T-­‐150	   cell	  culter	   flasks	   (Corning)	   so	   that	   there	   was	   approximately	   75%	   confluency	  following	  each	  passage.	  Cells	  were	   then	  exposed	   to	  media	  with	   the	  addition	  of	  DMSO	  and	  either	  BS181	  or	  BS194	  at	   several	   sub-­‐optimal	   concentrations	   (IC50	  values	   determined	   previously	   by	   an	   SRB	   assay).	   Cells	   were	  maintained	   at	   the	  highest	  tolerable	  dose	  of	  each	  drug	  until	  the	  flasks	  were	  at	  least	  50%	  confluent	  and	   could	   be	   split.	   Cells	   were	   then	   split	   into	   two	   smaller	   ‘daughter’	   T75	   cell	  culture	   vessels,	   where	   one	  would	  maintain	   the	   original	   highest	   tolerable	   dose	  and	   the	   other	  would	   receive	   an	   increased	   dose.	   This	  was	   repeated	   and	   at	   one	  month	   periods	   the	   cells	  were	   challenged	   to	   drugs	   in	   an	   SRB	   assay	   as	   detailed	  above.	  	  
2.2.10	  siRNA	  knockdown	  
	  The	   forward	   transfection	   method	   was	   used	   to	   transfect	   cells	   with	   siRNA.	  Volumes	   and	   concentrations	  of	   reagents	  used	  were	   adjusted	  depending	  on	   the	  volume	   of	   the	   cell	   culture	   vessel	   used	   according	   to	   the	   manufacturers	  instructions.	  Typically,	  10cm	  cell	  culture	  plates	  (Corning)	  were	  used.	  For	   10cm	   plates,	   cells	   were	   cultured	   in	   full	   media	   until	   approximately	   75%	  confluency	   was	   reached.	   Cells	   were	   trypsinised	   and	   spun-­‐down	   in	   media	  containing	   FCS	   only.	   500µl	   of	   antibiotic-­‐free	   and	  FCS-­‐free	  media	  was	   added	   to	  the	   centre	   of	   a	   10cm	  plate.	   For	   each	  plate	   800pmol	   siRNA	   (40µl	   from	  a	  20µM	  stock)	  was	   added	   to	   the	   additive-­‐free	  media,	   followed	   by	   the	   same	   volume	   of	  Lipofectamine	   RNAiMAX	   (Invitrogen,	   UK)	   and	   left	   to	   incubate	   at	   room	  temperature	  for	  20	  minutes.	  Cells	  were	  then	  resuspended	  in	  full	  media,	  counted	  with	   a	   haemocytometer	   and	   2.5	   x	   106	   cells	   were	   transferred	   to	   the	   plate	  containing	   the	   siRNA:Lipofectamine:media	   mixture	   in	   a	   total	   volume	   of	   10ml.	  Cells	  were	  left	  for	  48	  hours	  before	  harvesting	  or	  24	  hours	  if	  performing	  a	  second	  transfection.	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For	  double	  transfections,	  the	  first	  round	  of	  transfection	  was	  typically	  carried-­‐out	  in	   10cm	   plates	   and	   then	   the	   cells	   were	   trpypsinised,	   pooled	   (in	   the	   case	   of	  replicate	   samples),	   counted	   and	   then	   re-­‐seeded	   on	   6-­‐well	   plates	   for	   RNA	   or	  protein	   harvest	   and	   for	   FACS	   analysis,	   or	   to	   96-­‐well	   plates	   for	   cell	   growth	   via	  SRB.	   Volumes	   and	   concentrations	   of	   reagents	  were	   adjusted	   appropriately	   for	  the	  second	  round	  of	  transfection.	  	  
2.2.11	  Flow	  cytometry	  Cells	  were	  seeded	   in	  six-­‐well	  plates	  at	  a	  density	  of	  4	  x	  105	   in	  media	  containing	  10%	  FCS	  and	  allowed	  to	  adhere	  for	  48hrs,	  followed	  by	  addition	  of	  compounds	  or	  siRNA	   and	   incubation	   for	   a	   further	   48hrs.	   Cells	   were	   then	   trypsinized,	  centrifuged	   at	   1,100	   rpm	   for	   5	  min,	   and	   resuspended	   in	   5	  ml	   of	   ice-­‐cold	   PBS,	  centrifuged	   (as	   above),	   gently	   resuspended	   in	   1	  ml	   ice-­‐cold	   70%	   ethanol,	   and	  incubated	  at	  40C	  for	  1	  hr.	  Cells	  were	  washed	  twice	  with	  5	  ml	  of	  ice-­‐cold	  PBS	  and	  resuspended	  in	  100	  µlof	  PBS	  containing	  100	  µg/ml	  RNase	  (Sigma)	  and	  1	  ml	  of	  50	  
µg/ml	  propidium	   iodide	   (Sigma)	   in	  PBS.	  Following	   incubation	  overnight	   in	   the	  dark	  at	  40C	  and	  filtering	  through	  70-­‐µm	  muslin	  gauze	  into	  fluorescence-­‐activated	  cell	   sorting	   tubes	   (Becton	   Dickinson,	   UK)	   to	   remove	   cell	   clumps,	   stained	   cells	  were	  acquired	  using	  the	  RXP	  cytomics	  software	  on	  a	  Beckman	  Coulter	  Elite	  ESP	  (Beckman	  Coulter,	  High	  Wycombe)	  and	  data	  were	  analyzed	  using	  Flow	  Jo	  v7.2.5	  (Tree	  Star,	  Inc.).	  For	  dual	  labeling	  with	  propidium	  iodide	  and	  Annexin	  V,	  the	  cells	  were	   trypsinized	   and	   collected	  with	   the	   culture	  medium,	   centrifuged	   at	   1,100	  rpm	  for	  5	  min,	  and	  washed	  twice	  with	  5	  ml	  of	  ice-­‐cold	  PBS	  containing	  2%	  (w/v)	  bovine	  serum	  albumin	  (Sigma).	  Cells	  were	  labeled	  with	  Annexin	  V-­‐FITC	  using	  the	  Annexin	   V-­‐FITC	   apoptosis	   detection	   kit	   I	   (BD	   Pharmingen),	   as	   per	   the	  manufacturer’s	   instructions.	   Labeled	   cells	   were	   acquired	   within	   1hr	   using	   the	  RXP	   cytomics	   software	   on	   a	   Beckman	   Coulter	   Elite	   ESP,	   and	   the	   data	   were	  analyzed	   using	   Flow	   Jo	   v7.2.5.	   Statistical	   analysis	   was	   performed	   for	   three	  independent	   experiments,	   carried	   out	   using	   the	   unpaired	   Student’s	   t	   test	   to	  determine	  P	  values.	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2.2.12	  Proteasome	  inhibition	  with	  MG132	  
	  HCT-­‐116	   cells	   were	   transfected	  with	   SmartPOOL	   siRNA	   targeted	   to	   CDK7	   and	  non-­‐targeting	   siRNA	   (Dharmacon)	   for	   48hrs	   before	   being	   treated	   with	   the	  proteasome	  inhibitor	  MG132	  at	  a	  concentration	  of	  10µM	  for	  1,	  2	  and	  4hrs.	  DMSO	  was	  used	  as	  an	  internal	  control.	  Protein	  was	  harvested	  at	  the	  allotted	  times	  and	  subsequently	  analysed	  by	  immunoblotting.	  
	  
2.2.13	  Treatment	  of	  HCT-­‐116	  a/s	  cells	  with	  1-­‐NMPP1	  
	  Analogue	  sensitive	  (a/s)	  HCT-­‐116	  cells	  and	  their	  parental	  cell	  line	  were	  treated	  with	   the	   bulky	   synthetic	   ATP	   analogue	   1-­‐NMPP1	   as	   previously	   described	  (Larochelle,	  S.	  et	  al	  2007).	  Briefly,	  cells	  were	  seeded	  in	  10cm	  plates	  (Corning)	  at	  a	  density	  of	  2.5	  x	  106	  cells	  in	  a	  volume	  of	  10ml	  McCoy’s	  5A	  media	  (supplemented	  with	   FCS	   and	   antibiotics)	   and	   left	   for	   48hrs.	   A	   serial	   dilution	   of	   1-­‐NMPP1	  was	  then	  prepared	  from	  a	  starting	  concentration	  of	  10µM	  in	  a	  total	  volume	  of	  10ml	  full	   media.	   DMSO	   was	   used	   as	   a	   control.	   Cells	   were	   treated	   with	   the	   media	  containing	   1-­‐NMPP1	   and	   DMSO	   for	   14hrs.	   Protein	   was	   then	   collected	   and	  analysed.	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2.2.14	  Computer-­‐aided	  drug	  design	  of	  experimental	  drugs/lead	  compounds	  
	  The	   computer	   program	  GLIDE	   v4.5	   (Schrodinger,	   Camberley,	   UK)	  was	   used	   to	  simulate	   ligand	   docking	   into	   the	   CDK7	   ATP-­‐binding	   pocket.	   All	   ligands	   were	  docked	   into	   a	   grid	   structure	   using	   GLIDS	   SP	   mode	   to	   generate	   initial	   poses	  followed	  by	  XP	   and	  MMGBSA	  modes	   to	   evaluate	   and	   rank	  docking	   scores.	   Ten	  poses	  were	  generated	  for	  each	  run	  and	  the	  top	  one	  picked	  for	  further	  evaluation.	  
	  
2.2.15	  Synthetic	  methods	  for	  generating	  compounds	  
	  All	   manipulations	   of	   air-­‐	   or	   moisture-­‐	   sensitive	   materials	   were	   carried	   out	   in	  oven-­‐	  or	  flame-­‐dried	  glassware	  under	  an	  inert	  atmosphere	  of	  nitrogen	  or	  argon.	  Syringes,	  which	  were	  used	  to	  transfer	  reagents	  and	  solvents,	  were	  purged	  with	  nitrogen	   before	   use.	   Reaction	   solvents	   were	   distilled	   from	   CaH2	  (dichloromethane,	   toluene,	   triethylamine),	  Na/Ph2CO	   (tetrahydrofuran,	   diethyl	  ether),	  or	  obtained	  as	  dry	  or	  anhydrous	  from	  Aldrich	  Chemical	  Company	  (N,	  N-­‐	  dimethylformamide,	   acetonitrile)	   or	   BDH	   (ethanol).	   Other	   solvents	   and	   all	  reagents	   were	   obtained	   from	   commercial	   suppliers	   (Fluka,	   Aldrich	   Chemical	  Company,	   and	   Lancaster	   Chemicals)	   and	   were	   used	   as	   obtained	   if	   purity	   was	  >98%.	  All	   flash	  column	  chromatography	  experiments	  were	  carried	  out	  on	  BDH	  silica	  gel	  60,	  particle	  size	  0.040	  to	  0.063	  mm,	  unless	  otherwise	  stated.	  TLC	  was	  performed	   on	   precoated	   aluminum-­‐backed	   or	   glass-­‐backed	   plates	   (Merck	  Kieselgel	   60	   F254)	   and	   visualized	   with	   UV	   light	   (254	   nm)	   or	   potassium	  permanganate	   (KMnO4),	   vanillin	   or	   phosphomolybdic	   acid	   stains	   as	   deemed	  appropriate.	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2.2.16	  Drug	  treatment	  
2.2.16.1	  Drug	  treatment	  for	  microarray	  
	  HCT116	   cells	   were	   treated	   with	   BS181	   and	   BS194	   at	   the	   following	  concentrations	  as	  part	  of	  a	  pilot	  study	  to	  assess	  the	  optimum	  concentration	  treat	  cells	  for	  the	  microarray:	  
• BS194:	  0.1,	  1µM	  
• BS181:	  	  10,	  20,	  40µM	  In	  the	  initial	  study,	  cells	  were	  treated	  for	  0.5,	  1,	  1.5,	  2,	  4	  and	  6hrs	  before	  RNA	  was	  harvested.	  DMSO	  was	  included	  as	  a	  control.	  	  RT-­‐PCR	  was	  used	  to	  assess	  the	  total	  reduction	  of	  MCL-­‐1	  transcript	  over	  time	  following	  treatment.	  This	  was	  used	  as	  a	  general	  indicator	  of	  drug	  efficacy.	  For	   the	   microarray,	   HCT-­‐116	   cells	   were	   seeded	   in	   10cm	   cell	   culture	   plates	  (Corning,	  UK)	  at	  a	  density	  of	  2.5	  x	  106	  in	  a	  total	  volume	  of	  10ml	  RPMI	  (with	  FCS	  and	  antibiotics)	   and	   left	   for	  48hrs.	  Cells	  were	   treated	   in	   replicates	  of	   five	  with	  either	  1µM	  BS194	  or	  20µM	  BS181	  for	  1,	  2	  and	  6hrs.	  DMSO	  controls	  for	  the	  same	  time-­‐points	  were	   used	   for	   direct	   comparison.	  Media	  was	   gently	   removed	   from	  the	   plates	   and	   replaced	   with	   full	   media	   prepared	   with	   the	   appropriate	  concentration	   of	   compound.	   Once	   again,	   levels	   of	   MCL-­‐1	   were	   assessed	   as	   an	  indicator	  of	  efficacy.	  In	  addition,	  the	  levels	  of	  two	  house-­‐keeping	  genes,	  GAPDH	  and	  β-­‐actin	  were	  compared	  across	  each	  replicate	  to	  pick	  replicates	  with	  the	  least	  intra-­‐condition	  variation.	  Three	  samples	  were	  chosen	  on	  this	  basis	  and	  the	  RNA	  sent	  –off	  for	  the	  microarray	  experiment.	  Following	   microarray	   data	   analysis,	   lists	   of	   interesting	   genes	   were	   generated	  based	   on	   their	   expression	   profiles.	   The	   same	   drug-­‐treatment	   regime	   was	  repeated	  in	  a	  separate	  experiment	  in	  triplicate	  and	  RNA	  and	  protein	  collected	  in	  order	  to	  validate	  results	  obtained	  from	  the	  microarray.	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2.2.17	  Microarray	  
	  Microarrays	   were	   performed	   by	   Cambridge	   Genomic	   Services,	   Department	   of	  Pathology,	   University	   of	   Cambridge	   on	   Illumina	   HumanHT-­‐12	   v3	   Beadchips.	  (Illumina,	   Inc,	   Essex,	   UK).	   Total	   RNA	   samples	   were	   sent	   in	   duplicate	   1.5ml	  microfuge	   tubes	   (Sigma):	   3µl	   for	   sample	   quality	   control	   and	   1µg	   for	  experimental	  processing.	  Samples	  were	   typically	   in	   the	  range	  of	  400-­‐800ng/µl.	  For	  sample	  processing	  500ng	  total	  RNA	  was	  used.	  Each	  array	  on	  the	  HumanHT-­‐12	  BeadChip	  targets	  more	  than	  47,000	  probes	  derived	  from	  the	  NCBI	  and	  utilizes	  the	  Direct	  Hybridization	  Assay.	  This	  assay	  is	  performed	  in	  the	  following	  steps:	  
• Reverse	  transcription	  of	  RNA	  
o First	  strand	  synthesis	  reverse	  transcription	  
o Second	  strand	  synthesis	  reverse	  transcription	  
• cDNA	  purification	  
• in	  vitro	  transcription	  (IVT)	  incorporating	  biotin	  labelled	  nucleatides	  
• cRNA	  purification	  
• Hybridisation	  
• Washing	  and	  blocking	  steps	  
• Streptavadin-­‐Cy3	  staining	  
• Scanning	  Fluorescence	   emission	   by	   Cy3	   is	   detected	   and	   results	   interpreted	   by	  GenomeStudio	   software	   (Illumina,	   Inc).	   Both	   normalised	   and	   non-­‐normalised	  values	  were	  provided	  in	  the	  form	  of	  a	  standard	  text	  file	  format	  for	  analysis.	  
2.2.17.1	  Microarray	  analysis	  and	  statistical	  methods	  
	  Non-­‐normalised,	   non-­‐background	   corrected	   raw	   data	   was	   imported	   into	  GeneSpring	  GX	  v11	  (Agilent	  technologies,	  Edinborough,	  UK).	  	  Detection	  p-­‐values	  range	  for	  present	  and	  absent	  calls	  (call	  range)	  were	  set	  to	  0.99	  for	  present	  and	  0.95	  for	  absent.	  For	  pre-­‐processing	  of	  data,	  the	  threshold	  signal	  was	  set	  to	  1	  and	  samples	   were	   normalised	   using	   the	   quantile	   algorithm,	   with	   no	   baseline	  transformation.	   In	   the	   first	   instance,	   when	   creating	   an	   interpretation	   and	  selecting	   conditions,	   all	   flags	   were	   included	   (present,	   marginal	   and	   absent).	  
	   88	  















	   89	  
3	  Results	  
3.1	  siRNA	  abrogation	  of	  the	  CAK	  subunits,	  CDK7,	  cyclin	  H	  and	  MAT1	  	  Recent	  work	  from	  the	  laboratory	  has	  identified	  a	  CDK7	  selective	  small	  molecule	  inhibitor,	   BS181,	   which	   promotes	   cell	   cycle	   arrest,	   and	   in	   particular	   strongly	  induces	  apoptosis.	  In	  order	  to	  verify	  that	  CDK7	  inhibition	  is	  responsible	  for	  the	  growth	   inhibition,	   cell	   cycle	   arrest	   and	   apoptosis	   induced	   by	   BS181,	   the	  individual	  subunits	  making	  up	  the	  CAK	  complex	  were	  knocked-­‐down	  using	  small	  interfering	  RNA	   (siRNA)	   and	   the	   effects	  were	   determined	   by	  western	   blotting,	  quantitative	   Real	   Time	   PCR	   (qRT-­‐PCR)	   and	   by	   cell	   cycle	   analysis	   using	   flow	  cytometry.	  	  	  
3.1.1	  siRNA	  mediated	  knockdown	  of	  any	  of	  the	  CAK	  subunits	  reduces	  levels	  of	  the	  
whole	  complex	  	  siRNA-­‐mediated	  knockdown	  of	  CDK7,	  cyclin	  H	  or	  MAT1	  using	  a	  pool	  of	  4	  siRNAs	  purchased	  from	  Dharmacon	  typically	  gave	  a	  reduction	  in	  RNA	  levels	  of	  between	  80-­‐90%	   in	   HCT116	   cells,	   as	   measured	   by	   real-­‐time	   RT-­‐PCR	   (fig	   3.1	   A-­‐C).	  Immunoblotting	  confirmed	  knockdown	  at	  the	  protein	  level	  of	  each	  CAK	  subunit	  by	   the	   relevant	   siRNA,	   (Fig	   3.1D),	   a	   finding	   confirmed	   by	   quantification	   of	  immunoblotting	  data	  from	  three	  independent	  experiments	  (fig	  3.1	  E-­‐G),	  with	  60-­‐80%	  reduction	  in	  protein	  level.	  Knockdown	  of	  any	  one	  CAK	  subunit	  did	  not	  affect	  mRNA	   expression	   of	   the	   other	   two	   subunits.	   However,	   CDK7	   knockdown	  resulted	   in	  a	  reduction	   in	  cyclin	  H	  and	  MAT1	  protein,	  with	  reciprocal	  effects	  of	  cyclin	  H	  and	  MAT1	  knockdown	  on	  CDK7	  levels,	  as	  well	  as	  reduction	  in	  cyclin	  H	  protein	  by	  MAT1	  knockdown	  and	  vice	  versa.	  	  	  These	   findings	  show	  that	  a	   reduction	   in	  any	  one	  CAK	  subunit	   results	   in	   loss	  of	  the	   whole	   complex.	   This	   is	   in	   contrast	   to	   treatment	   with	   the	   CDK7	   inhibitor	  BS181,	  where	  no	  reduction	  in	  CAK	  levels	  is	  seen,	  presumably	  because	  inhibition	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of	  CDK7	  does	  not	  lead	  to	  reduction	  in	  its	  levels	  and	  consequently	  there	  is	  also	  no	  reduction	  in	  levels	  of	  cyclin	  H	  or	  MAT1.	  
	  	  
3.1.2	  siRNA	  mediated	  knockdown	  of	  the	  CAK	  subunits	  results	  in	  reduction	  in	  
phosphorylation	  of	  CDK7	  targets	  	  Knockdown	  of	  any	  of	  the	  three	  subunits	  of	  the	  CAK	  complex	  also	  led	  to	  a	  marked	  reduction	   in	   levels	   of	   phosphorylation	   of	   known	   cdk7	   substrates,	   including	  phospho-­‐cdk1	   (T-­‐161)	   and	   phospho-­‐cdk2	   (T-­‐160)	   (fig	   3.2).	   The	  hyperphosphorylated	   bands	   for	   both	   phospho-­‐cdk1	   and	   cdk2	   shown	   in	   the	  figure	  are	  the	  lower	  bands	  in	  the	  autoradiographs.	  However,	  phosphorylation	  of	  RNA	   polymerase	   II	   CTD	   at	   serine	   5	   (S5)	   showed	   inter-­‐experimental	   variation:	  pool	  siRNAs	  for	  CDK7,	  cyclin	  H	  or	  MAT1	  did	  not	  lead	  to	  a	  significant	  decrease	  in	  S5	  phosphorylation	  compared	   to	   the	  non-­‐targeting	   control	   (fig	  3.2	  F).	  Nor	  was	  phosphorylation	   of	   the	   CDK9	   target	   PolII	   CTD	   S2,	   reduced	   by	   CAK	   subunit	  knockdown.	   This	   is	   in	   contrast	   to	   the	   reduction	   in	   phosphorylation	   of	   S5	  observed	  with	  BS181	  treatment	  (Ali	  et	  al	  2009),	  suggesting	  that	  another	  kinase,	  likely	  CDK9	  may	  substitute	  for	  CDK7	  following	  loss	  of	  CDK7	  (and	  CAK)	  protein,	  but	  that	  treatment	  with	  CDK7	  selective	  small	  molecular	  inhibitors,	  which	  do	  not	  lead	  to	  reduced	  CAK	  levels,	  may	  not	  allow	  CDK9	  compensation	  for	  CDK7.	  There	  is	   no	   evidence	   in	   the	   literature	   that	   CDK9	   can	   compensate	   for	   CDK7	  phosphorylation	   of	   CDK1	   or	   CDK2.	   Indeed,	   in	   a	   series	   of	   elegant	   experiments	  undertaken	  in	  the	  Fisher	  lab,	  which	  used	  an	  HCT116-­‐derived	  cell	  line	  where	  wt	  
CDK7	   was	   replaced	   with	   an	   analogue	   sensitive	   (AS)	   mutant	   (CDK7as)	   by	  homologous	   recombination	   showed	   that	  when	   the	   bulky	   ATP	   analogue	   1	   NM-­‐PP1	  was	  administered	  to	  inhibit	  CDK7	  activity,	  HCT116as	  cells	  demonstrated	  cell	  cycle	   arrest	   (Larochelle,	   Merrick	   et	   al.	   2007),	   but	   no	   defect	   in	   PolII-­‐mediated	  transcription	   initiation,	   suggesting	   a	   compensatory	   role	   for	   CDK9	   or	   perhaps	  even	  CDK8	  	  (Glover-­‐Cutter,	  Larochelle	  et	  al.	  2009).	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Fig	  3.1.	  siRNA-­mediated	  knockdown	  of	  subunit	  in	  the	  CAK	  complex	  	  HCT116	  cells	  were	  transfected	  with	  pools	  of	  four	  siRNAs	  for	  CDK7,	  cyclin	  H,	  MAT1	  or	  a	  non-­‐targeting	   (NT)	   siRNA	   pool.	   (A-­‐C)	   Shown	   are	   real-­‐time	   RT-­‐PCR	   results	   for	   three	  independent	   experiments.	   CDK7	   (A),	   cyclin	   H	   (B)	   and	   MAT1	   (C)	   expression	   was	  determined	  relative	  to	  GAPDH	  and	  the	  bar	  charts	  show	  expression	  as	  fold	  relative	  to	  the	  non-­‐targeting	  siRNA.	  Control	  represents	  treatment	  of	  cells	  with	  the	  transfection	  reagent	  only;	   error	   bars	   show	   the	   standard	   errors	   of	   the	  mean;	   *	   =	   p<0.01	   relative	   to	  NT	   (D)	  Whole	   cell	   lysates	   prepared	   from	   HCT116	   cells	   following	   CDK7,	   cyclin	   H	   or	   MAT1	  knockdown,	   were	   immunoblotted,	   as	   shown.	   (E-­‐F)	   Protein	   levels	   were	   estimated	   by	  quantification	  of	  signals	  on	  autoradiographs	  using	  Image	  J.	  Bar	  charts	  show	  mean	  CDK7,	  cyclin	   H	   and	   MAT1	   protein	   levels	   relative	   to	   ß-­‐actin	   levels	   for	   three	   independent	  experiments,	   including	   the	   one	   shown	   in	   D.	   Error	   bars	   depict	   standard	   errors	   of	   the	  mean.	   siCH	   refers	   to	   siRNA	   pool	   for	   cyclin	   H;	   *	   =	   p<0.01,	   ¥	   =	   p<0.05	   relative	   to	   NT.	  	  NT	  =	  non-­‐targeting	  siRNA;	  control	  =	  transfection	  reagent	  only	  (mock	  transfection).	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Fig	  3.2.	  Effect	  of	  siRNA-­mediated	  knockdown	  of	  CAK	  subunits	  on	  phosphorylation	  
of	  CAK	  targets	  CDK1,	  CDK2	  and	  PolII.	  HCT116	  cells	  were	   transfected	  with	  a	  pool	  of	  four	  siRNAs	  for	  CDK7,	  cyclin	  H	  (CH),	  MAT1	  or	  a	  non-­‐targeting	  (NT)	  siRNA	  pool,	  as	  in	  Fig.	  3.1.	  Control	  represents	  transfection	  with	  the	  Lipofectamine	  reagent	  alone.	  (A-­‐H)	  Shown	  are	   representative	   immunoblots	   of	   whole	   cell	   lysates	   prepared	   from	   HCT116	   cells	  following	  knockdown.	  For	  pCDK1	  and	  pCDK2,	   the	  hyperphosphorylated	  bands	  are	   the	  lower	   bands	   in	   each	   autoradiograph.	   Bar	   charts	   show	   mean	   quantified	   protein	  expression	  levels	  relative	  to	  ß-­‐actin.	  Quantification	  was	  carried	  out	  using	  densitometry	  (ImageJ)	   for	   three	   independent	   experiments.	   Error	   bars	   =	   SEM;	   CH	   =	   siRNA	   pool	   for	  cyclin	  H;	  *	  =	  p<0.05	  relative	  to	  NT.	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3.1.3	  CDK7	  knockdown	  downregulates	  genes	  required	  for	  cell	  cycle	  progression	  
and	  apoptosis	  control	  	  In	   an	   independent	   experiment,	   whole	   cell	   lysates	   were	   immunoblotted	   for	  proteins	   involved	   with	   cell	   cycle	   progression,	   transcription	   and	   apoptosis	  following	  transfection	  with	  the	  CDK7	  siRNA	  pool	  and	  the	  two	  individual	  siRNAs	  from	  this	  pool	  (CDK7	  #10	  and	  #12).	   	  These	  two	  individual	  siRNAs	  were	  chosen	  from	  a	  pool	  of	  four;	  preliminary	  experiments	  showed	  that	  siCDK7	  #10	  lead	  to	  up	  to	  90%	  knockdown	  and	  #12	  lead	  to	  <10%	  (results	  not	  shown),	  hence,	  #12	  was	  used	  as	  a	  negative	  control	  in	  subsequent	  experiments.	  Immunoblotting	  for	  CDK7	  showed	   knockdown	  with	   the	   pool	   and	   CDK7	   siRNA	  #10,	   but	   no	   CDK7	   protein	  knockdown	   was	   observed	   with	   #12	   (Fig.	   3.3	   A)	   as	   would	   be	   expected.	   As	  observed	   previously,	   CDK7	   abrogation	   reduced	   levels	   of	   cyclin	   H	   and	   MAT1	  protein.	  	  	  CDK7	  knockdown	  resulted	  in	  reduction	  in	  most	  CDKs	  and	  cyclins	  examined	  (fig	  3.3B)	  and	  in	  agreement	  with	  the	  findings	  for	  BS181	  (Ali,	  Heathcote	  et	  al.	  2009),	  expression	   of	   the	   apoptosis	   proteins	   XIAP	   and	   MCL-­‐1	   and	   CDK4	   were	   also	  reduced	  (fig	  3.3C).	  Notably,	  cyclin	  E	  levels	  were	  not	  affected.	  MAT1	  and	  cyclin	  H	  had	  a	  similar	  effect.	  Interestingly,	  siRNA	  for	  CDK2	  did	  not	  result	  in	  a	  reduction	  in	  any	  of	  the	  cell	  cycle	  or	  apoptosis-­‐associated	  proteins.	  	  
	  
3.1.4	  Cell	  growth	  and	  FACS	  analysis	  following	  siRNA	  mediated	  knockdown	  of	  CDK7,	  
cyclin	  H	  and	  MAT1	  	  Following	   transfection	  with	  CDK7,	  cyclin	  H	  or	  MAT1	  siRNAs,	  a	   five-­‐day	  growth	  assay	   (SRB)	   was	   used	   to	   assess	   the	   effect	   of	   CAK	   subunits	   on	   HCT116	   cells.	  Knockdown	  of	  any	  of	  the	  CAK	  subunits	  coincided	  with	  a	  decrease	  in	  growth	  (fig	  3.4	  A-­‐C).	  Knockdown	  of	  CDK7	  had	  the	  most	  profound	  effect	  on	  cell	  growth.	  FACS	  analysis	   was	   also	   used	   to	   determine	   changes	   in	   the	   cell	   cycle,	   72	   hrs	   post	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transfection.	  As	  observed	   in	   the	   growth	   assay,	   CDK7	  knockdown	  had	   the	  most	  potent	   effect	   on	   the	   cell	   cycle,	  with	   a	   reduction	   in	   cells	   in	   the	  G1,	   S	   and	  G2/M	  phases	  and	  an	  increase	  of	  cells	  in	  the	  sub-­‐G1	  phase,	  relative	  to	  the	  non-­‐targeting	  and	  the	  vehicle-­‐only	  controls	  (fig	  3.5	  A).	  Cyclin	  H	  and	  MAT1	  knockdown	  similarly	  led	  to	  a	  reduction	  in	  cells	  in	  the	  different	  phases	  of	  the	  cell	  cycle	  and	  an	  increase	  in	  cells	  in	  the	  sub-­‐G1	  phase	  (fig	  3.4	  B,	  C).	  	  	  	  To	  confirm	  that	  the	  sub-­‐G1	  peak	  represents	  cells	  undergoing	  apoptosis,	  Annexin	  V	  and	  propidium	  iodide	  co-­‐staining	  was	  carried	  out.	  As	  expected,	  there	  was	  a	  far	  greater	  proportion	  of	  cells	  in	  early	  and	  late	  apoptosis	  following	  transfection	  with	  CDK7,	   cyclin	   H	   and	   MAT1	   siRNA,	   compared	   to	   the	   non-­‐targeting	   siRNA	   or	  lipofectamine	  only	  controls	  (fig	  3.5	  D-­‐H).	  	  	  	  





Fig	   3.3.	   The	   effect	   of	   siRNA-­mediated	   knockdown	   of	   CAK	   subunits	   and	   CDK2	   on	  
levels	  of	  proteins	  involved	  in	  the	  regulation	  of	  the	  cell	  cycle	  and	  apoptosis.	  siRNA-­‐mediated	  knockdowns	  were	  performed	  in	  HCT116	  cells.	  The	  autoradiographs	  of	  immunoblots	   for	   whole	   cell	   lysates	   prepared	   72	   hours	   following	   transfection,	   are	  shown.	  	  	  





Fig	  3.4.	  Cell	  growth	  analysis	  of	  HCT116	  cells	   transfected	  with	  siRNA	  against	  CAK	  
subunits.	  	  (A-­‐C)	  HCT116	  cells	  were	  transfected	  with	  the	  siRNA	  indicated	  and	  cultured	  over	  5	  days.	  One	  plate/treatment/day	  was	  used	  to	  assess	  growth	  using	  the	  the	  SRB	  assay.	  Growth	  is	  shown	  relative	  to	  the	  values	  obtained	  for	  the	  no-­‐treatment	  control	  on	  day	  5.	  The	  values	  represent	  the	  means	  of	  5	  replicates.	  Error	  bars	  =	  SEM;	  *	  =	  p<0.01	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Fig	  3.5.	  Cell	  cytometry	  and	  apoptosis	  in	  cells	  following	  siRNA	  mediated	  CDK7,	  
cyclin	  H	  and	  MAT	  knockdown.	  	  HCT116	  cells	  transfected	  with	  siRNA	  pools	   for	  CDK7,	  cyclin	  H,	  MAT	  or	  a	  non-­‐targeting	  pool	   were	   fixed	   72	   hours	   after	   transfection	   and	   FACS	   analysis	   was	   carried	   out	   to	  determine	  the	  proportion	  of	  cells	  in	  different	  phases	  of	  the	  cell	  cycle.	  Shown	  are	  the	  cell	  cycle	  profiles	  for	  HCT116	  following	  siRNA	  for	  CDK7	  (A),	  Cyclin	  H	  (B)	  and	  MAT1	  (C).	  The	  plots	   show	   profiles	   for	   reagent	   control	   (transfection	   reagent	   alone;	   red	   lines),	   non-­‐targeting	  siRNA	  pool	  (black	  lines)	  and	  the	  different	  CAK	  subunits	  (grey	  colouring	  under	  grey	   lines).	   Cells	   transfected	   as	   in	   A-­‐C	   were	   then	   analysed	   for	   apoptosis	   (D-­‐E)	   and	  stained	   for	   Annexin	   V	   (x-­‐axis)	   and	   propidium	   iodide	   (y-­‐axis).	   Cells	   in	   early	   apoptosis	  show	  in	  the	  bottom	  right	  quadrant	  and	  late	  apoptosis/necrosis,	  top	  right	  quadrant.	  The	  numbers	  shown	  in	  each	  quadrant	  represent	  the	  percentage	  of	  cells	  in	  each	  quadrant.	  	  
	   99	  
	  
3.2	   Investigation	   of	   potential	   for	   CDK	   inhibitors	   in	   overcoming	   resistance	   to	  
chemotherapy	  agents	  and	  mechanisms	  by	  which	  resistance	  to	  CDK	  inhibitors	  might	  
arise	  	  	  	  The	  findings	  described	  above	  demonstrate	  that	  knockdown	  of	  CDK7	  using	  siRNA	  inhibits	  cell	  growth	  by	  promoting	  cell	  cycle	  arrest	  and	  apoptosis.	  Knockdown	  of	  CDK7	  inhibits	  the	  phosphorylation	  of	  CDKs	  that	  regulate	  cell	  cycle	  progression.	  Interestingly,	  there	  was	  no	  clear	  reduction	  in	  phosphorylation	  of	  serine	  5	  in	  the	  C-­‐terminal	  domain	  of	  RNA	  polymerase	  II,	  suggesting	  that	  CDK7	  down-­‐regulation	  and	  accompanying	  down-­‐regulation	  of	   the	  CDK7-­‐associated	  cyclin	  H	  and	  MAT1	  protein	  may	  be	  accompanied	  by	  compensation	  by	  other	  CDKs,	  most	  likely	  CDK9.	  Despite	   the	   lack	   of	   a	   detectable	   effect	   on	   PolII	   phosphorylation,	   CDK7	  knockdown	   did	   cause	   reduction	   in	   levels	   of	   MCL-­‐1	   and	   XIAP,	   the	   mRNAs	   for	  which	  are	  rapidly	  turned	  over,	  suggesting	  that	  CDK7	  knockdown	  does	  impact	  on	  gene	  expression.	  Previous	  work	  from	  the	  laboratory	  has	  demonstrated	  that	  the	  CDK7	  selective	  small	  molecule	  inhibitor,	  BS181	  and	  the	  pan	  CDK	  inhibitor	  BS194	  similarly	  promote	  apoptosis	  and	  cause	  reduction	  in	  levels	  of	  proteins	  encoded	  by	  genes	  with	  short-­‐lived	  mRNA	  (Ali,	  Heathcote	  et	  al.	  2009;	  Heathcote,	  Patel	  et	  al.	  2010).	  Together,	   the	   findings	   reported	  here	   indicate	   that	   the	   cellular	   effects	  of	  BS181	   are	   indeed	  due	   to	   selective	   inhibition	  of	   CDK7.	  To	   further	   elucidate	   the	  mechanisms	   of	   action	   of	   BS181	   and	   BS194	   in	   cell	   cycle	   and	   transcription	  regulation,	   I	   have	   carried	   out	   gene	   expression	  microarray	   analysis,	   to	   identify	  genes	  whose	  expression	   is	  altered	  upon	  treatment	  with	   these	   inhibitors.	  These	  studies	   should	   provide	   new	   insights	   into	   the	   mechanisms	   of	   action	   of	   these	  inhibitors,	   but	  may	   also	   identify	   genes	   for	   development	   as	   biomarkers	   for	   the	  pre-­‐clinical	  and	  ultimately,	  clinical	  settings.	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3.2.1	  CDK	  inhibitors	  inhibit	  growth	  of	  endocrine	  resistant	  breast	  cancer	  cells	  	  Previous	   work	   from	   the	   laboratory	   has	   indicated	   that	   a	   key	   mechanism	   of	  endocrine	   resistance	   in	   breast	   cancer	   cell	   line	  models	   is	   up-­‐regulation	   of	   anti-­‐apoptotic	  genes	  and	  down-­‐regulation	  of	  pro-­‐apoptotic	  genes,	  thus	  promoting	  cell	  survival.	   Hence,	   MLET5	   cells,	   derived	   by	   long-­‐term	   culturing	   of	   the	   estrogen	  receptor	  a	  (ERa)-­‐positive	  and	  estrogen-­‐responsive	  MCF-­‐7	  breast	  cancer	  cell	  line,	  has	  increased	  expression	  of	  the	  anti-­‐apoptotic	  gene	  BCL2,	  and	  down-­‐regulation	  of	   the	   pro-­‐apoptotic	   genes,	   BIK	   and	   BID	   (Tolhurst,	   Thomas	   et	   al.	   2011).	   As	  expected,	  MLET5	  cells	  were	  more	  resistant	  to	  etoposide	  than	  the	  parental	  MCF-­‐7	  cells	  (Table	  3.1),	  as	  were	  two	  other	  estrogen-­‐independent	  MCF-­‐7	  derived	   lines,	  MLET1	   and	   MLET2.	   TAMR	   cells	   were	   generated	   by	   the	   Nicholson	   group,	  following	  long-­‐term	  culturing	  of	  MCF-­‐7	  cells	  in	  the	  presence	  of	  the	  anti-­‐estrogen	  tamoxifen	   (Knowlden	   et	   al	   2003).	   TAMR	   cells	   were	   similarly	   less	   sensitive	   to	  etoposide	  than	  parental	  MCF-­‐7	  cells.	  Finally,	  MCF-­‐7	  cells	  stably	  transfected	  with	  HER2	  (HER2-­‐18)	   (Benz,	  Scott	  et	  al.	  1992),	  which	  are	   tamoxifen-­‐resistant,	  were	  also	  less	  sensitive	  to	  etoposide	  than	  MCF-­‐7	  cells.	  The	  different	  lines	  were,	  by	  and	  large,	   equally	   sensitive	   to	   cisplatin	   and	   doxorubicin,	   suggesting	   that	   whilst	  resistance	   to	   etoposide	   may	   involve	   pathways	   similar	   to	   those	   mediating	  resistance	   to	  endocrine	  agents,	  alteration	   in	   these	  pathways	   is	  not	  sufficient	   to	  promote	   resistance	   to	   other	   chemotherapy	   agents.	   Testing	   CDK	   inhibitors	  showed	   that	   there	   is	   little	  difference	   in	  sensitivity	  of	   these	   lines	   to	   roscovitine.	  Interestingly,	  there	  was	  a	  difference	  in	  sensitivity	  to	  flavopiridol,	  in	  that	  MLET1	  and	  MLET2	  were	  about	  2-­‐fold	  less	  sensitive	  to	  flavopiridol	  than	  the	  other	  lines.	  As	  with	   these	   inhibitors,	  all	  of	   the	   lines	   tested	  were	  equally	  sensitive	   to	  BS181	  and	   BS194,	   although	   MLET1	   and	   MLET2	   cells	   were	   3-­‐4	   fold	   less	   sensitive	   to	  BS194,	   its	   inhibition	  profile	   being	   similar	   to	   that	   of	   flavopiridol,	   although	   they	  were	  still	  potently	  inhibited.	  In	  summary,	  there	  is	  little	  difference	  in	  sensitivity	  of	  endocrine	   responsive	   and	   resistant	   breast	   cancer	   cell	   lines	   to	   CDK	   inhibitors,	  suggesting	   that	   CDK	   inhibitors	  may	   have	   utility	   in	   the	   treatment	   of	   endocrine	  resistant	  breast	  cancer.	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Table	  3.1.	  GI50	  values	  for	  CDK	  inhibitors	  described	  in	  this	  thesis,	  as	  well	  as	  other	  
CDK	  inhibitors	  and	  chemotherapeutic	  agents.	  Shown	  are	  GI50	  values	  for	  3	  replicates,	  determined	  using	   the	  SRB	  assay	  across	  a	  panel	  of	   six	   cancer	   cell	   lines.	   Standard	  error	  shown	  in	  brackets.	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3.2.2	  Acquired	  resistance	  to	  BS194	  but	  not	  BS181	  can	  be	  mediated	  through	  
induction	  of	  ABC	  transporters	  implicated	  in	  multi-­‐drug	  resistance	  	  Towards	  development	  of	  our	  CDK	  inhibitors	  for	  clinical	  use,	  I	  determined	  if	  it	  is	  possible	   to	   generate	   cancer	   lines	   resistant	   to	  BS181	  and	  BS194.	  To	   investigate	  potential	   resistance	   mechanisms	   that	   may	   arise	   following	   BS181	   and	   BS194	  treatment,	  HCT116	   cells	  were	   cultured	   in	   the	  presence	   of	   these	   compounds	   at	  low	   doses	   (sub-­‐GI50	   concentrations	   at	   experimental	   inception)	   and	   passaged	  until	   resistant	   colonies	   were	   established.	   Culturing	   HCT116	   cells	   at	  concentrations	   of	   BS181	   20-­‐fold	   below	   the	   GI50,	   resulted	   in	   cell	   loss	   and	  culturing	  the	  remaining	  cells	  with	  BS181	  at	  the	  same	  concentration	  led	  to	  further	  cell	   loss.	   No	   cells	   emerged	   over	   a	   three-­‐month	   period	   that	   could	   grow	   in	   the	  presence	  of	  BS181.	  	  	  By	  contrast,	  culturing	  HCT116	  cells	   in	   the	  presence	  of	  BS194	  at	  concentrations	  twice	   or	   five	   times	   the	   GI50	   over	   a	   period	   of	   three	   months,	   yielded	   cells	   that	  continued	  to	  grow	  in	  the	  presence	  of	  BS194.	  Cells	  that	  emerged	  from	  long-­‐term	  culturing	  in	  the	  presence	  of	  500	  nM	  (5x	  GI50)	  were	  used	  to	  prepare	  RNA	  and	  in	  growth	   assays.	   BS194-­‐resistant	   HCT116	   cells	   were	   >8	   fold	   less	   sensitive	   to	  BS194	   than	   the	   parental	   cells	   (fig	   3.6	   A).	   Interestingly,	   there	   was	   no	   cross-­‐resistance	   in	   these	   cells	   to	   BS181,	   to	   which	   the	   BS194-­‐resistant	   HCT116	   cells	  remained	  as	  sensitive	  as	  the	  parental	  HCT116	  cells	  (fig	  3.6	  B).	  	  To	  investigate	  whether	  resistance	  to	  BS194	  was	  due	  simply	  to	  altered	  expression	  of	  ABC	  transporters	  linked	  to	  multidrug	  resistance,	  which	  act	  by	  pumping	  drugs	  out	  of	  cells	  and	  which	  are	  often	  over-­‐expressed	  in	  cancer	  cells,	  I	  first	  determined	  if	  cell	   lines	  over-­‐expressing	   the	  main	  ABC	  transporters	   implicated	   in	  multidrug	  resistance,	  are	  also	   resistant	   to	  BS194.	  PhaMDR1	  cells	  have	  been	  derived	   from	  3T3	  cells	  following	  stable	  over-­‐expression	  of	  ABCC1	  (MDR1,	  PgP)	  (Gichard	  et	  al,	  2005).	  PhaMDR1	  cells	  were	  6-­‐fold	  less	  sensitive	  to	  BS194	  than	  parental	  3T3	  cells	  (fig	   3.6C).	   MCF-­‐7/MX	   cells	   were	   selected	   against	   mitoxantrane	   and	   are	   cross-­‐
	   103	  
resistant	   to	   other	   cytotoxic	   drugs,	   due	   to	   over-­‐expression	   of	   ABCG2	   (BCRP)	  (Ross,	  Yang	  et	  al.	  1999).	  MCF-­‐7/MX	  cells	  were	  5-­‐fold	  less	  sensitive	  to	  BS194	  than	  MCF-­‐7	  cells	  (fig	  3.6C).	  Finally,	  NCI-­‐ADR	  cells,	  which	  are	  derived	  from	  an	  ovarian	  cancer	   cell	   line	   (Liscovitch	   and	   Ravid	   2007),	   are	   resistant	   to	   adriamycin	   and	  other	   cytotoxic	   drugs	   and	   strongly	   express	   ABCB1	   (MDR1),	   were	   extremely	  insensitive	  to	  BS194.	  These	  data	  indicate	  that	  BS194	  is	  a	  substrate	  for	  multidrug	  resistance	  pumps.	  	  To	   determine	   if	   the	   BS194-­‐resistant	   HCT116	   cells	   express	   these	   pumps,	   RNA	  harvested	  from	  HCT116	  cells	  that	  are	  insensitive	  to	  BS194	  at	  100,	  200	  or	  500nM	  BS194	  was	   analysed	   alongside	  RNA	  harvested	   from	   the	   control	   cell	   lines,	  NCI-­‐ADR	  and	  MCF-­‐7MX,	  and	  checked	  for	  expression	  of	  the	  three	  key	  ABC	  transporter	  genes	   (fig	   3.6D).	   As	   reported	   previously,	   NCI-­‐ADR	   cells	   over-­‐express	   ABCB1	  (MDR1).	   There	   was	   an	   increase	   in	   ABCB1	   expression	   in	   the	   BS194-­‐resistant	  HCT116	  cells,	  although	  such	  an	   increase	  was	  not	  observed	   for	  cells	  cultured	   in	  500	  nM	  BS194.	  The	  ABCG2	  (BCRP)	  gene	  was	  highly	  expressed	  in	  MCF7/MX	  cells,	  as	  has	  been	  reported	  and	  there	  was	  a	  small	  increase	  in	  ABCG2	  expression	  in	  the	  BS194	  resistant	  HCT116	  cells.	  No	  evidence	  of	  elevated	  expression	  of	  ABCC1	  was	  observed	   in	   the	   BS194	   insensitive	   cells.	   Together,	   these	   data	   indicate	   that	  resistance	   to	   BS194	   involves	   ABC	   transporters,	   although	   studies	   in	   which	  inhibitors	   for	   these	   transporters	  are	  added,	  are	  required	   to	  confirm	  the	  role	  of	  these	  transporters	  in	  BS194	  insensitivity.	  	  ICEC0942	   is	   a	   new	   generation	   CDK7	   selective	   inhibitor	   identified	   in	   the	  laboratory,	  and	  is	  chemically	  similar	  to	  BS194.	  This	  compound	  was	  tested	  to	  see	  if	  BS194	  resistant	  HCT116	  cells	  are	  also	  resistant	  to	  ICEC0942.	  As	  expected	  from	  the	  similarity	   in	   their	  structures,	   the	  BS194	  resistant	  HCT116	  cell	  are	   less	  well	  growth	  inhibited	  by	  ICEC0942	  than	  the	  parental	  HCT116.	  Additionally,	  the	  lines	  over-­‐expressing	   ABC	   transporters	   are	   also	   resistant	   to	   ICEC0942	   to	   similar	  extents	  as	  they	  are	  to	  BS194.	  By	  contrast,	  none	  of	  the	  lines	  showed	  evidence	  of	  resistance	   to	   BS181,	   indicating	   that	   BS181	   is	   not	   a	   substrate	   for	   multi-­‐drug	  resistance	  transporters.	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Fig	  3.6.	  Characterisation	  of	  HCT116	  cells	  resistant	  to	  BS194.	  HCT116	  cells	  cultured	  in	  BS194	  to	  develop	  resistance	  to	  BS194	  were	  assayed	  for	  growth	  inhibition	  in	  the	  presence	  of	  BS194	  (A)	  or	  BS181	  (B).	  Shown	  are	  dose	  response	  curves	  with	  the	  respective	  GI50	  values	  and	  standard	  errors	  of	   the	  mean	  (SEM).	  (C)	  GI50	  values	  (µM)	  for	  different	  cell	  lines	  treated	  with	  BS-­‐194,	  BS181	  or	  a	  more	  recently	  derived	  CDK7	  selective	   inhibitor	   ICEC0942,	   are	   shown	   and	   the	   growth	   curves	   were	   generated	   by	  subjecting	  cells	   to	  various	  concentrations	  of	   the	  compounds.	   In	  addition	   to	  GI50	  values	  (SEM)	   for	  HCT116	   and	  BS194	   resistant	  HCT116	   (HCT116R),	   SRB	   growth	   assays	  were	  performed	   for	   NIH3T3	   and	   NIH3T3	   over-­‐expressing	   ABCC1	   (PhamDR1),	   MCF-­‐7	   cells	  and	   MCF-­‐7	   cells	   expressing	   ABCG2	   (MCF-­‐7MX)	   and	   NCI-­‐ADR,	   which	   is	   resistant	   to	  adriamycin	   and	   expresses	  MDR1.	   (D)	  Real-­‐time	  RT-­‐PCR	  analysis	   for	   the	   expression	  of	  three	   ABC	   transporter	   genes	   linked	   to	   multidrug	   resistance,	   is	   shown	   for	   3	   RNA	  preparations.	  Error	  bars	  represent	  SEM.	   in	   the	  resistant	  cells	  and	  their	  parents.	   (E)	  Q-­‐RT-­‐PCR	  for	  ABCB1,	  ABCC1	  and	  ABCG2	  is	  shown	  for	  HCT116	  cells.	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3.2.3	  Pilot	  studies	  to	  identify	  treatment	  parameters	  for	  microarray	  analysis	  	  Previous	  work	  from	  the	  laboratory	  has	  shown	  that	  BS181	  and	  BS194	  treatment	  leads	   to	   the	   rapid	   downregulation	   of	   cyclin	   D1	   and	   several	   anti-­‐apoptotic	  proteins	   including	   XIAP,	  MCL-­‐1	   and	   BCL2	   in	  MCF-­‐7	   cells	   (Ali,	   Heathcote	   et	   al.	  2009;	  Heathcote,	  Patel	  et	  al.	  2010).	  In	  order	  to	  determine	  if	  the	  mRNA	  levels	  are	  also	   altered	   in	   response	   to	   these	   inhibitors,	   MCF-­‐7	   cells	   were	   treated	   with	  different	   concentrations	   of	   BS194	   (0.1μM	   and	   1μM)	   and	   BS181	   (10μM,	   20μM	  and	  40μM),	  based	  on	   their	  GI50	  values	  and	   the	   total	  RNA	  extracted	  at	   six	   time-­‐points	  (0.5,	  1,	  1.5,	  2,	  4	  and	  6	  hrs)	  following	  treatment.	  In	  this	  initial	  experiment,	  MCL-­‐1	   was	   downregulated	   by	   both	   inhibitors	   in	   a	   time	   and	   concentration-­‐dependent	  manor	  (data	  not	  shown).	  Additionally,	  BS194	  treatment	  also	  led	  to	  a	  decrease	  in	  CDK7	  RNA	  and	  showed	  some	  evidence	  of	  decreasing	  XIAP	  and	  cyclin	  D1,	  although	  none	  of	  these	  genes	  adhered	  to	  the	  clear	  dose	  and	  time	  trend	  seen	  for	  MCL1.	  Meanwhile,	  BS181	  only	  had	  mild	  effects	  on	  XIAP	  and	  cyclin	  D1	  and	  no	  appreciable	  effect	  on	  CDK7	  mRNA	  levels	  (data	  not	  shown).	  	  In	  the	  knowledge	  that	  MCL-­‐1	  is	  clearly	  altered	  in	  response	  to	  these	  compounds,	  a	  similar	   study	   was	   carried	   out	   in	   HCT116	   cells,	   using	   just	   one	   concentration,	  corresponding	   to	   the	   GI50,	   of	   BS194	   (1μM)	   and	   BS181	   (20μM)	   for	   five	   time-­‐points	  (fig	  3.7).	  Once	  again,	  MCL-­‐1	  expression	  was	  reduced	  in	  a	  time-­‐dependent	  manner	   following	   treatment	   with	   either	   inhibitor.	   However,	   there	   was	   no	  reduction	  in	  mRNA	  levels	  of	  the	  other	  genes.	  	  The	  experiment	  was	  repeated	  in	  HCT116	  cells	  once	  again,	  this	  time	  using	  a	  range	  of	  concentrations	  and	  an	  expanded	  number	  of	  time-­‐points,	  expression	  of	  MCL-­‐1	  being	   determined	   (data	   not	   shown).	   Based	   on	   these	   expression	   profiles,	   drug	  dose	   and	   time	   parameters	   were	   chosen	   and	   five	   independent	   replicates	   were	  generated	   for	   each	   of	   the	   chosen	   time	   and	   dose	   parameters.	   For	   both	  compounds,	  1,	  2	  and	  6	  hour	  time	  points	  were	  chosen	  for	  1μM	  BS194	  and	  20μM	  BS181	   (fig	  3.8	  A-­‐D).	  Of	   the	   five	   replicates,	   three	  RNA	  samples	  were	   chosen	   for	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microarray	  profiling	  for	  expression	  changes	  following	  treatment	  with	  BS194	  or	  BS181	   using	   the	   Illumina	  HumanHT-­‐12	   v3	   Beadchips.	   The	   samples	   chosen	   for	  microarray	  analysis	  are	   indicated	   in	   figure	  3.8	  with	  a	   tick	  above	   the	  respective	  samples.	  The	  RNA	  samples	  were	  processed	  and	  hybridized	  under	  contract	  by	  the	  gene	  expression	  microarray	  service	  offered	  by	  the	  Dept	  of	  Pathology,	  University	  of	  Cambridge.	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Fig	   3.7.	   RT-­qPCR	   Pilot	   studies	   showing	   the	   response	   of	   four	   rapidly	   processed	  
mRNAs	  following	  treatment	  of	  HCT116	  cells	  with	  BS194	  or	  BS181.	  Real-­‐time	   RT-­‐PCR	   was	   performed	   using	   RNA	   prepared	   from	   HCT116	   cells	   that	   were	  treated	   with	   (A)	   BS194	   (1μM)	   or	   (B)	   BS181	   (20μM)	   for	   0.5,	   1,	   1.5,	   2	   or	   4	   hours,	   as	  indicated.	   Gene	   expression	   was	   normalised	   to	   GAPDH	   expression	   and	   expression	  changes	   are	   shown	   relative	   to	   the	  vehicle	   treated	   samples.	  C=	  Untreated	   samples,	  V	  =	  vehicle	  (DMSO)	  treatment.	  D	  refers	  to	  RNA	  prepared	  from	  cells	  treated	  with	  BS194	  (A)	  or	  BS181	  (B).	  Each	  result	  represents	  the	  mean	  expression	  for	  three	  replicates	  for	  each	  of	  three	  independent	  RNA	  samples	  for	  each	  treatment.	  Error	  bars	  =	  SEM.	  *	  =	  p<0.01	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Fig	   3.8.	   RT-­qPCR	   pilot	   study	   showing	   the	   effect	   of	   BS194	   and	   BS181	   on	   MCL-­1	  
expression	  at	  three	  time	  intervals	  Real-­‐time	   RT-­‐PCR	   of	   MCL-­‐1	   expression	   was	   determined	   using	   RNA	   prepared	   from	  HCT116	  cells	   that	  were	  treated	  with	  1.0	  µM	  BS194	  for	  1-­‐6	  hours	  (A-­‐C),	  or	  with	  20	  µM	  BS181	   for	   the	   same	   period	   (D-­‐F)	  with	   five	   independent	   replicates	   (labeled	   as	   a-­‐e)	   as	  indicated	   on	   the	   X-­‐axis.	   Gene	   expression	   was	   normalized	   to	   GAPDH	   expression	   and	  expression	  changes	  are	  shown	  on	  the	  Y-­‐axis	  for	  treated	  samples	  (white	  bars)	  relative	  to	  the	  vehicle	  (DMSO;	  black	  bars).	  Each	  RT-­‐PCR	  reaction	  was	  performed	  in	  triplicate.	  Error	  bars	  =	  SEM;	  *	  =	  p<0.01;	  ¥	  =	  p<0.05;	  ✓=	  samples	  sent	  for	  microarray.	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3.2.4	  Microarray	  Analysis:	  BS181	  
3.2.4.1	  Principal	  Component	  Analysis	  	  Principal	   Component	   Analysis	   (PCA)	  was	   used	   to	   ascertain	   replicate	   similarity	  for	   the	   samples	   after	   the	   normalisation	   steps	   were	   completed.	   Samples	   were	  normalized	   by	   way	   of	   the	   quantile	   algorithm	   in	   GeneSpring	   GX	   v11,	   with	   no	  baseline	  transformation.	  For	  BS181	  analysis,	  all	  treatment	  time-­‐points	  (1,	  2	  and	  6hrs)	   were	   imported	   with	   the	   DMSO	   control	   time-­‐points	   (1	   and	   6hrs)	   into	  GeneSpring	  GX	   and	   a	   PCA	  plot	  was	   generated	   (fig	   3.9A).	  According	   to	   the	  PCA	  plot,	   there	   was	   one	   clear	   outlier	   for	   BS181	   (1hr	   sample	   E),	   which	   was	   also	  subsequently	   flagged	   on	   the	   correlation	   plot	   (fig	   3.9B),	   indicated	   by	   the	   black	  lines.	  This	  sample	  was	  excluded	  from	  subsequent	  analyses.	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Fig	   3.9.	   Principal	   component	   analysis	   for	   gene	   expression	   microarray	   data	   for	  
HCT116	  cells	  treated	  with	  BS181.	  (A)	  Principal	  component	  analysis	  (PCA)	  showing	  all	  time-­‐points	  for	  DMSO	  (blue	  shapes)	  and	   BS181	   (red	   shapes).	   Circled	   in	   red	   is	   the	   outlier	   (BS181,	   1hr	   sample	   E).	   (B)	  Correlation	  plot	   showing	   the	  degree	  of	   similarity	   in	  gene	  expression	  between	  samples	  using	   the	   Pearson	   correlation	   statistic,	   r.	   The	   key	   shows	   the	   closest	   similarity	   as	   red	  (closest	  to	  1)	  and	  most	  dissimilar	  entities	  as	  black	  (closer	  to	  zero).	  The	  outlier	  (181-­‐1-­‐E)	  can	  clearly	  be	  seen	  as	  the	  black	  band,	  indicating	  that	  this	  sample	  is	  related	  only	  to	  itself.	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3.2.4.2	  Expression	  over	  time:	  K-­‐means	  clustering	  	  In	  order	   to	  assess	   the	   change	   in	  gene	  expression	  over	   time,	   a	  one-­‐way	  ANOVA	  test	  was	  used	  to	  compare	  the	  change	  in	  gene	  expression	  between	  BS181	  samples	  (1-­‐6	   hrs)	   and	   the	   DMSO	   control	   (combined	   for	   1	   and	   6	   hrs).	   The	   K-­‐means	  clustering	   algorithm	   was	   then	   used	   in	   GeneSpring	   GX	   to	   generate	   12	   clusters	  from	  a	  total	  of	  597	  entities	  that	  were	  significantly	  changed	  with	  respect	  to	  DMSO	  (P<0.05)	  as	  determined	  by	  the	  ANOVA	  test.	  This	  algorithm	  clusters	   the	  entities	  based	  on	  expression	  magnitude	  and	  trend	  and	   is	  open	  to	  alteration	  so	   that	   the	  number	   of	   iterations,	   distance	   metrics	   and	   number	   of	   clusters	   can	   be	   user-­‐defined.	  For	  this	  interpretation,	  Euclidean	  distance	  metric	  was	  used	  to	  generate	  12	  clusters	  (fig	  3.10,	  0-­‐11).	  	  Of	  the	  generated	  clusters,	  cluster	  three	  was	  interrogated	  further	  since	  it	  showed	  the	  greatest	  magnitude	  change,	  with	  little	  or	  no	  changes	  over	  2	  hours	  and	  a	  large	  increase	  in	  expression	  over	  2-­‐6	  hours.	  This	  expression	  profile	  distinguished	  the	  cluster	  from	  almost	  all	  other	  clusters	  except	  cluster	  8,	  where	  some	  of	  the	  entities	  followed	  a	  similar	  trend.	  	  The	   13	   entities	   from	   cluster	   3	   (11	   genes)	  were	   analysed	   by	   DAVID,	   an	   online	  bioinformatics	   resource	   that	   can	   be	   used	   to	   sort	   gene	   lists	   according	   to	   Gene	  Ontology	   (GO)	  designation,	   in	  order	   to	   functionally	   group	  entities	   together	   (fig	  3.11A).	   This	   is	   particularly	   useful	  when	   handling	   the	   extensive	   lists	   generated	  from	  microarray	  experiments.	  	  	  As	  shown	  in	  figure	  3.11A,	  the	  entities	  segregated	  into	  nine	  significant	  GO	  terms,	  where	  enrichment	  scores	  were	  used	  to	  select	  significant	  groups	  with	  a	  cut-­‐off	  of	  >1.3	   (equating	   to	   a	   non-­‐log	   scale	   of	   0.05).	   The	   enrichment	   score	   indicates	   the	  geometric	  mean	   of	   p-­‐values	   for	   all	   entities	   in	   each	   group.	  Due	   to	   the	   so-­‐called	  “fuzzy”	   clustering	   algorithm	  DAVID	  uses,	   entities	   can	   appear	   in	  more	   than	  one	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functional	   group,	   explaining	   why	   some	   of	   the	   genes	   appeared	   in	   all	   three	   GO	  groups.	  The	   two	  most	   significant	   groupings	   (based	  on	  enrichment	   score)	  were	  transcriptional	  regulation	  (4.39)	  and	  regulation	  of	  apoptosis	  (4.11),	  although	  11	  functional	  groups	  were	  returned	  in	  total,	  including	  several	  marginal	  groups	  such	  as	   negative	   regulation	   of	   apoptosis	   (1.65)	   and	   positive	   regulation	   of	   apoptosis	  (1.5).	  Five	   genes	   identified	   in	   cluster	   3	   were	   validated	   to	   check	   the	   integrity	   of	   the	  expression	  magnitude	   predicted	   in	   GeneSpring:	   the	   normalized	   expression	   for	  each	  time-­‐point,	  as	  predicted	  in	  GeneSpring	  (fig	  3.11B)	  was	  validated	  using	  real-­‐time	   RT-­‐PCR	   assays	   with	   the	   same	   RNA	   preparations	   submitted	   for	   the	  microarray	   analysis	   (fig	   3.11C);	   the	   bar	   graphs	   indicate	   the	   relative	   gene	  expression	   of	   the	   drug-­‐treated	   samples	   (white	   bars)	   relative	   to	   DMSO	   (black	  bars),	   clearly	   mirroring	   the	   same	   trend	   predicted	   in	   GeneSpring.	   Finally	   RNA	  harvested	   from	   a	   separate	   24hr	   drug	   treatment	   experiment	   was	   also	   used	   to	  validate	  the	  expression	  profile	  for	  the	  same	  genes	  (fig	  3.12).	  Some	  of	  these	  genes	  (notably,	  DDIT4,	  BTG2	  and	  KLF10)	  did	  not	  reflect	  the	  same	  expression	  pattern	  as	  seen	  in	  figure	  3:11C	  in	  relation	  to	  DMSO.	  One	  possible	  explanation	  for	  this	  may	  be	  that	  in	  figure	  3:12,	  we	  are	  comparing	  the	  expression	  to	  just	  one	  DMSO	  sample,	  which	   was	   harvested	   at	   24	   hours,	   unlike	   in	   figure	   3:11C,	   which	   included	   a	  matched	  control	  at	  each	  time	  point.	  This	  may	  in	  fact	  account	  for	  the	  discrepancy	  observed,	   since	  you	  might	   expect	   that	   at	  24	  hours,	   some	  genes	   to	  be	  naturally	  higher	  or	  lower	  depending	  on,	  amongst	  other	  factors,	  the	  stage	  of	  the	  cell	  cycle	  these	  cells	  are	  occupying.	  However,	  although	  these	  genes	  (DDIT4,	  BTG2,	  KLF10)	  did	  not	  reflect	  an	  exact	  profile	  of	  the	  RNA	  samples	  used	  for	  the	  microarray,	  over	  the	   extended	   period,	   a	   similar	   trend	   did	   emerge	   for	   BTG2	   and	   KLF10.	   These,	  along	  with	   JUN	  and	   JUNB	  showed	  peak	  expression	  at	  12	  hours	  post-­‐treatment.	  This	   apparent	   “delay”	  may	   indeed	   reflect	   inter-­‐experimental	   variation.	  Broadly	  speaking,	   all	   validation	   experiments	   replicated	   the	   expression	   predicted	   in	  GeneSpring	   (in	   terms	   of	   the	   general	   trend	   and	   the	   magnitude	   of	   change),	  although	   notably,	   some	   of	   the	   6hr	   values	   fell	   short	   of	   the	   predicted	   ANOVA	  values	   including	   KLF10,	   JUN	   and	   JUNB.	   Moreover,	   the	   discrepancy	   observed	  between	  expression	  of	  DDIT4,	  BTG2	  and	  KLF10	  relative	  to	  DMSO	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Fig	  3.10.	  Time	  interpretation	  of	  gene	  expression	  patterns	  with	  BS181.	  The	  K-­‐means	  clustering	  algorithm	  in	  GeneSpring	  GX	  11	  generated	  12	  clusters	  from	  the	  597	   entities	   with	   a	   2-­‐fold	   expression	   change	   (p≤0.05)	   at	   one	   of	   the	   three	   BS181	  treatment	  time	  points,	  compared	  to	  the	  vehicle	  (V,	  DMSO)	  control.	  Normalized	  intensity	  (average	  expression;	  Y-­‐axis)	  of	  597	  entities	  that	  made	  the	  cut-­‐off	  parameters	  of	  at	  least	  2-­‐fold	  and	  with	  a	  p-­‐value	  cut-­‐off	  of	  ≤0.05	  relative	  to	  DMSO,	  as	  determined	  by	  the	  ANOVA	  statistical	  test.	  Each	  line	  represents	  one	  of	  the	  597	  entities.	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Fig	  3.11.	  Dissection	  of	  cluster	  3	  –	  GO	  analysis	  and	  validation.	  (A)	  Cluster	  3	  was	  chosen	  for	  further	  analysis	  because	  of	  its	  clear	  increase	  at	  the	  six-­‐hour	  time	  point	  and	  return	  to	  baseline	  with	  the	  DMSO	  control	  samples	  and	  subjected	  to	  gene	  ontology	   (GO)	   analysis	   using	   the	   online	   bioinformatics	   program	   DAVID.	   Using	   this	  program,	  a	  p-­‐value	  of	  ≤0.05	  is	  equivalent	  to	  a	  geometric	  mean	  enrichment	  score	  of	  ≥1.3.	  Nine	   significant	   GO	   groups	   are	   shown.	   Proportion	   involvement	   is	   the	   percentage	   of	  genes	   implicated	   in	   the	  particular	  GO	  group	   from	   the	   cluster.	  There	  were	  11	   separate	  genes	   in	   cluster	   3	   in	   total.	   (B)	   Genes	   of	   the	   three	   most	   significant	   GO	   groups	   are	  tabulated	   (left	   column),	   along	   with	   their	   expression	   profiles	   at	   1,	   2	   and	   6	   hrs.	   Blue	  colouring	  represents	  down-­‐regulated	  genes	  and	  red	  colouring	  represents	  up-­‐regulated	  genes.	  (C)	  The	  RNA	  used	  for	  the	  array	  was	  validated	  by	  RT-­‐qPCR;	  the	  bar	  graphs	  show	  the	   relative	  expression	   in	   the	   treated	   samples	   (white	  bars)	   versus	   the	  vehicle	   (DMSO;	  black	  bars)	  as	  determined	  by	  a	  RT-­‐qPCR	  SybrGreen	  assay.	  Bars	  represent	   the	  mean	  of	  the	  three	  independent	  RNA	  samples	  used	  for	  the	  array.	  Error	  bars	  =	  SEM;	  *	  =	  p<0.01;	  ¥	  =	  p<0.05	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Fig	  3.12.	  Dissection	  of	  cluster	  3:	  24	  hour	  time	  course	  experiment	  To	   further	   interrogate	   the	  expression	  pattern	  of	   the	   five	  genes	   that	  were	   shown	   to	  be	  modulated	   in	   K-­‐means	   cluster	   3	   over	   a	   6	   hour	   period	   (see	   fig	   3.18),	   an	   expanded	  treatment	   time-­‐course	  with	  BS181	  was	   carried	  out	   over	  24	  hours.	  RNA	  was	  prepared	  from	  HCT116	  cells	  grown	  on	  10cm	  cell	  culture	  plates	   in	  replicates	  of	   three.	  Cells	  were	  harvested	   in	   parallel	   to	   prepare	   RNA	   and	   SybrGreen	   RT-­‐qPCR	   assays	   were	   used	   to	  assess	  gene	  expression	  levels	  (Y-­‐axis).	  Expression	  is	  indicated	  for	  1,	  2,	  6,	  12	  and	  24	  hrs	  post	  BS181	  (20μM)	  treatment.	  V	  =	  vehicle	  (DMSO);	  *	  =	  p<0.01;	  ¥	  =	  p<0.05	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3.2.4.3	  Direct	  time-­‐point	  comparisons	  between	  control	  and	  treatment	  samples	  	  For	   the	  next	   analysis,	  which	   concentrated	  on	   gene	   expression	   at	   distinct	   time-­‐points,	   a	   t-­‐test	   was	   used	   to	   compare	   BS181	   treated	   groups	   directly	   with	   the	  DMSO	  control.	  Note	  that	  due	  to	  the	  absence	  of	  a	  control	  group	  for	  the	  2hr	  time-­‐point,	   the	   1hr	   DMSO	   triplicate	   group	   was	   used	   as	   a	   control	   for	   1hr	   and	   2hr	  BS181	  groups.	  	  At	  1hr	  post-­‐treatment,	  no	  genes	  were	  significantly	  changed	  (p<0.05)	  with	  BS181	  treatment.	  However,	  without	  a	  p-­‐value	  cut-­‐off,	  3220	  genes	  were	  changed	  with	  a	  fold	  change	  (FC)	  of	  >1.1,	  1673	  of	  which	  were	  increased	  and	  1547	  were	  decreased	  in	   expression.	   The	   parameters	  were	   then	   changed	   to	   allow	   for	   a	   FC	   cut-­‐off	   of	  >1.5,	   with	   no	   p-­‐value	   cut-­‐off.	   Seven	   genes	   were	   subsequently	   chosen	   and	  validated	   from	   this	   list	   (fig	   3.13A	  and	  B);	   as	  with	   all	   validation	   steps,	   this	  was	  performed	  on	  the	  original	  cDNA	  and	  one	  of	  the	  replicate	  experiments	  generated	  from	   the	   pilot	   studies.	   With	   the	   exception	   of	   BHLHE40	   and	   JUN,	   there	   was	  concordance	  between	  the	  array	  prediction,	  RNA	  preparations	  submitted	  for	  the	  microarray	  analysis	  (labelled	  as	  cDNA	  in	  figure)	  and	  repeat	  samples	  (fig	  3.13B).	  	  At	  the	  2hr	  time-­‐point,	  only	  5	  genes	  satisfied	  the	  p-­‐value	  cut-­‐off	  of	  <0.05	  but	  also	  had	  a	  FC	  >2.0	  (fig	  3.13C).	  These	  were	  validated	  as	  before	  with	  SybrGreen	  real-­‐time	  RT-­‐PCR	  assays	  (fig	  3.13D).	  The	  2hr	  list	  with	  a	  FC	  cut-­‐off	  of	  >1.1	  gave	  2863	  entities	   (1535	   of	   which	   were	   up-­‐regulated	   and	   1329	   down-­‐regulated).	  Interestingly,	   all	   genes	   that	   satisfied	   the	   p-­‐value	   and	   FC	   cut-­‐offs	   were	   down-­‐regulated	  at	  2	  hours	  and	  in	  the	  non-­‐restricted	  list,	  those	  with	  a	  p-­‐value	  <	  0.05	  or	  with	  marginal	  p-­‐values	  (P	  >	  0.05/<	  0.1)	  were	  more	  frequently	  associated	  with	  a	  fold	  change	  of	  at	  least	  1.5	  and	  were	  down-­‐regulated.	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For	  the	  6-­‐hr	  time-­‐point,	   there	  were	  many	  more	  genes	  that	  satisfied	  both	  the	  p-­‐value	   (<0.05)	   and	  FC	   (>2-­‐fold)	   cut-­‐offs;	   in	   total,	   470	  entities	  were	   significantly	  changed	   by	   >2.0	   (supplementary	   figure	   S1).	   Unlike	   the	   earlier	   time-­‐points,	   a	  much	   larger	   proportion	   of	   the	   entities	   were	   down-­‐regulated	   with	   379	   going	  down	  and	  91	  going	  up,	  many	  of	  the	  latter	  being	  immediate-­‐early	  response	  genes.	  Despite	   the	   relatively	   larger	   gene-­‐list	   for	   the	   six-­‐hour	   time-­‐point,	   it	   was	   still	  sufficiently	   small	   enough	   to	   enable	   a	   degree	   of	   manual	   interpretation	   before	  subjecting	  the	  list	  to	  GO	  analysis	  and	  as	  such	  for	  the	  initial	  validation,	  genes	  were	  chosen	   based	   upon	  magnitude	   change	   i.e.	   entities	  with	   the	   highest	   and	   lowest	  expression,	  and	  in	  an	  unbiased	  manner	  to	  enable	  a	  larger	  spread	  to	  be	  surveyed.	  However,	  emphasis	  was	  placed	  on	  the	  up-­‐regulated	  genes	  since	  it	  was	  noted	  that	  several	   of	   these	   were	   early-­‐response	   genes	   and	   thus	   make-­‐up	   a	   potentially	  interesting	   group.	   Therefore	   the	   initial	   validation	   process	   concentrated	   on	   14	  genes	   spread	   across	   the	   list,	   each	   of	   which	   exhibited	   the	   same	   trend	   in	   the	  samples	  used	   for	   the	  array	  and	   in	   the	   independent	   replicate	  RNA	  preparations	  (fig	  3.13E).	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Fig	  3.13.	  Entities	  changed	  at	  1,	  2	  and	  6	  hours	  post	  treatment	  with	  BS181	  relative	  
to	  DMSO	  at	  1	  hour.	  A	  students	  T-­‐test	  (unpaired,	  unequal	  variance)	  was	  used	  to	  find	  differentially	  expressed	  entities	  at	  the	  1,	  2	  and	  6	  hour	  time-­‐points	  compared	  to	  the	  vehicle	  (DMSO).	  All	  entities	  were	  down-­‐regulated	  at	  1	  and	  2	  hours	  (A-­‐D).	   In	   the	   tables,	  FCAbsolute	   is	   the	  absolute	  fold	   change	   as	   determined	   by	   the	   T-­‐test	   used	   to	   compare	   treatment	   with	   vehicle.	  Highlighted	   in	   blue	   are	   the	   genes	   that	   were	   selected	   for	   validation.	   The	   histograms	  compare	   the	   FC	   value	   relative	   to	   vehicle,	   as	   predicted	   by	   the	   T-­‐test	   carried	   out	   in	  GeneSpring	  (black	  bars)	  and	  the	  RT-­‐qPCR	  values	  as	  determined	  by	  SybrGreen	  detection	  on	  the	  microarray	  sample	  RNA	  (cDNA,	  white	  bars)	  and	  a	  repeat	  set	  made	  independently	  (grey	  bars).	  The	  bars	  for	  the	  RT-­‐qPCR	  validation	  (white	  and	  grey)	  are	  the	  mean	  of	  three	  independent	   samples.	   Error	   bars	   =	   p-­‐value	   (microarray)	   and	   SEM	   (sample	   RNA	   and	  repeat):	  (A)	  Gene	  list	  of	  1	  hour	  comparison	  for	  entities	  changed	  by	  at	  least	  1.5-­‐fold	  and	  no	   p-­‐value	   cut-­‐off.	   (B)	   Validation	   of	   selected	   1	   hour	   genes.	   (C)	   Gene	   list	   of	   2	   hour	  comparison	   showing	   entities	   satisfying	   a	   2-­‐fold	   cutoff	   and	   a	   P-­‐value	   ≤0.05	   and	   (D)	  validation	   of	   selected	   2-­‐hour	   genes.	   (E)	   An	   unpaired	   T-­‐test	   was	   used	   to	   find	  differentially	  expressed	  entities	  at	  6	  hours	  compared	  to	  DMSO	  satisfying	  a	   fold	  change	  cutoff	   ≥2.0	   and	   a	   p-­‐value	   ≤0.05.	   Fourteen	   genes	   were	   chosen	   to	   be	   validated	   by	   RT-­‐qPCR.	  Lists	  of	  entities	  for	  the	  6-­‐hour	  time	  point	  can	  be	  found	  in	  appendices	  1	  and	  2.	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3.2.4.3.1	  Functional	  grouping	  using	  DAVID	  	  Further	   analysis	   using	   the	   online	   bioinformatic	   resource	   DAVID,	   revealed	   that	  entities	   from	  the	  six-­‐hour	   list	   segregated	   into	  eight	   functional	  groups	  based	  on	  their	  GO	  descriptions.	  For	   the	  up-­‐regulated	  entities,	  using	  an	  enrichment	   score	  cut-­‐off	  of	  1.3,	   three	  genes	  (JUN,	   JUNB	  and	  FOS)	  were	   implicated	   in	   three	  of	   the	  four	  significant	  functional	  groups	  (fig	  3.14A):	  Basic	  leucine	  zipper	  transcription	  factors,	  Positive	  regulation	  of	  transcription	  and	  Regulation	  of	  apoptosis.	  FOS	  had	  been	   highlighted	   in	   earlier	   analyses	   so	   it	   was	   not	   surprising	   to	   find	   that	   two	  other	  Activator	   Protein-­‐1	   (AP1)	   transcription	   factors,	   JUN	   and	   JUNB	  were	   also	  upregulated	   (fig	   3.14C).	   Additionally,	   another	   transcription	   factor	   EGR1,	  previously	  validated	  due	  to	  being	  the	  highest	  up-­‐regulated	  gene	  at	  six	  hours	  was	  also	  placed	  into	  two	  functional	  groups	  -­‐	  Positive	  regulation	  of	  transcription	  and	  Regulation	  of	  Apoptosis.	  	  From	   the	   down-­‐regulated	   entity	   list,	   entities	   segregated	   into	   three	   functional	  groups	  that	  had	  an	  enrichment	  score	  of	  ≥1.3	  and	  another	  marginal	  category	  with	  an	   enrichment	   score	   of	   1.23.	   Unlike	   the	   up-­‐regulated	   functional	   groups,	   these	  groups	  appear	  functionally	  different	  from	  one	  another,	  each	  being	  composed	  of	  distinct	   members	   from	   the	   down-­‐regulated	   gene	   list	   (Fig	   3.14B).	   Once	   again,	  with	  the	  exception	  of	  one	  gene,	  DCLRE1A,	  all	  follow	  the	  same	  trend	  in	  predicted	  from	  the	  microarray	  (black	  bars)	  in	  the	  two	  cDNA	  sets	  (fig	  3.14C).	  Of	  particular	  interest	   is	   that	   in	   the	  marginal	   group,	  RNA	  polymerase	   complex,	   each	  member	  validated	  (POLR1C,	  POLR3H	  and	  POLR3B)	  followed	  the	  predicted	  trend	  in	  both	  sets.	  
	  







	   126	  
Fig	  3.14.	  Functional	  grouping	  of	  entities	  significantly	  changed	  at	  6	  hours.	  Functional	   grouping	   was	   carried	   out	   using	   the	   online	   tool	   DAVID,	   which	   sorted	   the	  entities	   into	   functional	   groups	   based	   on	   their	   most	   likely	   GO	   groupings.	   (A)	   Most	  significantly	  enriched	  GO	  groups	  from	  the	  up-­‐regulated	  gene	  list.	  (B)	  Most	  significantly	  enriched	   GO	   groups	   from	   the	   down-­‐regulated	   gene	   list.	   In	   each	   case	   the	   enrichment	  score	   (geometric	  mean)	  was	   used	   to	   cut-­‐off	   groups	   at	   1.3	   (p	   ≤0.05).	   (C)	   Validation	   of	  selected	  genes	  appearing	  in	  the	  significantly	  enriched	  ‘up’	  and	  ‘down’	  GO	  groups:	  Black	  bars	  (microarray	  value	  relative	  to	  DMSO),	  white	  and	  grey	  bars	  (sample	  RNA	  [cDNA]	  and	  repeat	   set,	   respectively).	   White	   and	   grey	   Bars	   represent	   RT-­‐qPCR	   mean	   fold	   change	  values	  of	   three	   independent	  samples	  relative	  to	  vehicle	  (DMSO).	  Error	  bars	  =	  T-­‐test	  p-­‐value	  (microarray),	  SEM	  (cDNA	  and	  repeat).	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3.2.4.3.2	  Pathway	  analysis	  using	  Onto-­‐tools	  Pathway-­‐Express	  	  The	  6hr	  list	  was	  then	  analysed	  using	  Pathway-­‐Express,	  a	  freely	  available	  online	  program,	   which	   is	   part	   of	   the	   OntoTools	   suite	  (http://vortex.cs.wayne.edu/projects.html).	  Lists	  were	  entered	  separately	  as	  up	  and	   down-­‐regulated	   entities	   and	   significant	   pathways	   calculated	   based	   on	   the	  number	  of	  genes	   in	  a	  given	  pathway	  and	  the	  number	  of	   these	  genes	  present	   in	  the	   list	   and	   microarray	   chip	   used.	   The	   program	   ranks	   the	   output	   (a	   KEGG	  pathway)	  based	  on	  either	  p-­‐value	  or	  impact	  factor	  (IF).	  The	  IF	  is	  calculated	  using	  a	  perturbation	  factor	  generated	  for	  each	  gene	  in	  the	  list	  (PF(g)),	  which	  takes	  into	  account	   the	  FC	  and	  number	  of	  genes	  downstream	   from	   it	   in	   the	  pathway,	   thus	  reflecting	   the	   importance	   of	   each	   differentially	   regulated	   gene	   (Khatri,	   P	   et	   al.	  2005).	  The	  IF	  is	  a	  probability	  that	  takes	  into	  account	  each	  PF(g)	  of	  the	  pathway	  and	  the	  number	  of	  differentially	  regulated	  genes	   in	  an	  entire	  pathway.	  For	   this	  analysis	   however,	   the	   pathway	   p-­‐value	   was	   used	   as	   an	   alternative.	   The	   most	  significant	  pathways	  were	  determined	   from	  a	   cut-­‐off	   of	  p<0.05	  and	   the	   results	  from	   Pathway-­‐Express	   analysis	   for	   up	   and	   down-­‐regulated	   genes	   are	   shown	  (Table	  3.2).	  Due	  to	  there	  being	  a	  larger	  proportion	  of	  down-­‐regulated	  genes,	  this	  is	   reflected	   in	   the	   number	   of	   significant	   pathways	   and	   interestingly,	   there	  appears	   to	   be	   no	   suggestion	   of	   what	   pathways	   might	   be	   perturbed	   by	   the	  previous	   functional	   group	   analysis	   for	   up-­‐regulated	   genes	   (fig	   3.14)	   –	   for	  instance,	   DAVID	   did	   not	   partition	   any	   entities	   into	   functional	   groups	   that	  indicated	  cell	   cycle	  or	  p53	  signalling.	  However,	   functional	  groupings	  generated	  with	  the	  down-­‐regulated	  list	  did	  overlap	  with	  the	  subsequent	  pathway	  analysis	  since	  the	  pathway	  “RNA	  polymerase”	  and	  “Cell	  cycle”	  share	  entities	  with	  DAVID-­‐generated	   GO	   terms	   (“RNA	   polymerase	   complex”	   and	   “Mitosis”	   respectively).	  Indeed,	   in	  addition	   to	   this,	  down-­‐regulated	  entities	  were	  also	   implicated	   in	   the	  KEGG-­‐determined	   “Pathways	   in	   cancer”,	   “Mismatch	   repair”,	   “Hedgehog	  signalling	  pathway”	  and	  “Wnt	  signaling	  pathway”	  -­‐	  none	  of	  which	  were	  hinted	  at	  by	  previously	  generated	  GO	  groupings.	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Table	   3.2.	   Results	   from	  Onto-­tools	   pathway	   analysis	   for	   differentially	   regulated	  
entities	  at	  6	  hours	  post	  BS181	  treatment:	  GO	   functional	   groups	   from	   6	   hours	   post-­‐treatment	   were	   subject	   to	   pathway	   analysis	  using	  Pathway-­‐Express	  (Onto-­‐Tools).	  Significant	  pathways	  based	  on	  a	  P-­‐value	  of	  ≤0.05	  were	   generated	   for	   (A)	   up-­‐regulated	   entities	   and	   (B)	   down-­‐regulated	   entities.	   For	   the	  purposes	   of	   this	   table,	   pathways	   have	   been	   sorted	   according	   to	   P-­‐value	   and	   not	   the	  Impact	  Factor,	  a	  perturbation	  factor	  generated	  for	  each	  gene	  name	  within	  the	  input	  list.	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3.2.4.4	   Protein	   and	   gene	   expression	   in	   an	   extended	   BS181	   time-­‐course	   and	  
comparison	  to	  other	  inhibitors	  
3.2.4.4.1	  Expression	  of	  p53	  following	  BS181	  and	  BS194	  treatment	  	  Since	   pathway	   analysis	   indicated	   that	   p53	   signalling	   was	   induced	   following	  BS181	  treatment,	  I	  explored	  this	  further	  by	  conducting	  an	  extended	  time-­‐course	  of	   BS181	   treatment	   in	   HCT116	   cells	   followed	   by	   immunoblotting	   to	   confirm	  whether	   or	   not	   p53	   protein	   is	   expressed	   in	   response	   to	   treatment;	   by	  way	   of	  comparison,	  I	  also	  carried-­‐out	  the	  same	  experiment	  with	  the	  pan-­‐CDK	  inhibitor	  BS194,	  in	  parallel.	  RNA	  and	  protein	  were	  harvested	  at	  1,	  2,	  6,	  12	  and	  24hrs	  post	  treatment.	  Several	  markers	  for	  CDK7	  activity	  were	  used	  as	  positive	  controls	  for	  the	  optimal	  inhibitory	  action	  of	  BS181	  over	  the	  time-­‐course	  and	  according	  to	  the	  loss	  of	  CDK1	  and	  RNAPII	  phosphorylation,	  maximal	  inhibition	  was	  determined	  at	  around	   6-­‐12hrs	   post-­‐treatment	   (fig	   3.15,	   upper	   panels	   (I)).	   Interestingly,	   this	  appeared	  to	  coincide	  with	  a	  peak	  in	  p53	  protein	  following	  BS181	  treatment	  (fig	  3.15	  (II)),	  and	  also	  by	  a	  decrease	  in	  p21	  at	  the	  same	  time-­‐points.	  However,	  when	  BS194	  treatment	  was	  extended	  over	  24	  hours,	  a	  p53	  peak	  was	  also	  observed	  but	  this	   occurred	   much	   later	   in	   the	   time	   course,	   peaking	   at	   12-­‐24	   hours	   post-­‐treatment.	  To	   confirm	   p53	   upregulation,	   immunofluorescence	   was	   used	   to	   look	   at	   p53	  levels	   following	   treatment	  with	  our	  CDK7	   inhibitors,	   together	  with	   flavopiridol	  over	  a	  24hr	  time-­‐course	  with	  concentrations	  of	  25	  and	  50μM	  (fig	  3.16	  A	  and	  B).	  flavopiridol	   is	   another	   pan-­‐CDK	   inhibitor,	   with	   an	   inhibitory	   profile	   similar	   to	  BS194.	  In	  agreement	  with	  the	  immunoblotting	  results,	  at	  the	  lower	  dose	  (fig	  3.16	  A),	  p53	  expression	  peaks	  at	  the	  4hr	  time	  point	  with	  BS181	  but	  peaks	  much	  later	  with	  BS194	  treatment.	  The	  same	  is	  not	  true	  at	  the	  higher	  dose	  (fig	  3.16B).	  In	  line	  with	   this,	   previous	   data	   suggests	   that	   BS181	   causes	   apoptosis	   in	   both	   a	   p53	  dependent	  and	  independent	  manor	  and	  in	  p53-­‐deficient	  cell	  lines,	  a	  higher	  dose	  was	   required	   (50μM)	   to	   cause	   an	   increase	   in	   apoptosis	   (Ali,	   Heathcote	   et	   al.	  2009).	  	  	  











Fig	  3.15.	  An	  extended	  time-­course	  treatment	  for	  BS181	  (20	  μM)	  and	  BS194	  (1	  μM).	  Immunoblots	  showing	  the	  long-­‐term	  trend	  in	  protein	  expression	  of	  CAK	  target	  genes	  (I)	  and	   p53,	   its	   phoshorylated	   forms	   and	   its	   target	   p21	   (II).	   For	   comparison,	   the	   p53	  immunoblots	  were	  repeated	  for	  BS194	  treatment	  (II).	  Blots	  are	  representative	  of	  three	  independent	  experiments.	  V	  =	  vehicle	  (DMSO).	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Fig	  3.16.	  Immunofluorescence	  staining	  of	  p53	  in	  a	  time-­course	  of	  treatment	  with	  
BS181,	   BS194	   ICEC0942	   and	   flavopiridol	   in	   HCT116	   cells.	   HCT116	   cells	   were	  treated	  with	  the	  indicated	  compounds	  at	  a	  concentration	  of	  (A)	  25μM	  or	  (B)	  50μM.	  Cells	  were	  then	  fixed	  at	  the	  indicated	  time-­‐points,	  blocked	  and	  incubated	  with	  primary	  anti-­‐p53	  antibodies.	  Cells	  were	  also	  co-­‐stained	  with	  β-­‐actin	  antibodies	  and	  nuclear	  DNA	  was	  stained	  with	  TO-­‐PRO-­‐3	  iodide	  (not	  shown).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   133	  
3.2.4.4.2	  Comparison	  of	  BS181	  with	  other	  CDK	  inhibitors	  
	  In	   order	   to	   determine	   if	   selected	   genes	   showing	   altered	   expression	   following	  BS181	   treatment	   in	   the	  microarray	  were	   also	   altered	   by	   other	   CDK	   inhibitors,	  HCT116	   cells	   were	   also	   treated	   with	   another	   CDK7	   selective	   inhibitor	  (ICEC0942),	  the	  pan-­‐CDK	  inhibitor	  BS194	  and	  the	  CDK7/9	  inhibitor	  flavopiridol,	  over	  a	  time	  course	  of	  24	  hours	  (fig	  3.17).	  The	  premise	  behind	  using	  an	  extended	  time-­‐course	   was	   to	   allow	   adequate	   time	   for	   each	   inhibitor	   to	   take	   effect.	  ICEC0942	   inhibits	   CDK7	   at	   doses	   similar	   to	   BS181	   (IC50	   ICEC0942	   0.04μM	   cf	  BS181	   0.02μM)	   but	   inhibits	   the	   growth	   of	  HCT116	   cells	   at	   considerably	   lower	  concentrations	  (GI50	  ICEC0942	  1.13μM	  cf	  BS181	  13μM),	  the	  difference	  in	  growth	  inhibition	  being	   likely	  due	  to	   the	  poor	  cell	  permeability	  of	  BS181	  (unpublished	  data;	  Ali,	  Heathcote	  et	  al.	  2009.	  	  In	  terms	  of	  gene	  expression	  patterns,	   it	   is	   interesting	  to	  note	  that	  for	  the	  genes	  surveyed	   (JUNB,	   MYC,	   NOTCH1,	   JAG1	   and	   BHLHE40)	   BS194	   and	   ICEC0942	  treatment	  gave	  an	  almost	  identical	  profile,	  both	  in	  terms	  of	  trend	  and	  magnitude.	  Similarly,	  BS181	  and	  flavopiridol	  treatments	  resulted	  in	  two	  further	  distinct	  RNA	  profiles	  across	   the	  genes	   tested.	   	   Indeed	  with	   JUNB	  and	  MYC	   they	   illustrated	  a	  directly	  inverse	  relationship.	  	  	  






Fig	   3.17.	   A	   direct	   comparison	   of	   BS181	   and	   BS194	   with	   other	   CDK	   antagonists	  
over	  an	  extended	  time-­course.	  RT-­‐qPCR	  data	  showing	  RNA	  levels	  of	   five	  genes	  shown	  to	  be	  differentially	  regulated	  in	  the	  microarray	  at	  6	  hours	  post	  BS181	  treatment;	  Y	  axis	  shows	  the	   fold	  change	  (FC)	  of	  gene	   expression	   relative	   to	   the	   vehicle	   (DMSO).	   Normalized	   values	   were	   relative	   to	  DMSO.	  Error	  bars	  	  =	  SEM.	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Fig	  3.18.	  Principal	  component	  analysis	  (PCA)	  of	  all	  BS194	  samples.	  Principal	   component	   analysis	   plot	   showing	   each	   treatment	   sample	   in	   triplicate.	   Grey	  spheres	   are	   the	   vehicle	   samples	   (DMSO)	   and	   red,	   blue	   and	   brown	   spheres	   represent	  RNA	   samples	   extracted	   from	   HCT116	   cells	   treated	   with	   BS194	   for	   1,	   2	   and	   6	   hours,	  respectively.	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3.2.5.1	  Gene	  ontology	  and	  pathway	  analysis	  of	  BS194-­‐regulated	  genes	  	  A	   list	   of	  differentially	   altered	  entities	  was	  generated	  by	   conducting	  a	  T-­‐test	   on	  the	  6	  hour	  BS194	  samples	  and	  6	  hour	  DMSO	  control	  samples,	  which	  satisfied	  a	  FC	   cut-­‐off	   of	   ≥2.0	   and	   a	   p-­‐value	   cut-­‐off	   of	   <0.05	   (supplementary	   figure	   S2).	   In	  total,	   1534	   entities	   were	   differentially	   regulated	   following	   6	   hours	   BS194	  treatment	  at	  these	  cut-­‐offs.	  Of	  these,	  333	  genes	  was	  up-­‐regulated	  and	  1201	  were	  down-­‐regulated.	   This	   gene	   list	   was	   subjected	   to	   several	   Gene	   Ontology	   and	  pathway	   analysis	   tools.	   Firstly,	   up-­‐regulated	   entities	   were	   submitted	   to	   the	  DAVID	   functional	   clustering	   tool,	  which	   returned	   two	   clusters	   that	   satisfied	   an	  enrichment	  score	  ≥1.3	  (Table	  3.3	  A	  and	  B).	  The	  most	  significantly	  enriched	  group	  included	  a	  series	  of	  terms	  that	  indicated	  protein	  kinase	  activity	  (including	  terms	  from	  SMART	  [Simple	  Modular	  Architecture	  Research	  Tool]	  and	  InterPro	  [EMBL-­‐EBI],	  which	  provides	  functional	  analysis	  of	  protein	  sequences	  by	  classifying	  them	  into	  families	  and	  predicting	  the	  presence	  of	  domains	  and	  other	  important	  sites).	  A	   second	   group	   was	   composed	   of	   terms	   indicating	   lipid	   storage	   from	   a	   Gene	  Ontology	  group	  annotation.	  Pathway	  analysis	  (Table	  3.3C)	  was	  undertaken	  using	  the	  Significant	  Pathway	   tool	   in	  GeneSpring,	  which	   can	  be	   filtered	  based	  on	   the	  number	  of	  entities	  involved	  or	  significance	  (p-­‐value).	  In	  this	   instance,	  a	  p-­‐value	  cut-­‐off	   of	   ≤0.05	   was	   used	   and	   the	   resulting	   list	   of	   significant	   pathways	   was	  sorted	   according	   to	   the	   percentage	   of	   entities	   involved.	   In	   agreement	  with	   the	  functional	   groupings	   (table	   3.3	   A	   and	  B),	   three	   pathways	   satisfying	   the	   cut-­‐off	  were	  involved	  in	  kinase	  activity:	  AKT	  phosphorylation,	  PI3K/AKT	  signalling	  and	  p38	   signalling.	   AKT	   phosphorylation	   was	   incidentally	   the	   most	   significant	   in	  terms	   of	   percentage	   of	   entities	   involved	   and	   p-­‐value.	   There	   was	   no	   obvious	  indication	  of	  lipid	  storage	  pathways	  in	  the	  list	  however.	  	  Down-­‐regulated	  entities	  were	  then	  also	  subjected	  to	  GO	  analysis.	  Initially,	  these	  entities	   were	   subjected	   to	   Gene	   Ontology	   tool	   in	   GeneSpring	   (Table	   3.4)	   and	  subsequently	   to	   functional	  clustering	  using	  DAVID	  (Table	  3.5),	  which	  was	  used	  to	  give	  further	  definition	  to	  the	  GO	  terms	  by	  segregating	  the	  individual	  entities.	  	  Interestingly,	   the	   two	   methods	   gave	   only	   limited	   overlap.	   This	   is	   likely	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attributable	  to	  the	  methodology	  used	  to	  calculate	  the	  significance	  value	  however,	  it	   should	   be	   noted	   that	   it	   was	   possible	   to	   change	   the	   stringency	   using	   DAVID	  when	   assigning	   entities	   into	   functional	   groups,	   which	   was	   not	   possible	   using	  GeneSpring.	   Since	   the	   most	   conservative	   options	   were	   chosen	   for	   this,	   it	   is	  possible	  that	  this	  may	  account	  for	  the	  smaller	  number	  of	  groupings	  satisfying	  the	  cut-­‐off	  of	  P	  ≤0.05	  (equivalent	  to	  an	  enrichment	  score	  ≥1.3	  within	  DAVID).	  There	  is	  also	   significant	   redundancy	  with	   the	  groups	  generated	  using	   the	  GeneSpring	  tool,	   accounting	   for	   the	   numerous	   similar	   terms	   -­‐	   particularly	   noticeable	   in	  transcription	   and	   kinase	   groups.	   The	   GeneSpring	   GO	   analysis	   list	   sorted	  according	   to	  p-­‐value	  (Table	  3.4	  B)	   is	  most	  comparable	   to	   the	  DAVID	   functional	  groups	  (Table	  3.5)	  since	  this	  also	  bases	  the	  enrichment	  score	  on	  a	  p-­‐value.	  	  	  Transcriptional	   terms	   ranked	   as	   the	   most	   significant	   by	   GeneSpring	   were	  noticeably	   absent	   in	   DAVID	   analysis.	   Again,	   perhaps	   this	   reflects	   the	   higher	  stringency.	   However	   mitosis,	   negative	   regulation	   of	   cell	   growth	   and	   kinase	  activity	  were	   all	   represented	   in	   the	  DAVID	  analysis.	  Apoptosis	  was	   featured	   in	  the	   DAVID	   analysis	   but	   not	   in	   GeneSpring,	   although	   it	   is	   likely	   that	   there	   is	   a	  degree	  of	  overlap	  with	  the	  cell	  growth	  groups	  –	  present	  in	  both	  analyses.	  Indeed,	  several	   entities	   appear	   in	   both	   groups	   in	   the	   DAVID	   analysis	   (BCL6,	   Activin	   A	  receptor,	  p21).	  	  The	  same	  entity	   list	  was	   subsequently	  analysed	  using	   the	  Significant	  Pathways	  tool	  in	  GeneSpring	  (Table	  3.6)	  and	  sorted	  according	  to	  the	  p-­‐value.	  As	  before,	  all	  pathways	   met	   a	   pre-­‐specified	   cut-­‐off	   p-­‐value	   ≤0.05.	   Once	   again,	   in	   agreement	  with	   the	   GO	   analysis	   there	   were	   several	   pathways	   representative	   of	   the	   cell	  cycle,	  kinase	  activity	  and	  apoptosis/cell	  growth.	  TGFβ-­‐R,	  regulation	  of	  Rb,	  EGFR,	  polo-­‐like	  kinase,	  E2F	  and	  TNF-­‐α	  signaling	  are	  all	  within	  the	  top	  10	  in	  this	  list	  and	  several	  other	  pathways	  such	  as	  Mitosis,	  extrinsic	  apoptosis,	  NOTCH,	  G1/S	  check	  point	  and	  Aurora	  B	  signaling	  pathways	  all	  had	  significant	  	  p-­‐values.	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Table	   3.3.	   Functional	   clustering	   for	   entities	   up-­regulated	   at	   6	   hours	   post	   BS194	  
treatment:	  An	  entity	  list	  of	  up-­‐regulated	  genes	  was	  generated	  by	  conducting	  a	  T-­‐test	  on	  the	   6	   hour	   BS194	   treated	   samples	   and	   the	   6	   hour	   vehicle	   (DMSO)	   treated	   samples.	  Entities	  that	  satisfied	  a	  FC	  cut-­‐off	  of	  ≥2.0	  and	  a	  P-­‐value	  of	  ≤0.05	  were	  submitted	  to	  the	  online	  functional	  clustering	  tool	  DAVID	  which	  returned	  two	  clusters	  with	  an	  enrichment	  score	   ≥1.3	   (A	   and	   B).	   Pathway	   analysis	   (C)	  was	   performed	   on	   the	   same	   entity	   list	   in	  GeneSpring	  using	  the	  Significant	  Pathway	  tool.	  The	  pathway	  analysis	  also	  used	  a	  P-­‐value	  cut-­‐off	   of	   ≤0.05	   and	   the	   list	   shown	  was	   sorted	   according	   to	   the	  percentage	   of	   entities	  included	  within	  each	  pathway.	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Table	  3.4.	  GO	  analysis	  of	  BS914-­down	  regulated	  entities	  at	  6	  hour	  post-­treatment:	  Entities	  that	  were	  down-­‐regulated	  at	  6	  hours	  post-­‐BS194	  treatment	  were	  subject	  to	  GO	  analysis	  using	  the	  Gene	  Ontology	  tool	  in	  GeneSpring.	  The	  GO	  terms	  satisfying	  a	  p-­‐value	  cut-­‐off	   of	   ≤0.05	  were	   tabulated	   and	   sorted	   according	   to	   (A)	   Enrichment,	   which	   takes	  into	  account	  the	  number	  of	  entities	  falling	  into	  a	  given	  GO	  group	  as	  a	  proportion	  of	  the	  total	  number	  of	  probes	  on	  the	  array	  and	  	  (B)	  p-­‐value.	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Table	  3.5.	  Functional	  clustering	  of	  BS914-­down	  regulated	  entities	  at	  6	  hour	  post-­
treatment:	   Entities	   that	   were	   downregulated	   at	   6	   hours	   post-­‐BS194	   treatment	   were	  subject	   to	   functional	   clustering	   analysis	   using	   DAVID.	   The	   GO	   functional	   groups	  were	  considered	   significant	   if	   the	   enrichment	   score	   shown	   in	   brackets	   was	   ≥1.3.	   In	   this	  analysis,	  Mitosis	  was	  the	  most	  functionally	  enriched	  group.	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Table	  3.6.	  Significant	  Pathway	  analysis	  of	  BS914	  downregulated	  entities	  at	  6	  hour	  
post-­treatment:	   Entities	   that	   were	   downregulated	   at	   6	   hours	   post-­‐BS194	   treatment	  were	  subject	   to	   the	  Significant	  Pathways	  tool	   in	  GeneSpring.	  A	  cut-­‐off	  p-­‐value	  of	  ≤0.05	  was	  used.	  Here,	  all	   significant	  pathways	  are	  shown	  and	  have	  been	  sorted	  according	   to	  their	  p-­‐values.	  The	  Number	  of	  Entities	  column	  are	  the	  number	  of	  genes	  in	  the	  respective	  pathway	   (as	   determined	   by	   KEGG),	   the	   Matched	   with	   Technology	   column	   are	   the	  number	  of	   genes	   in	   the	  pathway	   that	   are	   also	   included	  on	   the	   array	   and	   the	  Matched	  with	  Entity	  List	  column	  are	  those	  genes	  in	  the	  Number	  of	  Entities	  column	  that	  appear	  in	  the	  inputted	  list.	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3.2.6	  Meta-­‐analysis:	  BS181	  and	  BS194	  	  Thanks	   to	   the	   abundance	   of	   freely	   available	   on-­‐line	   tools	   and	   the	   applications	  available	  within	  many	  microarray	  analysis	  packages,	  it	  was	  possible	  to	  get	  some	  idea	   of	   the	   changes	  happening	   to	  whole	   functional	   gene	   groups	   and	  molecular	  pathways	  following	  treatment	  from	  our	  novel	  inhibitors.	  A	  pattern	  seemed	  to	  be	  emerging,	   making	   it	   tempting	   to	   speculate	   about	   fundamental	   differences	  between	   the	   mode	   of	   action	   of	   BS181	   and	   BS194.	   Therefore	   to	   further	  understand	   the	   mode	   of	   action	   of	   these	   drugs,	   several	   meta-­‐analyses	   were	  undertaken	   with	   datasets	   made	   publically	   available	   on	   the	   Gene	   Expression	  Omnibus	  (GEO)	  website	  (http://www.ncbi.nlm.nih.gov/geo/).	  
	  
3.2.6.1	  Global	  changes	  in	  gene	  expression	  	  To	  assess	   the	   impact	  of	  our	   compounds	  on	  global	  gene	  expression,	   each	  of	   the	  eight	   conditions	  were	   clustered	  with	   each	   probe	   from	   the	   Illumina	   bead	   array	  (48790).	   The	   signal	   from	   each	   probe	   was	   averaged	   over	   replicates	   for	   signal	  intensity.	  The	  result	  of	  this	  analysis	  gave	  two	  main	  branches	  with	  respect	  to	  the	  expression	   profiles	   in	   the	   hierarchical	   cluster	   (fig	   3.19A),	   indicating	   that	   the	  condition	   BS194	   6hrs	   (194-­‐6)	   remained	   quite	   separate	   from	   the	   other	  conditions.	   Of	   the	   second	   main	   branch,	   the	   condition	   BS181	   6hrs	   (181-­‐6)	  appeared	   closest	   to	  194-­‐6,	   as	   one	  might	   expect.	   In	   summary	   there	  was	   a	   clear	  difference	   between	   the	   inhibitors	   and	   DMSO	   at	   the	   six-­‐hour	   time-­‐point.	   Time	  appeared	  to	  be	  the	  main	  determining	  variable	  here,	  because	  conditions	  grouped	  adjacently	   based	   on	   the	   time	   of	   treatment,	   not	   treatment	   type.	  Unsurprisingly,	  the	  control	  conditions	  (DMSO-­‐1	  and	  DMSO-­‐6)	  grouped	  together	  as	  did	  the	  1	  hour	  samples	   (181-­‐1	   and	  194-­‐1).	  The	  proximity	  of	   the	   controls	   to	   the	  1	  hour	   and	  2	  hour	  conditions	  suggested	  there	  was	   little	  change	  at	  1	  hour	  but	  that	  there	  may	  have	   been	   some	   degree	   of	   differential	   gene	   expression	   brought	   about	   by	  treatment	  at	  2	  hours,	  since	  the	  2	  hour	  samples	  grouped	  together	  and	  were	  closer	  to	  the	  6	  hour	  conditions.	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  Since	  the	  global	  picture	  appeared	  to	  suggest	  6	  hours	  treatment	  with	  BS194	  leads	  to	  a	  global	  downregulation	  of	  gene	  expression	  (indicated	  by	  blue	  colouring	  in	  fig	  3.19A),	  the	  same	  conditions	  were	  clustered	  on	  a	  list	  of	  genes	  previously	  shown	  to	   be	   significantly	   changed	   following	   treatment	   with	   300	   nm	   flavopiridol	   (fig	  3.19B),	   as	   determined	   by	   an	   unpaired	   T-­‐test.	   This	   dataset	   (GSE18504)	   was	  downloaded	  from	  the	  GEO	  web	  source	  and	  analysed	  with	  GeneSpring	  GX11	  (see	  methods).	   Flavopiridol	   is	   known	   to	   be	   a	   global	   regulator	   of	   transcription	   at	  certain	  dose	  thresholds	  and	  exhibits	  the	  same	  mode	  of	  action	  as	  Actinomycin	  D	  and	  DRB	  (Lam,	  Pickeral	  et	  al.	  2001;	  Lu,	  Burgan	  et	  al.	  2004)	  and	  therefore	  it	  was	  reasoned	  that	  the	  global	  down-­‐regulation	  seen	  with	  BS194	  at	  6hrs	  may	  reflect	  a	  similar	  pattern	  with	  respect	  to	  significantly	  altered	  genes.	  Indeed,	  a	  similar	  gene	  expression	   profile	   was	   seen,	   with	   BS194-­‐6	   remaining	   distinct	   and	   showing	  greater	   down-­‐regulation	   of	   the	   1399	   genes	   that	   were	   changed	   following	  Flavopiridol	   treatment	   (Fig	  3.19B).	   In	   fact,	   the	  order	   in	  which	   conditions	  were	  clustered	  was	  identical	  to	  that	  of	  the	  global	  analysis	  in	  part	  A.	  	  Finally,	   the	   expression	   of	   nine	   housekeeping	   genes	   was	   checked	   to	   assess	  whether	   the	  use	  of	   these	   compounds	  was	   likely	   to	   impact	  on	  genes	   commonly	  used	  as	  internal	  standards.	  The	  relative	  expression	  (to	  DMSO	  1hr	  and	  6hrs)	  over	  the	   time-­‐course	   is	   shown	  (fig	  3.20).	  Some	  genes	  are	   represented	  with	  multiple	  probes	  on	  the	  Illumina	  bead	  array;	  each	  of	  these	  were	  averaged	  for	  the	  purposes	  of	  the	  graphs	  shown	  here.	  Variation	  in	  gene	  expression	  over	  time	  was	  small	  and	  insignificant	  (P	  >0.05).	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Fig	  3.19.	  Global	  gene	  expression	  change	  of	  48000	  probes	   following	   treatment	  of	  
HCT116	  cells	  with	  BS181	  and	  BS194	  and	  DMSO:	  (A)	  Conditions	  were	  clustered	  using	  the	   hierarchical	   method.	   Average	   probe	   intensity	   after	   normalization	   was	   used	   to	  cluster	  all	  conditions	  with	  respect	  to	  one	  another	  in	  order	  to	  gauge	  the	  global	  expression	  pattern	  of	  genes.	  (B)	  The	  8	  conditions	  were	  clustered	  with	  respect	  to	  a	  set	  of	  1399	  genes	  previously	   shown	   to	   be	   down-­‐regulated	   following	   treatment	   of	   300	   nm	   flavopiridol.	  This	   data	   set	   was	   downloaded	   from	   Gene	   Expression	   Omnibus	   (GSE18504)	   and	  analysed	  using	  GeneSpring	  GX11.	  Genes	  meeting	  a	  fold	  change	  cut-­‐off	  ≥2.0	  down	  and	  a	  P-­‐value	   of	   ≤0.05	  were	   included	   from	   the	   flavopiridol	   data	   set	   and	   these	  were	   used	   to	  cluster	  the	  probes	  significantly	  changed	  in	  our	  conditions.	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Fig	  3.20.	  Expression	  of	  house-­‐keeping	  genes	  over	  a	  period	  of	  six	  hours	  post	  treatment	  of	  
BS181	  and	  BS194.	  The	  expression	  of	  nine	  house-­‐keeping	  genes	  were	  measured	  directly	  from	  
the	  microarray	  for	  each	  treatment	  time	  and	  averaged	  from	  each	  replicate	  relative	  to	  the	  
DMSO	  sample	  relevant	  for	  each	  time-­‐point	  (DMSO-­‐1	  for	  1	  and	  2hr	  treatments	  and	  DMSO-­‐6	  
for	  6hr	  treatments).	  Shown	  in	  the	  graphs	  are	  the	  average	  signal	  intensity	  for	  each	  gene	  and	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3.2.6.2	  BS181	  and	  BS194:	  differences	  in	  mode	  of	  action	  	  Venn	  diagrams	  were	  used	  to	   look	  at	  similarity	  between	  differentially	  regulated	  genes	  by	  at	  least	  two-­‐fold	  in	  the	  flavopiridol	  set	  (GSE18504),	  BS181	  and	  BS194	  (relative	   to	   DMSO	   6hr	   control).	   There	   were	   no	   up-­‐regulated	   entities	   shared	  between	   the	   flavopiridol	   set	   and	   either	   the	   BS181	   and	   BS194	   sets	   (data	   not	  shown).	  However,	  there	  was	  considerable	  overlap	  with	  down-­‐regulated	  entities	  (fig	  3.21A).	  Although	  both	  BS181	  and	  BS194	  shared	  a	  number	  of	  entities	  with	  the	  flavopiridol	   data	   set,	   BS194	   shared	   approximately	   10%	   more	   entities	   with	  BS181	   than	   did	   flavopridiol	   (37%	   vs	   28%,	   respectively).	   Moreover,	   when	   the	  intersection	  of	  shared	  entities	  was	  analysed	  with	  DAVID,	  it	  was	  evident	  that	  our	  two	   inhibitors	   had	   some	   common	   functional	   groups	   but	   also	   some	   distinct	  groups	   (fig	   3.21B	   and	   C).	   Notably,	   whilst	   some	   Transcription	   groups	   and	  Apoptosis	  appeared	   in	  both	   lists	   the	  Kinetochore	  group	  was	  distinct	   for	  BS194	  (fig	  3.21B)	  as	  was	  the	  Microtubule	  cytoskeleton	  organization	  group	  to	  BS181	  (fig	  2.21C),	   although	   given	   the	   similarities	   between	   the	   biology	   of	   these	   groups,	   it	  was	  not	  surprising	  to	   find	  two	  entities	   that	  appear	   in	  both	  groups	  (NDC80	  and	  Centromere	  Protein	  A).	  One	  more	  notable	  difference	  was	  that	  the	  Transcription	  GO	  groups	  from	  BS194	  appeared	  to	  be	  much	  larger	  and	  also	  appeared	  enriched	  in	  transcription	  factors	  and	  auxiliary	  proteins	  that	  assist	  with	  RNA	  polymerase	  II	  binding.	  Again,	   even	   though	   some	  of	   these	   items	  also	  appear	  within	  BS181	  GO	  groups,	  there	  was	  less	  enrichment.	  Finally,	  it	  is	  noteworthy	  that	  in	  the	  lack	  of	  shared	  up-­‐regulated	  entities	  between	  our	   data	   sets	   and	   the	   flavopiridol	   set,	   there	   were	   several	   flavopiridol	   down-­‐regulated	  genes	  that	  were	  in	  fact	  up-­‐regulated	  with	  BS181	  (BCL10,	  BTG2,	  CLK1,	  DDIT4,	   GDF15,	   HERPUD1,	   IER5L,	   JUNB,	   LDLR,	   SETAD3,	   SESN1	   and	   TIPARP).	  Interestingly,	  there	  were	  no	  genes	  down-­‐regulated	  for	  flavopiridol	  that	  were	  up-­‐regulated	  for	  BS914.	  Given	  the	  distinct	  global	  expression	  patterns	  demonstrated	  by	  BS181	  and	  BS194	  and	   that	   BS194-­‐6	   in	   particular	   appeared	   to	   segregate	   with	   respect	   to	   the	  significantly	  changed	  genes	  from	  flavopiridol-­‐treated	  samples,	  it	  is	  possible	  that	  BS194	   has	   a	  mode	   of	   action	   similar	   to	   flavopiridol,	   that	   is	   to	   say	   with	   agents	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characterized	   by	   global	   transcription	   repression.	   	   Indeed,	   in	   a	   meta-­‐analysis	  comparing	   the	  BS181	   and	  BS194	   gene	   sets	   at	   six	   hours	  with	   another	   gene	   list	  generated	  from	  flavopiridol	  treatment	  (Lu,	  Burgan	  et	  al.	  2004),	  there	  was	  some	  degree	  of	  overlap	  with	  BS194	  	  (2.7%)	  and	  to	  a	  smaller	  degree	  with	  BS181	  (0.5%)	  and	  once	  again,	  there	  were	  no	  up-­‐regulated	  genes	  shared	  (fig	  3.22A).	  Analysis	  of	  these	   shared	   entities	   indicated	   that	   of	   the	   16	   entities	   in	   common	   to	   all	   three	  treatment	  groups	  (fig	  3.22B),	  5	  clustered	  into	  functional	  groups	  associated	  with	  ATP	  binding,	  which	  was	   the	   only	   term	   to	   have	   an	   impact	   factor	   of	   ≥1.3.	  Other	  groups	  included	  Mitotic	  cell	  cycle	  and	  DNA	  repair	  (fig	  3.22B).	  Of	  the	  32	  entities	  distinct	  to	  BS194	  and	  flavopiridol	  (fig	  3.22C),	  the	  GO	  terms	  with	  an	  impact	  factor	  above	  1.3	  were	  Transcription	  from	  RNA	  polymerase	  II	  promoter	  and	  Regulation	  of	   transcription.	   A	   third,	   Zinc	   finger	   did	   not	   quite	   meet	   the	   cut-­‐off	   of	   1.3.	   It	  therefore	  seemed	  likely	  that	  there	  were	  some	  fundamental	  differences	  between	  BS181	  and	  BS194	  in	  their	  mode	  of	  action.	  To	  explore	   this	   further,	   another	  meta-­‐analysis	  was	   carried	  out	  with	   a	   gene	   set	  identified	   as	   being	   enriched	   in	   labile	   mRNAs	   that	   were	   down-­‐regulated	   by	  flavopiridol	  in	  OCI-­‐Ly3	  cells	  (Lam,	  Pickeral	  et	  al.	  2001).	  It	  was	  hypothesized	  that	  BS194	   might	   also	   down-­‐regulate	   the	   expression	   of	   these	   labile	   mRNAs	  (determined	   to	   have	   a	   half	   life	   <	   2hrs),	   in	   a	   time-­‐dependent	   fashion	   and	   in	   a	  similar	  way	  to	  what	  was	  shown	  with	  flavopiridol	  (Lam,	  Pickeral	  et	  al.	  2001)	  and	  in	   previous	   studies	   with	   Actinomycin	   D	   (Choong,	   Yang	   et	   al.	   2009).	   Indeed,	  hierarchical	   clustering	   on	   this	   group	   of	   genes	   (fig	   3.23A	   and	   B)	   once	   again	  highlighted	  a	  higher	  degree	  of	  down-­‐regulation	  with	  BS194	  compared	  to	  BS181,	  even	   though	  most	   of	   these	   genes	  were	   down-­‐regulated	   under	   both	   conditions.	  However,	   there	   were	   also	   some	   sub-­‐groups	   that	   showed	   a	   time-­‐dependent	  decrease	   with	   BS194	   but	   which	   were	   unchanged	   over	   the	   time-­‐course	   with	  BS181	  (fig	  3.23B	  (I),	  (II),	  (III)).	  This	  appeared	  to	  be	  distinct	  to	  BS194	  treatment.	  The	  corresponding	  probes	  to	  these	  genes	  were	  located	  in	  the	  Illumina	  array	  and	  absolute	   values	   compared	   between	   the	   two	   treatments	   (fig	   3.23C).	   Group	   (II)	  showed	   the	   most	   significant	   difference	   in	   expression	   between	   the	   two	  treatments	   and	   at	   six	   hours,	   all	   genes	  were	   significantly	   changed	  with	   BS194,	  indicated	  on	  the	  graphs	  by	  asterisks	  (p	  <	  0.05).	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Fig	   3.21.	   Analysis	   of	   shared	   entities	   between	  BS181	   and	  BS194-­treated	   samples	  
and	  flavopiridol-­treated	  cells.	  The	  entity	  lists	  generated	  from	  our	  analysis	  of	  HCT116	  cells	   treated	   with	   BS181	   and	   BS194	   were	   compared	   to	   down-­‐regulated	   genes	   from	  another	  microarray	  that	  treated	  A2780	  cells	  with	  300	  nM	  flavopiridol	  for	  6	  hours.	  The	  venn	  diagram	  (A)	  shows	   the	  shared	  entities	  and	   the	   tables	  summarise	   the	  results	  of	  a	  functional	   clustering	   analysis	   carried	   out	   in	   the	   bioinformatics	   resource	   DAVID	   on	  common	  genes	  between	  flavopiridol	  and	  BS194	  (B)	  and	  BS181	  (C).	  
	   152	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Fig	   3.22.	   Analysis	   of	   shared	   entities	   between	  BS181	   and	  BS194-­treated	   samples	  
and	   flavopiridol-­treated	   cells.	   A	   meta	   analysis	   was	   carried	   out	   using	   a	   gene	   list	  filtered	   on	   flags	   present	   in	   GeneSpring	   GX11	   from	   a	   previous	  microarray	   experiment	  treating	  four	  cell	  lines	  (PC3,	  DU145,	  SF359	  and	  U251)	  with	  flavopiridol	  doses	  that	  lead	  to	  LC90	  toxicity	  	  (Lu	  et	  al	  2004)	  and	  compared	  the	  combined	  number	  of	  down-­‐regulated	  entities	  by	  at	  least	  2-­‐fold	  (180	  entities)	  with	  the	  total	  number	  of	  down-­‐regulated	  entities	  from	  BS181	  and	  BS194-­‐treated	  HCT116	  cells.	  (A)	  Venn	  diagram	  illustrating	  the	  extent	  of	  overlap	   between	   down-­‐regulated	   entities.	   (B)	   Entities	   shared	   between	   all	   three	  treatments	   and	   subsequent	   functional	   classification	   and	   (C)	   32	   entities	   shared	   only	  between	   BS194	   and	   flavopiridol	   and	   the	   resulting	   functional	   classification	   as	  determined	  by	  DAVID.	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Fig	  3.23.	  Meta	  analysis	  looking	  at	  labile	  mRNA	  expression	  following	  treatment	  of	  
BS194	  and	  BS181.	  A	  group	  of	  labile	  mRNAs	  were	  identified	  from	  a	  previous	  study	  (Lam	  et	  al	  2001),	  which	   looked	  at	   the	  effect	  of	   flavopiridol	  on	  OCI-­‐Ly3	  cell	  gene	  expression.	  The	   expression	   levels	   of	   these	   were	   compared	   to	   the	   values	   on	   the	   array	   following	  BS181	  (A)	  and	  BS194	  (B)	   treatment	   to	   look	   for	  a	  similar	  reduction	  of	  expression	  over	  time,	  shown	  to	  be	  characteristic	  of	  labile	  mRNAs.	  Hierarchical	  clustering	  of	  these	  labile	  mRNAs	  in	  the	  BS181	  group	  (A)	  and	  BS194	  group	  (B)	  illustrated	  several	  genes	  that	  were	  decreased	   in	  a	   time-­‐dependent	  manner	  with	  BS194	  but	  not	  BS181	  (I,	   II,	   III	  on	  B).	  The	  normalized	   expression	   levels	   of	   these	   genes	   following	   BS181	   and	   BS194	   were	  subsequently	   recorded	   from	   GeneSpring	   (C).	   Shown	   are	   the	   fold	   change	   (FC)	   of	   gene	  expression	  relative	  to	  the	  vehicle	  (DMSO)	  for	  each	  time	  point	  *	  =	  significant	  difference	  compared	  to	  DMSO	  (P≤0.05)	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4	  Discussion	  
	  
4.1	  Interdependency	  of	  the	  CAK	  complex	  	  	  	  The	  siRNA	  experiments	  carried	  out	  on	  CDK7,	  MAT1	  and	  cyclin	  H	  highlight,	  to	  my	  knowledge,	  a	  previously	  unreported	  biological	  facet	  of	  the	  CAK	  complex:	  each	  component	  has	  a	  mutual	  dependence	  on	  every	  other	  component	  being	  present.	  Hence	  in	  instances	  where	  one	  of	  the	  constituent	  parts	  is	  abrogated	  through	  siRNA	  knockdown,	  the	  protein	  levels	  of	  the	  remaining	  two	  CAK	  members	  (as	  determined	  by	  immunoblotting)	  is	  compromised,	  but	  mRNA	  levels	  are	  not.	  It	  is	  anticipated	  that	  this	  is	  facilitated	  through	  increased	  protein	  degradation.	  Although	  I	  did	  not	  determine	  the	  molecular	  mechanisms	  by	  which	  levels	  of	  the	  CAK	  components	  are	  reduced,	  preliminary	  experiments	  carried	  out	  with	  the	  proteasome	  inhibitor	  MG132	  (results	  not	  shown)	  indicated	  that	  the	  components	  are	  lost	  through	  a	  mechanism	  involving	  proteasome	  mediated	  degradation.	  Moreover,	  the	  fact	  that	  inhibition	  of	  CDK7	  with	  the	  selective	  inhibitor	  BS181	  does	  not	  show	  reduction	  of	  either	  cyclin	  H	  or	  MAT1	  protein,	  suggests	  that	  they	  have	  a	  dependence	  on	  the	  CDK7	  protein	  simply	  being	  present	  but	  not	  necessarily	  functioning,	  adding	  credence	  to	  the	  notion	  that	  the	  existence	  of	  the	  complex	  relies	  foremost	  on	  the	  structural	  integrity	  of	  each	  member.	  	  	  	  	  That	  both	  MAT1	  and	  cyclin	  H	  appear	  to	  be	  required	  for	  down-­‐stream	  CAK-­‐mediated	  phosphorylation	  (exemplified	  by	  a	  reduction	  in	  phospho-­‐CDK1	  and	  phospho-­‐CDK2	  upon	  cyclin	  H	  and	  MAT1	  knockdown)	  demonstrates	  that	  there	  is	  also	  a	  functional	  dependency	  on	  the	  presence	  of	  all	  three	  members.	  It	  is	  curious	  that	  mammals	  have	  evolved	  this	  dependence,	  since	  in	  yeast,	  the	  respective	  CDK7	  ortholog,	  KIN28,	  is	  monomeric.	  Therefore,	  it	  is	  likely	  that	  the	  addition	  of	  MAT1	  in	  higher	  organisms	  serves	  to	  switch	  substrate	  selectivity	  towards	  the	  RNA	  polymerase	  complex	  when	  associated	  with	  the	  general	  transcription	  factor	  TFIIH	  (Yankulov	  and	  Bentley	  1997).	  It	  would	  be	  interesting	  therefore	  to	  determine	  if	  siRNA-­‐mediated	  CDK7	  complex	  knockdown	  impacts	  on	  the	  integrity	  of	  the	  TFIIH	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complex.	  The	  CAK	  complex	  is	  not	  part	  of	  the	  core	  TFIIH	  complex	  and	  CAK	  recruitment	  to	  TFIIH	  is	  mediated	  by	  its	  interaction	  with	  the	  p62	  subunit	  of	  TFIIH.	  It	  is	  likely	  therefore	  that	  CAK	  knockdown	  does	  not	  result	  in	  down-­‐regulation	  of	  other	  TFIIH	  subunits,	  but	  this	  can	  of	  course	  readily	  be	  tested.	  	  	  
4.2	  siRNA-­‐directed	  abrogation	  of	  CDK7	  leads	  to	  a	  cellular	  phenotype	  distinct	  to	  
abrogation	  mediated	  by	  the	  selective	  CDK7	  inhibitor	  BS181	  	  CAK	  activity	  is	  lost	  after	  knockdown	  of	  any	  of	  its	  constituent	  sub-­‐units	  as	  shown	  by	  the	  loss	  of	  known	  substrates	  phospho-­‐CDK1	  (T-­‐161)	  and	  phospho-­‐CDK2	  (T-­‐160)	  and	  several	  cell	  cycle-­‐related	  proteins.	  This	  is	  consistent	  with	  what	  has	  previously	  been	  shown	  with	  our	  selective	  CDK7	  inhibitor,	  BS181.	  However,	  in	  contrast	  to	  BS181-­‐mediated	  inhibition,	  the	  heptapeptide	  repeat	  unit	  in	  the	  C-­‐terminal	  domain	  (CTD)	  of	  polymerase	  II	  (PolII)	  did	  not	  show	  a	  clear	  reduction	  in	  phosphorylation.	  It	  seems	  reasonable	  to	  suggest	  that	  in	  light	  of	  similar	  reports	  (Kanin,	  Kipp	  et	  al.	  2007;	  Glover-­‐Cutter,	  Larochelle	  et	  al.	  2009),	  phosphorylation	  of	  the	  PolII	  CTD	  at	  S5	  may	  be	  compensated	  by	  another	  kinase	  with	  CTD-­‐directed	  activity,	  most	  likely	  CDK9	  and/or	  possibly	  also	  CDK8.	  This	  has	  also	  been	  demonstrated	  by	  way	  of	  chemical	  genetic	  inhibition	  of	  CDK7	  (Glover-­‐Cutter,	  Kim	  et	  al.	  2008).	  In	  this	  investigation,	  it	  was	  determined	  that	  CDK7	  and	  CDK9/PTEFb	  both	  contribute	  to	  phosphorylation	  at	  Ser5	  and	  that	  in	  vivo	  inhibition	  of	  CDK7	  reduced	  the	  promoter-­‐proximal	  pausing	  event,	  which	  functions	  to	  enhance	  co-­‐transcriptional	  mRNA	  capping,	  an	  obligate	  step	  in	  the	  PolII-­‐mediated	  gene	  transcription.	  Furthermore,	  this	  coincided	  with	  a	  reduced	  recruitment	  of	  the	  negative	  elongation	  factor	  (NELF),	  which	  is	  critical	  for	  establishing	  the	  promoter-­‐proximal	  pause	  at	  transcription	  start	  sites	  and	  thus	  facilitating	  gene	  activation.	  An	  earlier	  in	  vivo	  observation	  in	  yeast,	  whereby	  mutant	  strains	  engineered	  with	  CDK7as	  (Kin28as)	  were	  found	  to	  have	  no	  difference	  in	  global	  transcription	  rates	  compared	  to	  wt	  strains	  when	  treated	  with	  a	  synthetic,	  bulky	  ATP	  analogue	  (effectively	  blocking	  the	  kinase	  function	  by	  irreversibly	  binding	  to	  the	  kinase	  active	  site).	  However,	  in	  published	  microarray	  data	  generated	  from	  a	  temperature	  sensitive	  strain	  (Kin28ts)	  (Kanin,	  Kipp	  et	  al.	  2007),	  they	  reported	  a	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general	  paucity	  in	  global	  transcription.	  They	  conclude	  that	  this	  difference	  is	  owing	  to	  the	  fact	  that	  small-­‐molecule	  inhibition	  does	  not	  perturb	  protein-­‐protein	  interactions,	  nor	  promote	  dissociation	  of	  TFIIH	  from	  gene	  promoter	  regions	  and	  therefore	  the	  kinase	  activity	  of	  CDK7	  is	  not	  essential	  for	  global	  transcription.	  However	  this	  also	  highlights	  the	  fact	  that	  siRNA	  may	  serve	  as	  a	  poor	  surrogate	  by	  which	  to	  validate	  the	  transcriptional	  consequences	  of	  BS181	  administration	  and	  indeed	  investigate	  the	  activity	  of	  CAK.	  Hence,	  comparison	  of	  CAK	  subunit	  knockdown	  and	  the	  use	  of	  our	  highly	  selective	  CDK7	  inhibitors	  provide	  a	  powerful	  means	  to	  determine	  if,	  in	  mammalian	  cells,	  CAK	  activity	  is	  similarly	  not	  essential	  for	  global	  transcription,	  perhaps	  because	  CDK9	  (and/or	  CDK8)	  can	  compensate	  for	  CDK7.	  	  	  In	  summary,	  PolII	  inhibition	  by	  BS181	  but	  not	  by	  siRNA	  may	  be	  a	  reflection	  of	  two	  possible	  scenarios:	  (i)	  inhibition	  of	  CDK7	  activity	  is	  achieved	  by	  BS181	  treatment,	  but	  when	  CDK7	  protein	  is	  physically	  lost	  following	  siRNA	  treatment,	  functional	  compensation	  is	  mediated	  by	  CDK9:	  in	  this	  scenario,	  BS181	  could	  be	  seen	  as	  promoting	  a	  dominant	  negative	  enzyme	  complex.	  (ii)	  that	  at	  the	  concentrations	  of	  BS181	  used	  in	  these	  experiments,	  CDK9	  is	  inhibited	  in	  addition	  to	  CDK7,	  hence	  PolII	  phosphorylation	  is	  reduced	  for	  BS181	  treatment	  but	  not	  for	  siCDK7.	  These	  possibilities,	  together	  with	  determination	  of	  TFIIH	  subunit	  integrity	  can	  be	  addressed	  by	  siRNA-­‐mediated	  CAK	  knockdown	  followed	  by	  BS181	  treatment,	  whilst	  redundancy	  could	  be	  addressed	  by	  knockdown	  of	  CDK7	  and	  CDK9	  simultaneously.	  	  It	  is	  somewhat	  of	  a	  paradox	  that	  there	  was	  a	  noticeable	  reduction	  in	  cyclin	  D1,	  MCL-­‐1	  and	  XIAP	  protein,	  suggesting	  that	  despite	  the	  fact	  that	  phosphorylation	  at	  S5	  and	  S2	  of	  the	  PolII	  CTD	  was	  not	  compromised,	  there	  is	  inhibition	  of	  transcriptional	  activity,	  since	  each	  of	  these	  genes	  are	  characterized	  by	  having	  labile	  transcripts.	  Incidentally,	  the	  reduction	  in	  MCL-­‐1	  and	  XIAP	  probably	  explains	  the	  increase	  of	  cells	  in	  the	  sub-­‐G1	  peak	  and	  positive	  annexin	  staining,	  
	   159	  
both	  being	  indicative	  of	  apoptosis	  and	  replicating	  what	  was	  previously	  reported	  with	  BS181	  (Ali,	  Heathcote	  et	  al.	  2009).	  	  In	  agreement	  with	  what	  was	  previously	  reported	  with	  BS181,	  cell	  growth	  was	  reduced	  following	  knockdown	  to	  any	  of	  the	  CAK	  subunits;	  this	  was	  more	  pronounced	  following	  CDK7	  knockdown.	  Similarly,	  CDK7	  knockdown	  led	  to	  a	  higher	  proportion	  of	  cells	  in	  the	  sub-­‐G1	  peak	  than	  cyclin	  H	  or	  MAT1	  and	  positive	  annexin	  and	  propidium	  iodide	  staining	  indicated	  that	  there	  was	  a	  higher	  proportion	  of	  late	  apoptotic	  cells	  following	  CDK7	  knockdown	  compared	  to	  knockdown	  of	  cyclin	  H	  or	  MAT1.	  Together,	  this	  confirms	  that	  selective	  disruption	  of	  the	  CAK	  complex	  leads	  to	  apoptosis.	  Why	  CDK7	  abrogation	  should	  have	  a	  more	  profound	  effect	  than	  knockdown	  of	  either	  cyclin	  H	  or	  MAT1	  may	  indicate	  that	  CDK7	  together	  with	  cyclin	  H	  or	  MAT1	  as	  a	  dimeric	  enzyme,	  or	  on	  its	  own	  as	  a	  monomeric	  unit,	  still	  has	  residual	  kinase	  activity.	  This	  has	  been	  reported	  previously	  on	  the	  condition	  that	  CDK7	  is	  dually	  phosphorylated	  at	  its	  T176	  and	  S170	  residues	  (Martinez,	  Afshar	  et	  al.	  1997).	  Moreover,	  because	  CAK	  activity	  is	  thought	  to	  be	  fully	  active	  upon	  subsequent	  cyclin	  H	  binding	  (Martinez,	  Afshar	  et	  al.	  1997)	  and	  MAT1	  is	  thought	  to	  act	  primarily	  as	  an	  assembly	  factor	  but	  also	  as	  a	  determinant	  of	  substrate	  specificity	  (Yankulov	  and	  Bentley	  1997),	  this	  could	  explain	  the	  elevated	  apoptosis	  observed	  with	  cyclin	  H	  compared	  with	  MAT1	  knockdown.	  However,	  repeat	  experiments	  would	  need	  to	  be	  completed	  in	  order	  to	  validate	  this	  relationship.	  	  	  	  Although	  knockdown	  of	  CDK7	  appears	  to	  elicit	  the	  greatest	  impact	  on	  cell	  growth,	  the	  cell	  cycle	  and	  apoptosis,	  it	  is	  also	  interesting	  to	  consider	  the	  substrate	  determining	  role	  of	  MAT1	  toward	  PolII	  CTD:	  in	  the	  absence	  of	  MAT1	  (as	  recapitulated	  during	  siRNA	  knockdown),	  one	  might	  reasonably	  expect	  PolII	  CTD	  S5	  phosphorylation	  (and	  thus	  transcription)	  to	  be	  reduced,	  but	  instead	  what	  was	  observed	  in	  this	  initial	  experiment,	  is	  a	  level	  of	  apoptosis	  lower	  than	  that	  observed	  following	  CDK7	  and	  cyclin	  H	  knockdown,	  which	  might	  infer	  that	  anti-­‐apoptotic	  regulators	  such	  as	  XIAP	  or	  MCL-­‐1	  (both	  labile	  in	  nature)	  have	  not	  been	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affected.	  As	  shown	  with	  immunoblots	  of	  XIAP	  and	  MCL-­‐1	  (fig	  3.3C),	  it	  is	  not	  fully	  clear	  whether	  this	  is	  the	  case	  or	  not;	  whilst	  there	  is	  a	  clear	  reduction	  of	  both	  XIAP	  and	  MCL-­‐1	  following	  CDK7	  abrogation,	  there	  is	  no	  clear	  indication	  of	  MCL-­‐1	  reduction	  following	  cyclin	  H	  or	  MAT1	  abrogation.	  Furthermore,	  there	  is	  moderate	  reduction	  of	  XIAP	  and	  cyclin	  D1	  (another	  labile	  transcript),	  most	  notably	  by	  CDK7	  and	  cyclin	  H	  knockdown.	  	  	  Once	  again,	  these	  observations	  are	  discordant	  to	  what	  was	  seen	  with	  previous	  studies	  undertaken	  with	  BS181,	  which	  illustrated	  a	  clear	  dose-­‐dependent	  reduction	  of	  XIAP	  and	  cyclin	  D1	  as	  well	  as	  Bcl-­‐xL,	  another	  short-­‐lived	  transcript	  (Ali,	  Heathcote	  et	  al.	  2009),	  but	  rather	  in	  agreement	  with	  findings	  from	  the	  Fisher	  lab	  (Larochelle,	  Batliner	  et	  al.	  2006;	  Glover-­‐Cutter,	  Larochelle	  et	  al.	  2009),	  which	  conclude	  that	  CDK7	  kinase	  activity	  is	  not	  essential	  for	  transcription.	  In	  contrast,	  the	  negative	  effects	  seen	  on	  the	  cell	  cycle,	  stimulation	  of	  apoptosis	  and	  the	  notable	  decrease	  of	  the	  aforementioned	  labile	  proteins	  when	  CDK7	  is	  depleted	  could	  be	  indicative	  of	  a	  general	  inhibition	  of	  transcription,	  likely	  mediated	  through	  structural	  disruption	  to	  CAK,	  analogous	  to	  what	  has	  previously	  demonstrated	  in	  temperature	  sensitive	  models.	  	  	  Therefore,	  this	  implies	  that	  the	  “selective”	  inhibition	  of	  BS181	  is	  not	  selective	  in	  the	  same	  way	  as	  bulky	  ATP	  analogues	  are	  to	  CDK7as	  in	  mutant	  cell	  lines.	  Indeed,	  BS181	  does	  have	  activity	  against	  other	  CDKs,	  including	  CDK9	  with	  an	  IC50	  value	  of	  4.2μmol/L,	  possibly	  explaining	  the	  transcriptional	  inhibition	  reported	  for	  BS181	  (Ali,	  Heathcote	  et	  al.	  2009).	  	  In	  summary,	  experiments	  undertaken	  with	  siRNA	  have	  shed	  some	  light	  on	  the	  structural	  and	  functional	  relationships	  between	  CAK	  subunits	  and	  also	  clarified	  some	  uncertainties	  about	  the	  mode	  of	  action	  of	  BS181.	  Specifically,	  the	  structural	  integrity	  of	  the	  CAK	  trimeric	  complex	  appears	  to	  have	  a	  mutual	  dependency	  on	  each	  member	  being	  present;	  it	  is	  unclear	  whether	  the	  loss	  of	  CAK	  subunits	  is	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proteasome-­‐dependent	  but	  preliminary	  experiments,	  along	  with	  a	  lack	  of	  appreciable	  decrease	  of	  CAK	  subunit	  mRNA	  would	  appear	  to	  indicate	  this	  to	  be	  the	  case.	  In	  response	  to	  CAK	  disruption:	  CAK	  activity,	  cell	  growth	  and	  the	  cell	  cycle	  are	  disrupted,	  with	  a	  noticeable	  increase	  in	  apoptosis,	  although	  this	  is	  more	  remarkable	  in	  cells	  having	  undergone	  CDK7	  ablation.	  This	  would	  seem	  to	  indicate	  that	  CDK7	  may	  retain	  a	  basal	  level	  of	  activity	  as	  a	  monomer,	  which	  has	  been	  suggested	  previously	  (Martinez,	  Afshar	  et	  al.	  1997).	  Interestingly,	  this	  also	  suggests	  that	  the	  elevated	  apoptosis	  achieved	  through	  CDK7	  and	  cyclin	  H	  abrogation	  reflects	  an	  inhibition	  of	  transcription,	  as	  evidenced	  by	  some	  labile	  transcripts	  such	  as	  XIAP	  and	  cyclin	  D1,	  which	  show	  a	  marked	  decrease	  in	  their	  protein	  expression	  thus	  appearing	  synonymous	  to	  the	  mode	  of	  action	  demonstrated	  by	  BS181.	  However,	  a	  general	  paucity	  of	  CTD	  phosphorylation	  at	  S5	  of	  PolII,	  suggests	  either	  that	  there	  is	  sufficient	  residual	  activity	  left	  after	  siRNA	  depletion	  or	  that	  another	  CDK,	  probably	  CDK9	  (or	  CDK8)	  is	  compensating.	  The	  paradoxical	  observation	  of	  phospho-­‐S5	  reduction	  seen	  with	  BS181	  can	  be	  explained	  by	  the	  fact	  that	  it	  also	  inhibits	  CDK9	  at	  the	  concentrations	  used.	  In	  all,	  these	  results	  are	  in	  agreement	  with	  previous	  reports	  that	  CDK7	  kinase	  activity	  is	  dispensable	  for	  transcription	  but	  the	  physical	  presence	  of	  CAK	  is	  not.	  Therefore,	  BS181-­‐directed	  inhibition	  may	  not	  represent	  the	  ‘cleanest’	  methodology	  for	  exploring	  the	  functional	  and	  structural	  facets	  of	  CAK	  and	  similarly,	  siRNA-­‐mediated	  knockdown	  may	  not	  either.	  A	  better	  method	  of	  exploration	  in	  this	  context	  may	  lie	  in	  the	  use	  of	  more	  selective	  CDK7	  inhibitors	  such	  as	  ICEC0942,	  analogue-­‐sensitive	  mutants	  or	  immunopurified	  CAK	  following	  sequential	  siRNA	  knockdown	  of	  each	  member	  to	  look	  for	  residual	  activity.	  ICEC0942,	  developed	  over	  the	  last	  12	  months,	  is	  particularly	  interesting	  as	  it	  inhibits	  CDK7	  with	  an	  IC50	  of	  0.041	  µM,	  compared	  with	  CDK9	  IC50	  of	  1.1	  µM	  and	  mean	  GI50	  =	  0.28µM	  (Patel	  et	  al.	  unpublished).	  By	  comparison,	  the	  CDK7	  IC50=0.02µM,	  CDK9	  IC50=1.2	  µM,	  but	  effective	  GI50=20	  µM,	  means	  that	  the	  concentrations	  of	  BS181	  that	  need	  to	  be	  used	  for	  cell-­‐based	  studies	  would	  be	  sufficiently	  high	  to	  inhibit	  CDK9,	  whereas	  concentration	  of	  ICEC0942	  can	  be	  kept	  sufficiently	  below	  the	  CDK9	  IC50	  for	  selective	  CDK7	  inhibition.	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4.3	  Potential	  mechanisms	  of	  resistance	  to	  CDK	  inhibitors	  	  The	  findings	  presented	  above	  and	  previously	  (Ali,	  Heathcote	  et	  al.	  2009)	  indicate	  that	  the	  cellular	  effects	  of	  BS181	  are	  mediated	  through	  dual	  inhibition	  of	  the	  cell	  cycle	  and	  transcription.	  Although	  BS181	  is	  selective	  for	  CDK7,	  at	  some	  of	  the	  concentrations	  used	  in	  published	  data,	  one	  might	  reasonably	  expect	  CDK9	  to	  be	  inhibited	  also	  at	  the	  concentrations	  used.	  In	  our	  previous	  data,	  appreciable	  cell	  cycle	  effects	  (decrease	  of	  cells	  in	  G1	  phase;	  increase	  in	  sub-­‐G1)	  were	  only	  statistically	  significant	  at	  BS181	  concentrations	  of	  ≥25μmol,	  therefore	  it	  is	  not	  clear	  whether	  this	  is	  totally	  attributable	  to	  CDK7	  inhibition.	  To	  further	  characterize	  how	  BS181	  may	  be	  working,	  a	  head-­‐to-­‐head	  comparison	  with	  BS194,	  another	  small	  molecule	  inhibitor	  was	  undertaken	  by	  way	  of	  microarray	  analysis.	  BS194	  was	  developed	  in	  the	  same	  way	  as	  BS181	  but	  inhibits	  CDK2	  with	  an	  IC50	  of	  3nmol/L,	  CDK1	  at	  30nmol/L	  and	  CDK9	  at	  90nmol/L	  but	  CDK7	  at	  250nmol/L	  (Heathcote,	  Patel	  et	  al.	  2010).	  Using	  a	  serial	  range	  of	  concentrations	  and	  at	  2	  time-­‐points	  (4	  hours	  and	  24	  hours),	  this	  study	  showed	  that	  BS194	  began	  to	  lead	  to	  the	  reduction	  of	  several	  proteins,	  indicative	  of	  a	  block	  on	  the	  cell	  cycle	  (including	  phospho-­‐RB,	  phospho-­‐CDK	  and	  cyclin	  D1,	  A	  and	  B)	  and	  of	  transcription	  (PolII	  Ser	  2	  and	  Ser5)	  at	  100nmol/L,	  although	  this	  was	  generally	  more	  obvious	  at	  24	  hours.	  Changes	  to	  the	  cell	  cycle	  (increase	  in	  sub	  G1,	  decrease	  in	  G0/G1	  and	  increase	  in	  G2/M)	  were	  also	  only	  significant	  at	  concentrations	  ≥100nmol/L	  reflecting	  the	  activity	  of	  BS194	  for	  CDK1	  and	  CDK2.	  Thus	  BS194	  represents	  a	  pan-­‐CDK	  inhibitor	  compared	  to	  BS181	  with	  a	  distinct	  pharmacodynamic	  profile,	  making	  it	  an	  ideal	  candidate	  to	  compare	  BS181	  with	  in	  terms	  of	  global	  transcription	  patterns.	  Moreover,	  there	  is	  potential	  clinical	  utility	  in	  both	  of	  these	  compounds,	  so	  defining	  the	  mechanism	  of	  action	  and	  identifying	  predictive	  biomarkers	  of	  their	  activity	  could	  be	  of	  future	  importance.	  To	  test	  their	  clinical	  potential,	  a	  panel	  of	  endocrine-­‐sensitive	  and	  endocrine-­‐resistant	  breast	  cancer	  cell	  lines	  was	  tested	  against	  several	  chemotherapy	  agents	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and	  small	  molecule	  CDK	  inhibitors,	  including	  BS181	  and	  BS194.	  The	  sensitive	  and	  resistant	  lines	  showed	  no	  difference	  in	  sensitivity	  to	  BS194	  or	  to	  BS181.	  	  In	  an	  attempt	  to	  generate	  cellular	  resistance	  to	  both	  inhibitors,	  HCT116	  cells	  were	  passaged	  in	  gradually	  increasing	  concentrations	  of	  each	  agent.	  Interestingly,	  BS181	  did	  not	  appear	  to	  be	  a	  substrate	  for	  any	  of	  the	  multi-­‐drug	  resistance	  pumps	  that	  were	  assayed	  for,	  whereas	  cell	  lines	  over-­‐expressing	  MDR1	  and	  BCRP	  were	  less	  sensitive	  to	  BS194,	  implying	  that	  BS194	  is	  a	  substrate	  for	  these	  pumps.	  Incidentally,	  a	  third	  small	  molecule	  inhibitor	  developed	  at	  the	  same	  time,	  ICEC0942	  also	  appeared	  to	  be	  a	  substrate	  for	  these	  pumps.	  This	  compound	  was	  developed	  as	  a	  selective	  inhibitor	  for	  CDK7	  but	  with	  bioavailability	  properties	  equal	  to	  that	  of	  BS194,	  therefore	  it	  is	  structurally	  similar	  to	  BS194	  but	  selective	  for	  CDK7.	  	  Although	  it	  is	  clear	  that	  BS194	  is	  a	  substrate	  for	  these	  pumps,	  further	  experiments	  are	  required	  to	  further	  delineate	  the	  mechanism	  of	  resistance	  and	  confirm	  that	  BS194	  resistance	  is	  actually	  due	  to	  these	  pumps,	  given	  that	  their	  expression	  was	  still	  quite	  low	  compared	  to	  the	  positive	  controls.	  Immediate	  studies	  should	  focus	  on	  the	  use	  of	  pump	  inhibitors	  such	  as	  varapamil	  and	  other	  multidrug-­‐resistance	  modulators	  (quinine,	  thioridazine,	  clomipramine	  or	  diltiazem)	  whilst	  dye	  exclusion	  experiments	  would	  allow	  the	  function	  of	  the	  pumps	  to	  be	  determined.	  	  	  Importantly,	  BS181	  was	  not	  a	  substrate	  for	  these	  pumps,	  so	  clinical	  resistance	  to	  BS181	  may	  be	  unlikely	  to	  result	  from	  multidrug	  resistant	  pathways.	  Since	  both	  BS194	  and	  the	  related	  ICEC0942	  are	  substrates	  for	  multidrug	  resistance	  pumps,	  it	  would	  be	  helpful	  to	  use	  the	  information	  gained	  from	  these	  studies	  to	  aid	  the	  development	  of	  CDK7	  inhibitors	  that	  would	  not	  be	  affected	  by	  this	  resistance	  mechanism.	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4.4	  Gene	  expression	  microarray	  analysis	  identifies	  genes	  whose	  expression	  is	  
elevated	  or	  downregulated	  following	  CDK	  inhibitor	  treatments	  
	  To	  establish	  which	  concentration	  of	  BS181	  and	  BS194	  would	  be	  the	  optimum	  for	  microarray	  analysis,	  a	  range	  of	  concentrations	  (BS194,	  0.1	  and	  1μmol/L;	  BS181,	  10,	  20	  and	  40	  μmol/L)	  and	  time	  points	  (0.5,	  1,	  1.5,	  2,	  4	  and	  6	  hrs)	  were	  used	  in	  MCF-­‐7	  cells	  and	  several	  labile	  mRNA	  transcripts,	  previously	  shown	  to	  be	  reduced	  following	  treatment	  by	  these	  agents,	  were	  used	  to	  indicate	  cellular	  activity	  akin	  to	  that	  previously	  reported	  (Ali,	  Heathcote	  et	  al.	  2009;	  Heathcote,	  Patel	  et	  al.	  2010).	  MCL-­‐1,	  cyclin	  D1	  and	  XIAP	  were	  reduced	  by	  both	  inhibitors,	  MCL-­‐1	  showing	  a	  clear	  dose	  and	  time-­‐dependent	  response,	  whereas	  BCL2,	  remained	  unchanged.	  The	  fact	  that	  MCL-­‐1	  showed	  a	  clear	  reduction	  both	  in	  a	  dose-­‐dependent	  and	  time-­‐dependent	  manner	  was	  an	  indication	  that	  both	  inhibitors	  were	  probably	  having	  an	  effect	  on	  transcription	  and	  so,	  to	  remain	  consistent	  with	  the	  concentrations	  that	  initiated	  the	  cellular	  effects	  seen	  in	  the	  published	  data,	  1μmol/L	  BS194	  and	  20μmol/L	  BS181	  were	  chosen	  to	  take	  forward	  for	  further	  experimentation	  in	  HCT116	  cells.	  This	  choice	  was	  made	  so	  as	  not	  to	  exaggerate	  a	  transcriptional	  block	  and	  by	  doing	  so	  obtain	  a	  true	  representation	  of	  global	  transcription	  at	  drug	  concentrations	  previously	  shown	  to	  establish	  the	  distinct	  cell	  cycle	  and	  pharmacodynamic	  profiles,	  since	  these	  concentrations	  are	  likely	  to	  form	  the	  basis	  of	  dosing	  schedules	  used	  for	  any	  future	  clinical	  evaluation.	  Therefore,	  in	  HCT116	  cells	  a	  further	  time-­‐course	  experiment	  was	  undertaken	  with	  the	  chosen	  inhibitor	  concentrations.	  RT-­‐PCR	  was	  used	  to	  check	  transcript	  levels	  of	  the	  aforementioned	  marker	  genes;	  once	  again	  MCL-­‐1	  showed	  a	  clear	  time-­‐dependent	  decrease,	  mirroring	  what	  was	  previously	  observed	  in	  MCF-­‐7	  cells.	  An	  extended	  time-­‐course	  experiment	  was	  carried	  out	  in	  the	  same	  cell	  line	  to	  establish	  with	  five	  replicates	  for	  each	  time-­‐point	  and	  MCL-­‐1	  was	  once	  again	  used	  as	  a	  key	  indicator	  for	  inhibitor	  effect.	  Three	  of	  these	  samples	  formed	  the	  basis	  for	  subsequent	  microarray	  analysis.	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  From	  the	  K-­‐means	  analysis,	  which	  looked	  at	  the	  expression	  of	  597	  entities	  that	  satisfied	  a	  2-­‐fold	  change	  and	  p-­‐value	  cut-­‐off	  of	  ≤0.05	  following	  BS181	  treatment,	  cluster	  3	  showed	  the	  most	  exaggerated	  expression	  profile,	  the	  others	  remaining	  languid	  by	  comparison,	  with	  the	  possible	  exception	  of	  cluster	  8.	  Given	  that	  cluster	  3	  entities	  tended	  to	  increase	  sharply	  between	  2	  and	  6	  hours	  post	  treatment,	  this	  was	  of	  particular	  interest	  since	  large	  numbers	  of	  entities	  appeared	  to	  become	  gradually	  down-­‐regulated	  over	  time	  (clusters	  2,	  4,	  5,	  7	  and	  10)	  or	  fluctuated	  around	  the	  median,	  therefore	  it	  was	  reasoned	  that	  clusters	  3	  and	  8	  may	  contain	  potential	  ‘signature’	  transcripts	  of	  BS181.	  	  	  The	  11	  genes	  in	  cluster	  3	  were	  determined	  by	  DAVID	  analysis	  to	  fall	  into	  9	  functional	  groups	  with	  transcriptional	  regulation	  and	  regulation	  of	  apoptosis	  the	  most	  enriched	  groups.	  Incidentally,	  cluster	  8	  (not	  shown)	  had	  28	  separate	  entities,	  which	  also	  segregated	  into	  similar	  functional	  groups,	  including	  transcription	  regulation	  and	  cyclin-­‐like	  F-­‐box	  proteins.	  F-­‐box	  proteins	  are	  thought	  to	  play	  a	  crucial	  role	  in	  determining	  substrates	  for	  ubiquitination	  and	  are	  thought	  regulate	  the	  mechanisms	  behind	  a	  range	  of	  cellular	  processes	  through	  mediating	  protein	  stability	  (Ho,	  Tsai	  et	  al.	  2006).	  In	  all,	  a	  comparatively	  small	  subset	  of	  genes	  are	  regulated	  by	  BS181	  over	  the	  6	  hour	  treatment	  period	  and	  as	  such,	  may	  be	  responsible	  for	  the	  cellular	  phenotype	  evident	  in	  our	  previous	  published	  data.	  	  	  A	  number	  of	  genes	  from	  this	  analysis	  are	  included	  across	  several	  significant	  functional	  groups.	  The	  same	  genes	  are	  shared	  amongst	  the	  top	  three	  (most	  significant)	  functional	  groups,	  indicating	  that	  they	  perform	  multiple	  (and	  largely	  related)	  functions.	  Validation	  of	  these	  by	  RT-­‐qPCR	  confirms	  what	  is	  predicted	  in	  the	  microarray,	  with	  all	  genes	  being	  significantly	  upregulated	  at	  6	  hours	  compared	  to	  the	  DMSO	  control.	  Together	  with	  a	  24-­‐hour	  time	  course	  of	  BS181	  most	  of	  these	  genes	  display	  the	  same	  trend.	  In	  fact,	  the	  longer	  time-­‐course	  suggests	  that	  their	  expression	  would	  carry	  on	  being	  elevated	  up	  at	  12	  hours	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post-­‐treatment	  and	  possibly	  a	  good	  deal	  further,	  before	  returning	  to	  basal	  levels	  at	  24	  hours.	  This	  suggests	  that	  at	  20	  μM	  BS181,	  transcription	  is	  not	  globally	  shut-­‐down,	  unlike	  what	  has	  been	  shown	  with	  some	  other	  inhibitors	  such	  as	  DRB	  or	  actinomcyin-­‐D	  (Bensaude	  2011).	  	  	  In	  agreement	  with	  the	  notion	  that	  at	  a	  concentration	  of	  20	  μM	  BS181	  does	  not	  potentiate	  a	  global	  transcriptional	  block,	  in	  a	  series	  of	  direct	  comparisons	  of	  BS181	  with	  DMSO-­‐treated	  cells	  at	  each	  time-­‐point	  (by	  way	  of	  a	  students	  T-­‐test),	  there	  were	  a	  number	  of	  genes	  that	  were	  up-­‐regulated	  at	  6	  hours	  (see	  Appendix	  1	  for	  full	  list)	  –	  many	  of	  which	  also	  reside	  in	  K-­‐means	  cluster	  3.	  For	  the	  earlier	  time-­‐points	  however,	  all	  entities	  were	  downregulated,	  although	  hardly	  any	  satisfied	  a	  p-­‐value	  of	  0.05	  and	  a	  fold	  change	  factor	  of	  2.0.	  In	  fact	  the	  fold	  change	  cut-­‐off	  needed	  to	  dropped	  to1.5	  and	  p-­‐value	  cut-­‐off	  omitted	  to	  obtain	  just	  36	  entities	  at	  1	  hour.	  Only	  at	  6	  hours	  were	  appreciable	  numbers	  of	  entities	  changed,	  albeit	  in	  both	  directions.	  In	  all,	  the	  trend	  observed	  at	  individual	  time-­‐points	  mirrors	  that	  previously	  shown	  with	  the	  K-­‐means	  algorithm	  namely,	  that	  expression	  decreases	  or	  is	  unchanged	  between	  1	  and	  2	  hours	  before	  changing	  radically	  at	  6	  hours,	  with	  a	  select	  number	  of	  genes	  being	  up-­‐regulated.	  It	  is	  likely	  that	  BS181	  does	  not	  take	  effect	  immediately;	  published	  data	  (Ali,	  Heathcote	  et	  al.	  2009)	  indicates	  that	  reduction	  of	  key	  cell	  cycle	  and	  transcription	  proteins	  begins	  at	  4	  hours	  post-­‐treatment,	  which	  is	  consistent	  with	  the	  present	  observations.	  	  	  Although	  there	  is	  no	  indication	  of	  a	  complete	  block	  on	  global	  transcription	  levels,	  induction	  of	  p53	  signalling	  indicates	  that	  transcription	  did	  become	  compromised	  as	  evidenced	  by	  the	  pathway	  analysis	  (Onto-­‐tools)	  undertaken	  on	  significantly	  changed	  genes	  at	  6	  hours	  and	  by	  subsequent	  immunoblotting,	  where	  p53	  and	  its	  hyperphosphorylated	  forms	  were	  expressed	  maximally	  at	  6	  and	  12	  hours.	  	  	  P53	  induction	  at	  6-­‐12	  hours	  is	  consistent	  with	  the	  apoptosis	  observed	  in	  the	  published	  data	  and	  the	  decrease	  in	  anti-­‐apoptotic	  proteins	  MCL-­‐1,	  XIAP	  and	  Bcl-­‐
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XL.	  It	  is	  also	  consistent	  with	  siRNA-­‐mediated	  knockdown	  of	  CDK7	  shown	  earlier,	  where	  apoptosis	  and	  a	  concomitant	  reduction	  of	  XIAP	  was	  observed.	  	  Interestingly,	  previously	  published	  data	  suggests	  BS181	  induces	  both	  p53	  dependent	  and	  independent	  apoptosis.	  In	  a	  p53	  deficient	  HCT116	  cell	  line,	  apoptosis	  was	  achieved	  at	  approximately	  double	  the	  concentration	  for	  p53	  wt	  HCT116	  cells.	  This	  was	  also	  reported	  to	  be	  the	  case	  with	  actinomycin	  D	  (Blagosklonny,	  Darzynkiewicz	  et	  al.	  2002;	  Blagosklonny,	  Demidenko	  et	  al.	  2002;	  Choong,	  Yang	  et	  al.	  2009).	  However,	  it	  is	  not	  clear	  whether	  p53	  induction	  seen	  here	  is	  due	  to	  DNA	  damage	  or	  through	  inhibition	  of	  transcription.	  Since	  p53-­‐mediated	  apoptosis	  can	  be	  transcription-­‐dependent	  or	  independent	  and	  since	  many	  DNA	  damaging	  agents	  tend	  to	  also	  inhibit	  transcription	  at	  high	  doses,	  it	  is	  not	  surprising	  that	  these	  also	  lead	  to	  transcription-­‐dependent	  p53	  induction.	  Transcription-­‐induced	  p53	  stabilization	  can	  be	  mediated	  through	  Mdm-­‐2	  down-­‐regulation,	  which	  normally	  binds	  to	  p53,	  targeting	  it	  for	  degradation	  through	  the	  proteasome	  pathway.	  Thus	  placing	  a	  transcriptional	  block	  on	  Mdm-­‐2	  allows	  p53	  to	  stably	  accumulate,	  at	  least	  transiently.	  My	  results	  seem	  to	  indicate	  that	  p53	  induction	  in	  this	  case	  is	  mediated	  through	  a	  block	  in	  transcription,	  since	  the	  opposing	  pattern	  of	  p53	  and	  p21	  expression	  fits	  that	  described	  in	  another	  study	  undertaken	  with	  several	  known	  transcription	  inhibitors	  (Blagosklonny,	  Darzynkiewicz	  et	  al.	  2002;	  Blagosklonny,	  Demidenko	  et	  al.	  2002).	  In	  that	  study,	  the	  authors	  observe	  that	  α-­‐amanitin	  and	  DRB	  initially	  lead	  to	  a	  down-­‐regulation	  of	  Mdm-­‐2	  and	  p21	  through	  transcription	  blockade,	  accompanied	  by	  accumulation	  of	  p53.	  Normally,	  p53	  and	  p21	  levels	  are	  tightly	  linked	  and	  have	  a	  similar	  expression	  profile	  owing	  to	  the	  fact	  that	  p21	  expression	  is	  controlled	  by	  p53	  activity	  –	  exemplified	  by	  p53-­‐mediated	  expression	  of	  p21	  in	  cell	  cycle	  arrest.	  	  However,	  when	  Blagosklonny	  and	  cooleagues	  removed	  DRB	  (a	  reversible	  inhibitor	  of	  transcription)	  from	  the	  media	  and	  p53	  levels	  returned	  to	  normal,	  they	  noted	  a	  delayed,	  but	  dramatic,	  p21	  induction,	  reminiscent	  of	  the	  present	  observations.	  In	  our	  previously	  published	  data	  (Ali,	  Heathcote	  et	  al.	  2009),	  despite	  the	  fact	  that	  BS181	  was	  not	  removed	  from	  the	  medium,	  pharmacokinetic	  studies	  indicate	  that	  BS181	  has	  a	  half	  life	  of	  around	  six	  hours	  and	  therefore	  	  is	  probably	  degraded,	  thus	  accounting	  for	  the	  reduced	  activity	  seen	  at	  24	  hours	  in	  the	  present	  study.	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  Immunofluorescence	  staining	  of	  p53	  is	  also	  in	  agreement	  with	  this	  model;	  at	  the	  lower	  dose	  of	  BS181	  (25	  μM),	  p53	  induction	  appears	  maximal	  at	  4	  and	  8	  hours,	  before	  dropping-­‐off	  at	  16	  and	  24	  hours,	  which	  would	  seem	  to	  agree	  with	  the	  immunoblot	  data.	  By	  comparison,	  BS194	  and	  flavopiridol	  show	  a	  much	  more	  sustained	  p53	  induction,	  with	  maximal	  induction	  occurring	  later	  than	  with	  BS181.	  Interestingly,	  at	  the	  higher	  dose	  (50	  μM),	  BS181	  induces	  a	  delayed	  and	  less	  obvious	  p53	  induction.	  This	  was	  previously	  observed	  following	  treatment	  with	  actinomycin	  D	  (Choong,	  Yang	  et	  al.	  2009),	  where	  a	  low	  dose	  was	  associated	  with	  p53-­‐mediated	  cell-­‐cycle	  profile	  changes	  and	  a	  distinct	  transcription	  profile,	  whereas	  higher	  doses	  potentiated	  p53-­‐independent	  effects,	  both	  on	  the	  cell	  cycle	  and	  on	  global	  transcription.	  It	  is	  therefore	  likely	  that	  the	  effects	  bought	  about	  through	  BS181	  at	  relatively	  low	  doses	  (≤	  25μM)	  manifest	  in	  p53	  induced	  apoptosis	  (most	  likely	  through	  transcription	  inhibition	  as	  opposed	  to	  DNA	  damage)	  but	  at	  higher	  doses,	  as	  previously	  shown	  by	  the	  elevated	  dose	  required	  to	  induce	  apoptosis	  in	  the	  isogenic	  p53-­/-­	  HCT116	  cell	  line,	  this	  is	  p53-­‐independent	  (Ali,	  Heathcote	  et	  al.	  2009);	  this	  is	  likely	  mediated	  through	  DNA	  damage	  (in	  a	  manner	  analogous	  to	  doxorubicin	  treatment)	  or	  through	  complete	  transcription	  blockade,	  in	  a	  manner	  analogous	  to	  high	  dose	  DRB	  treatment	  (Gomes,	  Bjerke	  et	  al.	  2006).	  Indeed	  actinomycin	  D	  has	  been	  shown	  to	  cause	  DNA	  double	  strand	  breaks	  at	  high	  enough	  concentrations	  (Ljungman,	  Zhang	  et	  al.	  1999).	  
	  
4.5	  Analysis	  of	  the	  BS181	  and	  BS194	  transcriptome	  at	  6-­‐hours	  post-­‐treatment	  	  At	  6	  hours	  post-­‐treatment,	  BS181	  induced	  the	  expression	  of	  91	  entities	  and	  down-­‐regulated	  379	  entities	  (Supplementary	  figure	  S1).	  Many	  of	  the	  up-­‐regulated	  entities	  were	  immediate-­‐early	  genes	  (IEGs);	  this	  is	  not	  surprising	  given	  the	  fact	  that	  many	  immediate	  early	  genes	  are	  expressed	  in	  response	  to	  cellular	  stress.	  IEGs	  are	  defined	  as	  genes	  that	  are	  very	  rapidly	  induced	  upon	  treatment	  of	  mammalian	  cells	  with	  serum	  or	  growth	  factors	  without	  the	  need	  for	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protein	  synthesis	  (O'Donnell,	  Odrowaz	  et	  al.	  2012).	  	  They	  are	  therefore	  transcribed	  in	  the	  presence	  of	  cyclohexamide.	  However,	  IEGs	  are	  normally	  induced	  within	  seconds	  and	  minutes	  of	  the	  stimulus,	  not	  hours	  after.	  Moreover,	  the	  majority	  of	  entities	  are	  downregulated	  upon	  BS181	  treatment,	  presumably	  because,	  at	  least	  part	  of	  its	  mode	  if	  action	  inhibits	  transcription.	  However,	  there	  is	  evidence	  of	  some	  of	  these	  genes	  (IER3,	  JUN,	  GADD45B,	  ID2,	  KLF6,	  KLF10)	  being	  downregulated	  by	  at	  least	  1.6	  fold	  at	  the	  1	  hour	  time	  point,	  despite	  p-­‐values	  being	  insignificant.	  It	  is	  possible	  therefore	  that	  these	  genes	  are	  initially	  down-­‐regulated,	  either	  as	  a	  response	  to	  cellular	  stress	  or	  through	  transcription	  inhibition,	  before	  being	  elevated	  at	  a	  later	  time-­‐point,	  either	  because	  BS181	  has	  been	  metabolized	  or	  because	  of	  a	  feedback	  mechanism;	  moreover,	  the	  24	  hour	  time-­‐course	  experiment	  would	  seem	  to	  suggest	  that	  at	  least	  some	  of	  these	  genes	  continue	  to	  be	  elevated	  far	  beyond	  6	  hours.	  Interestingly,	  a	  microarray	  study	  undertaken	  in	  immortalized	  human	  fibroblasts	  that	  were	  treated	  with	  flavopiridol	  (a	  potent	  CDK9	  inhibitor),	  showed	  a	  similar	  pattern	  of	  IEG	  induction	  (Keskin,	  Garriga	  et	  al.	  2012);	  this	  study	  reported	  a	  biphasic	  expression	  of	  some	  IRGs	  (EGR1,	  JUNB,	  FOS,	  GADD45B)	  where	  initial	  down-­‐regulation	  at	  30	  minutes	  to	  4	  hours,	  was	  superseded	  by	  induction	  from	  8	  hours	  and	  in	  most	  cases,	  this	  was	  sustained	  over	  a	  24	  hour	  period.	  Furthermore,	  for	  some	  IEGs	  this	  was	  found	  to	  be	  independent	  of	  CDK9-­‐mediated	  transcription,	  leading	  to	  the	  interpretation	  that	  an	  alternative	  mechanism	  for	  their	  transcription	  exists,	  probably	  as	  part	  of	  a	  stress	  response	  to	  transcription	  inhibition.	  A	  possible	  reason	  for	  this	  oscillation	  is	  loss	  of	  BS181	  activity,	  however	  in	  agreement	  with	  what	  was	  observed	  by	  Keskin	  et	  al	  our	  previous	  studies	  suggest	  firstly,	  that	  CTD	  phosphorylation	  is	  compromised	  at	  later	  time,	  secondly	  not	  all	  IEGs	  are	  induced	  at	  later	  time-­‐points,	  thirdly	  some	  of	  these	  IEGs	  are	  up-­‐regulated	  by	  several	  fold	  where	  several	  house-­‐keeping	  genes	  are	  not	  modulated	  and	  finally,	  it	  has	  been	  shown	  that	  some	  genes	  are	  transcribed	  independently	  of	  CDK9,	  such	  as	  certain	  p53	  target	  genes	  (Gomes,	  Bjerke	  et	  al.	  2006),	  which	  would	  also	  appear	  to	  fit	  with	  our	  observations	  of	  p53	  induction	  and	  p53-­‐mediated	  apoptosis.	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Pathway	  analysis	  of	  the	  6	  hours	  BS181	  treatment	  group	  highlighted	  the	  RNA	  polymerase	  pathway	  as	  the	  most	  significantly	  down-­‐regulated	  pathway	  (Table	  3.2).	  From	  29	  KEGG	  annotated	  entities	  in	  this	  pathway,	  3	  appeared	  in	  the	  down-­‐regulated	  list	  generated	  from	  our	  microarray	  (POLR1C,	  POLR3B,	  POLR3H).	  This	  fits	  with	  the	  observation	  of	  transcription	  being	  suppressed,	  although	  none	  of	  these	  genes	  are	  components	  of	  the	  polymerase	  II	  apparatus.	  DAVID	  functional	  anaylsis	  flagged	  “RNA	  polymerase	  complex”	  (GO	  term)	  as	  also	  being	  an	  altered	  functional	  group,	  but	  this	  was	  not	  significant	  (IF	  <	  1.3).	  Instead,	  the	  functional	  groups	  “negative	  regulation	  of	  apoptosis”	  and	  “mitosis”	  were	  the	  most	  significant	  functional	  groups	  as	  determined	  by	  DAVID.	  	  It	  is	  interesting	  but	  not	  surprising	  that	  DAVID	  functional	  analysis	  associated	  BS181	  up-­‐regulated	  entities	  with	  ‘positive	  regulation	  of	  transcription	  factor’	  and	  down-­‐regulated	  entities	  with	  ‘negative	  regulation	  of	  transcription’.	  What	  is	  remarkable	  is	  that	  DAVID	  determined	  these	  two	  opposing	  functional	  groups	  as	  the	  most	  significant,	  suggesting	  that	  transcription	  is	  a	  process	  that	  is	  significantly	  altered	  with	  BS181.	  	  Although	  BS194	  treatment	  led	  to	  approximately	  equal	  numbers	  of	  genes	  being	  up-­‐regulated	  at	  6	  hours	  compared	  to	  BS181	  (18.5%	  vs	  20%,	  respectively),	  in	  contrast,	  BS194	  treatment	  largely	  lead	  to	  a	  down-­‐regulation	  of	  many	  transcriptional	  genes	  and	  the	  majority	  of	  up-­‐regulated	  genes,	  as	  determined	  by	  DAVID	  functional	  analysis,	  fell	  into	  only	  two	  statistically	  significant	  groups	  (Table	  3.3:	  kinase	  activity;	  enrichment	  score	  2.2	  and	  lipid	  storage;	  enrichment	  score	  1.9)	  however,	  pathway	  analysis	  undertaken	  in	  GeneSpring	  highlighted	  several	  interesting	  pathways	  that	  were	  significantly	  altered	  including	  PI3K/AKT,	  tubulin	  folding	  and	  p38	  signalling.	  It	  is	  not	  uncommon	  for	  these	  pathways	  to	  become	  activated	  in	  response	  to	  drug	  treatment	  (Keskin,	  Garriga	  et	  al.	  2012).	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Similar	  to	  BS181,	  negative	  transcription	  regulation	  and	  repressor	  activity	  was	  downregulated,	  with	  the	  majority	  of	  down-­‐regulated	  genes	  falling	  into	  this	  category	  as	  assessed	  by	  the	  GO	  analysis	  tool	  in	  GeneSpring	  (table	  3.4B).	  There	  were	  207	  entities	  listed	  in	  the	  “transcription”	  group	  in	  total,	  which	  was	  also	  highly	  significant	  group	  (p=6.22E-­‐33);	  by	  contrast,	  the	  “transcription	  repressor	  activity”	  group,	  which	  was	  also	  significant	  (p=3.05E-­‐04),	  was	  composed	  of	  only	  31	  genes.	  Thus	  the	  balance	  of	  transcription	  would	  appear	  to	  be	  characterized	  by	  a	  general	  down-­‐regulation.	  This	  contrasts	  with	  BS181,	  where	  the	  only	  significant	  transcriptional	  functional	  group	  identified	  by	  DAVID	  on	  the	  6	  hour	  down	  list	  was	  “negative	  regulation	  of	  transcription”,	  composed	  of	  12	  genes	  and	  indeed	  two	  of	  these,	  MYC	  and	  NOTCH1,	  were	  subsequently	  validated	  by	  qRT-­‐PCR.	  Of	  note,	  MYC	  has	  been	  shown	  to	  be	  repressed	  in	  a	  p53-­‐dependent	  manner	  (Ho,	  Ma	  et	  al.	  2005)	  although	  NOTCH1	  is	  normally	  induced	  by	  p53	  (Lefort,	  Mandinova	  et	  al.	  2007;	  Secchiero,	  Melloni	  et	  al.	  2009;	  Yugawa,	  Narisawa-­‐Saito	  et	  al.	  2010).	  Although	  MYC	  is	  often	  associated	  with	  the	  activation	  of	  many	  genes,	  MYC-­‐dependent	  gene	  repression	  is	  a	  well-­‐defined	  mechanism	  and	  is	  responsible	  for	  repressing	  negative	  regulators	  of	  cell	  proliferation	  including	  the	  cell	  cycle	  inhibitors	  p21,	  p27,	  p18	  and	  p57	  (Herkert	  and	  Eilers	  2010).	  Therefore,	  whilst	  it	  is	  inaccurate	  to	  say	  that	  BS181	  is	  associated	  with	  a	  global	  induction	  of	  transcription,	  since	  clearly,	  RNA	  polymerase	  II	  transcription	  is	  compromised,	  a	  small	  number	  of	  genes	  (many	  of	  which	  are	  themselves	  transcription	  factors	  and	  function	  in	  apoptosis),	  are	  up-­‐regulated.	  This	  is	  also	  accompanied	  by	  down-­‐regulation	  of	  negative	  transcription	  regulators.	  BS194	  by	  contrast,	  although	  also	  has	  a	  similar	  number	  of	  up-­‐regulated	  genes	  at	  6	  hours,	  is	  not	  characterized	  by	  such	  a	  collection	  of	  IEGs.	  The	  IEGs	  that	  were	  validated	  for	  up-­‐regulation	  by	  BS181	  are	  either	  significantly	  downregulated	  in	  the	  BS194	  list	  or	  do	  not	  appear	  at	  all.	  In	  fact	  several	  IEGs	  including	  FOS,	  JUN,	  KLF6	  and	  BHLHE40	  were	  downregulated	  by	  at	  least	  2.5	  fold	  in	  the	  microarray	  (see	  appendix	  S2).	  Protein	  levels	  of	  c-­‐Jun	  and	  JunB	  were	  similarly	  decreased	  with	  BS194	  as	  determined	  by	  immunoblotting.	  	  Another	  functional	  group	  that	  was	  associated	  with	  down-­‐regulated	  genes	  from	  both	  BS181	  and	  BS194	  treatments	  was	  “Mitosis”.	  Whilst	  this	  group	  was	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significant	  with	  both	  treatments,	  it	  was	  more	  significant	  with	  BS194	  (enrichment	  score	  of	  6.3;	  table	  3.5)	  than	  with	  BS181,	  (enrichment	  score	  1.68	  –	  just	  above	  the	  recommended	  DAVID	  cut-­‐off	  of	  1.3).	  Similarly,	  as	  determined	  by	  pathway	  analysis,	  BS181	  down-­‐regulated	  entities	  were	  also	  associated	  with	  the	  cell	  cycle	  pathway	  (Table	  3.2	  B),	  although	  again	  this	  was	  marginal	  in	  terms	  of	  p-­‐value	  (p=0.05),	  whereas	  GeneSpring	  GO	  analysis	  flagged	  4	  groups	  that	  were	  clearly	  associated	  with	  mitosis	  and	  the	  cell	  cycle	  (Table	  3.4;	  “Mitosis”,	  “Cell	  division”,	  “M	  phase	  of	  mitotic	  cell	  cycle”	  and	  “Spindle”).	  The	  significant	  pathways	  tool	  in	  GeneSpring	  also	  identified	  “Polo-­‐like	  kinase	  signaling”,	  “cell-­‐cycle	  (mitotic)”,	  “G1/S	  transition”	  and	  “Aurora	  B	  signling”	  as	  being	  significant	  for	  BS194	  down-­‐regulated	  genes	  (Table	  3.6).	  In	  all,	  GO	  and	  pathway	  analyses	  suggest	  that	  the	  cell	  cycle,	  particularly	  mitosis,	  is	  an	  important	  biological	  function	  perturbed	  by	  BS914.	  This	  is	  consistent	  with	  BS194	  being	  a	  potent	  inhibitor	  of	  CDK1.	  	  	  The	  BS194	  down-­‐regulated	  entities	  were	  also	  associated	  with	  negative	  regulation	  of	  apoptosis	  as	  determined	  by	  DAVID	  functional	  clustering	  (Table	  3.5)	  and	  significant	  pathway	  analysis	  (Table	  3.6).	  This	  is	  exemplified	  by	  the	  down-­‐regulation	  of	  genes	  such	  as	  several	  BCL10,	  BCL6	  and	  several	  other	  BCL2-­‐associated	  genes	  such	  as	  MCL-­‐1,	  c-­‐MYC,	  several	  serine-­‐threonine	  kinases	  such	  as	  pim-­‐2	  and	  pim-­‐3,	  which	  promote	  survival	  by	  inducing	  the	  release	  of	  BCL-­‐XL	  and	  BCL2L1	  (Hammerman,	  Fox	  et	  al.	  2004)	  and	  p21	  which	  has	  been	  shown	  to	  play	  a	  role	  in	  preventing	  apoptosis	  (Gartel	  and	  Tyner	  2002).	  Interestingly,	  the	  ability	  of	  PIM-­‐2	  to	  function	  oncogenically,	  depends	  on	  sustained	  NF-­‐kβ	  signaling	  (Hammerman,	  Fox	  et	  al.	  2004)	  where	  transcription	  of	  PIM-­‐2	  is	  thought	  to	  initiate	  a	  novel	  NF-­‐Kβ	  pathway	  that	  enhances	  cell	  survival;	  the	  NF-­‐Kβ	  pathway	  is	  another	  significant	  pathway	  associated	  BS194	  down-­‐regulated	  entities	  (Table	  3.6).	  	  	  Although	  functional	  group	  analysis	  of	  BS181	  down-­‐regulated	  entities	  did	  not	  highlight	  “negative	  regulation	  of	  apoptosis”	  as	  a	  significant	  group,	  BS181	  up-­‐regulated	  genes	  were	  partitioned	  into	  “positive	  regulation	  of	  apoptosis”	  and	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subsequent	  pathway	  analysis	  using	  Onto-­‐tools	  highlighted	  p53	  signalling	  as	  the	  most	  significant	  pathway	  for	  the	  same	  genes.	  Incidentally,	  increased	  p53	  signalling	  may	  explain	  the	  association	  of	  Wnt	  signalling	  with	  BS181	  down-­‐regulated	  entities	  (Kim,	  Kim	  et	  al.	  2011).	  NOTCH1	  signalling	  is	  also	  significantly	  altered	  at	  6	  hours	  and	  negative	  regulation	  of	  this	  pathway	  has	  also	  been	  proposed	  to	  be	  mediated	  through	  p53	  (Lefort,	  Mandinova	  et	  al.	  2007).	  It	  is	  thus	  tempting	  to	  speculate	  that	  the	  mode	  of	  apoptosis	  caused	  by	  BS181	  and	  BS194	  is	  fundamentally	  different;	  BS181	  mediating	  p53-­‐depednent	  apoptosis	  and	  BS194	  mediating	  extrinsic	  apoptotic	  pathways.	  This	  idea	  certainly	  fits	  with	  several	  genes	  that	  appear	  in	  the	  “negative	  regulation	  of	  apoptosis”	  group	  (pim-­‐2,	  pim-­‐3,	  several	  BCL-­‐2	  related	  proteins,	  MCL-­‐1,	  HSP70)	  and	  the	  fact	  that	  the	  “Extrinsic	  pathway	  for	  apoptosis”	  pathway	  is	  one	  of	  the	  significant	  pathways	  altered	  from	  the	  pathway	  analysis	  (table	  3.6).	  Other	  related	  pathways	  such	  as	  TGFβ,	  TNFα,	  Death	  receptor	  signalling	  were	  also	  highlighted	  as	  having	  been	  altered.	  In	  agreement	  with	  p53-­‐independent	  mode	  of	  apoptosis	  is	  the	  fact	  that	  p53	  levels	  rose	  much	  later	  following	  BS194	  treatment	  than	  was	  observed	  for	  BS181.	  	  ‘Phosphorylation’,	  a	  functional	  cluster	  that	  was	  significantly	  enriched	  for	  by	  entities	  in	  the	  BS194	  treatment,	  represents	  many	  possible	  pathways	  due	  to	  the	  ubiquity	  by	  which	  kinase	  activity	  is	  relied	  upon	  for	  transducing	  cellular	  signals.	  Therefore,	  the	  genes	  shown	  (table	  3.5)	  constitute	  many	  possible	  diverse	  pathways	  and	  biological	  processes:	  MAPK	  signaling,	  cell	  cycle,	  anti-­‐apoptotic	  pathways	  and	  transcription	  are	  just	  some	  of	  the	  many	  pathways	  that	  rely	  on	  phosphorylation.	  However,	  the	  presence	  of	  several	  cell-­‐cycle	  regulating	  genes	  including	  CDK7,	  cyclin	  E2,	  p21	  (Cip1),	  p27	  (Kip1),	  CDC25	  and	  CKS2	  are	  all	  down-­‐regulated	  indicating	  that	  BS194	  not	  only	  effects	  the	  mitotic	  phase	  but	  also	  the	  earlier	  phases	  of	  the	  cell	  cycle,	  since	  cyclin	  E	  is	  a	  binding	  partner	  for	  CDK2	  during	  the	  G1-­‐S	  transition	  and	  together,	  function	  not	  only	  to	  phosphorylate	  Rb	  (to	  traverse	  the	  restriction	  point),	  but	  also	  phosphorylate	  p21	  and	  p27,	  causing	  destabilization	  and	  leading	  to	  their	  subsequent	  degradation	  (Sheaff,	  Groudine	  et	  al.	  1997;	  Zhu,	  Nie	  et	  al.	  2005).	  These	  is	  not	  entirely	  unexpected	  since	  BS194	  inhibits	  CDK2	  with	  greater	  affinity	  than	  other	  CDKs	  (<3	  nm),	  however,	  unless	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this	  decrease	  of	  expression	  is	  mediated	  through	  inhibition	  of	  transcription,	  it	  suggests	  that	  BS194	  inhibition	  of	  CDK2	  may	  potentiate	  negative	  feedback,	  whereby	  further	  cyclin	  E	  transcription	  is	  prevented.	  Indeed	  cyclin	  expression	  is	  cyclical	  in	  nature	  and	  since	  BS194	  mediates	  cell	  cycle	  arrest	  in	  the	  S	  and	  G2/M	  phases,	  one	  can	  reasonably	  expect	  cyclin	  E	  expression	  to	  eventually	  cease	  after	  6	  hours	  of	  BS194	  exposure.	  The	  decrease	  in	  p21	  and	  p27	  expression	  may	  be	  concomitant,	  further	  reflecting	  their	  own	  dependence	  on	  CDK2/cyclin	  E	  function;	  given	  that	  p21	  and	  p27	  primarily	  inhibit	  CDKs,	  including	  CDK2,	  this	  would	  seem	  a	  reasonable	  assumption.	  	  Interestingly,	  there	  is	  also	  a	  decrease	  in	  CDK7;	  this	  was	  not	  seen	  at	  the	  protein	  level	  in	  the	  published	  data,	  however	  this	  probably	  reflects	  the	  wider	  effects	  on	  arrest	  of	  the	  cell	  cycle.	  
	  
4.6	  Global	  expression	  changes	  mediated	  by	  BS181	  and	  BS194	  and	  further	  insight	  
into	  their	  mechanism	  of	  action	  	  To	  gain	  further	  insight	  into	  the	  global	  changes	  that	  occur	  following	  treatment	  of	  HCT116	  cells	  with	  BS181	  and	  BS194,	  hierarchical	  clustering	  of	  all	  treatment	  groups	  was	  undertaken,	  first	  on	  all	  probes	  on	  the	  Illumina	  bead	  array	  (48790	  total)	  and	  then	  on	  a	  selected	  1399	  genes,	  previously	  demonstrated	  to	  be	  down-­‐regulated	  by	  flavopiridol	  treatment	  (Iorio,	  Bosotti	  et	  al.	  2010).	  When	  hierarchical	  clustering	  was	  performed	  on	  all	  probes,	  there	  was	  little	  change	  between	  1	  hour	  DMSO	  treatment	  and	  the	  1-­‐hour	  treatment	  of	  both	  BS181	  and	  BS194,	  indicated	  by	  the	  shared	  branches	  between	  these	  groups.	  Indeed,	  gene	  expression	  is	  almost	  identical	  between	  BS181	  1	  hour,	  BS194	  1	  hours,	  DMSO	  1	  hour	  and	  DMSO	  6hours,	  with	  2-­‐hour	  treatments	  showing	  subtle	  differences	  in	  the	  magnitude	  of	  expression	  in	  certain	  regions	  of	  the	  heat	  map,	  which	  is	  reflected	  by	  both	  2	  hour	  treatments	  appearing	  on	  distinct	  branches.	  Only	  at	  6-­‐hours	  post-­‐treatment	  was	  there	  any	  appreciable	  change,	  consistent	  with	  what	  has	  previously	  been	  demonstrated.	  This	  distinct	  pattern	  ensured	  BS194	  and	  BS181	  6	  hours	  remained	  separate	  from	  all	  other	  treatments	  branches	  however,	  BS194	  6	  hours	  was	  markedly	  different	  to	  BS181	  6	  hours,	  being	  further	  segregated	  on	  a	  distinct	  branch.	  Strikingly,	  there	  is	  a	  subtlety	  of	  change	  over	  time	  with	  each	  condition:	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with	  true	  global	  transcription	  inhibitors	  such	  as	  DRB,	  actinomycin-­‐D	  or	  flavopiridol,	  the	  effect	  on	  global	  gene	  expression	  is	  palpable,	  often	  occurring	  early	  (within	  minutes)	  of	  administration.	  I	  subsequently	  analysed	  the	  expression	  of	  a	  panel	  of	  house-­‐keeping	  genes	  from	  each	  time-­‐point	  relative	  to	  DMSO;	  most	  of	  these,	  with	  the	  exception	  of	  EIF4A2,	  did	  not	  fluctuate	  significantly	  over	  the	  time-­‐period	  with	  either	  treatment,	  indicating	  that	  in	  fact,	  neither	  treatment	  at	  the	  concentrations	  used	  potentiates	  an	  indiscriminative	  transcriptional	  block.	  From	  extended	  time-­‐course	  experiments	  carried	  out	  with	  BS181	  and	  BS194,	  and	  from	  the	  observed	  change	  in	  several	  significantly	  changed	  genes	  picked	  from	  the	  array,	  it	  is	  probable	  that	  the	  contrast	  between	  conditions	  in	  global	  expression	  would	  be	  much	  starker	  at	  12	  hours,	  or	  with	  a	  higher	  concentrations	  of	  the	  inhibitors.	  	  	  When	  each	  condition	  was	  clustered	  on	  a	  background	  of	  genes	  that	  were	  identified	  as	  being	  down-­‐regulated	  following	  treatment	  flavopiridol,	  there	  was	  a	  more	  noticeable	  and	  generalised	  down-­‐regulation	  with	  the	  BS194	  6-­‐hour	  treatment,	  suggesting	  that	  it	  might	  share	  a	  transcriptional	  profile	  similar	  to	  flavopiridol,	  at	  least	  with	  respect	  to	  the	  down-­‐regulated	  entities	  clustered	  against	  on	  the	  heat	  map.	  	  Hence	  further	  comparisons	  were	  made	  between	  BS181,	  BS194	  (both	  6	  hours)	  and	  flavopiridol	  to	  identify	  shared	  entities	  that	  are	  downregulated	  by	  at	  least	  2-­‐fold.	  In	  summary,	  there	  is	  more	  similarity	  in	  terms	  of	  down-­‐regulated	  entities	  between	  BS194	  and	  flavopiridol	  than	  between	  BS181	  and	  flavopiridol	  (47%	  vs	  27%),	  although	  BS181	  shares	  a	  high	  percentage	  of	  its	  genes	  (70%)	  with	  BS194.	  	  	  When	  DAVID	  was	  used	  to	  look	  for	  significantly	  enriched	  functional	  groups	  of	  the	  shared	  entities,	  “Transcription	  regulation”	  was	  by	  far	  the	  most	  significantly	  represented	  functional	  group	  of	  the	  intersection	  between	  BS194	  and	  flavopiridol	  (enrichment	  score	  13.02);	  this	  was	  substantially	  higher	  than	  the	  other	  functional	  group	  in	  the	  same	  intersection	  and	  of	  any	  of	  the	  functional	  groups	  found	  to	  be	  significantly	  enriched	  in	  the	  intersection	  of	  BS181	  and	  flavopiridol.	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  At	  the	  concentration	  used	  for	  the	  microarray	  (1	  μm),	  BS194	  inhibits	  CDK9	  (IC50	  90	  nmol/L),	  which	  likely	  explains	  the	  observed	  reduction	  in	  Pol	  II	  CTD	  phosphorylation	  at	  the	  S2	  position	  shown	  previously	  (and	  most	  probably	  the	  S5	  position	  also,	  since	  this	  concentration	  is	  below	  the	  threshold	  for	  CDK7	  inhibition).	  However	  it	  is	  worth	  noting	  that	  for	  the	  flavopiridol	  entity	  list	  used	  in	  this	  meta-­‐analysis	  (GSE18504),	  flavopiridol	  was	  used	  at	  a	  concentration	  of	  5	  times	  the	  IC50	  for	  the	  cell	  line	  used	  (A2780	  cells),	  making	  a	  direct	  comparison	  with	  BS194	  and	  BS181	  difficult	  to	  interpret.	  Therefore	  a	  comparison	  was	  made	  with	  another	  published	  set	  of	  flavopiridol	  microarray	  data,	  used	  at	  doses	  that	  gave	  LC90	  toxicity	  in	  four	  different	  cell	  lines	  (unfortunately,	  this	  did	  not	  include	  HCT116	  cells).	  In	  agreement	  with	  the	  previous	  analysis,	  there	  was	  greater	  overlap	  between	  BS194	  and	  flavopiridol	  but	  the	  degree	  of	  overlap	  was	  substantially	  lower	  than	  the	  previous	  analysis	  shown	  in	  figure	  3.21,	  although	  at	  this	  concentration,	  flavopiridol	  is	  arguably	  more	  comparable	  to	  BS194	  and	  BS181	  treatments,	  despite	  not	  being	  in	  the	  same	  cell	  line.	  In	  agreement,	  with	  the	  previous	  analysis,	  functional	  clustering	  with	  DAVID	  highlighted	  that	  the	  two	  significant	  groups	  (≥1.3)	  and	  the	  marginal	  group	  (1.2)	  from	  the	  intersection	  between	  BS194	  and	  flavopiridol	  were	  all	  transcription-­‐related.	  	  Finally,	  in	  a	  comparison	  with	  a	  set	  of	  labile	  mRNAs	  (half	  life	  <	  2hrs),	  from	  an	  experiment	  that	  used	  flavopiridol	  to	  identify	  genes	  that	  were	  down-­‐regulated	  in	  a	  time-­‐dependent	  manner	  shortly	  after	  exposure	  (Lam,	  Pickeral	  et	  al.	  2001).	  The	  heat	  maps	  (fig	  3.23A	  and	  B)	  show	  the	  results	  of	  hierarchical	  clustering	  of	  the	  significantly	  changed	  entities	  from	  BS194	  and	  BS181	  at	  6	  hours	  (p<0.05;	  ≥2.0	  FC)	  on	  a	  background	  of	  labile	  transcripts	  found	  to	  be	  significantly	  changed	  from	  the	  published	  experiment	  (Lam,	  Pickeral	  et	  al.	  2001);	  firstly,	  with	  BS181	  and	  BS194,	  many	  of	  the	  genes	  are	  also	  down-­‐regulated,	  which	  is	  not	  surprising	  since	  perturbation	  to	  the	  normal	  cellular	  level	  of	  transcription	  would	  affect	  labile	  transcripts	  first.	  Secondly	  however,	  three	  small	  groups	  of	  genes	  were	  identified	  that	  were	  down-­‐regulated	  in	  a	  time-­‐dependent	  manner	  with	  BS194,	  the	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noramalised	  expression	  of	  which	  (relative	  to	  DMSO)	  is	  shown	  in	  line	  graphs	  (fig	  2.23C);	  the	  expression	  of	  most	  of	  these	  genes	  were	  identified	  in	  previous	  analyses	  to	  be	  differentially	  expressed	  with	  BS194.	  In	  the	  published	  article	  that	  generated	  this	  list	  of	  labile	  transcripts	  (Lam,	  Pickeral	  et	  al.	  2001),	  flavopiridol	  also	  had	  a	  similar	  effect	  over	  a	  similar	  time-­‐period	  for	  these	  genes;	  once	  again,	  because	  BS181	  treatment	  in	  general	  did	  not	  show	  this	  and,	  on	  the	  contrary,	  actually	  appeared	  to	  induce	  the	  expression	  of	  some	  genes	  over	  time	  (MCL1,	  PIM1,	  NFKMIA,	  ID2,	  BTG1	  and	  HSPA5),	  BS194	  could	  be	  viewed	  as	  having	  a	  mode	  of	  action	  more	  similar	  to	  flavopiridol.	  Moreover,	  since	  BS194	  has	  been	  shown	  to	  illicit	  a	  more	  potent	  effect	  at	  around	  12	  hours,	  it	  is	  tempting	  to	  speculate	  that	  the	  differences	  observed	  here	  would	  be	  even	  more	  marked	  if	  a	  comparison	  was	  made	  at	  later	  time	  points.	  Furthermore,	  by	  comparing	  the	  expression	  of	  selected	  genes	  found	  to	  be	  differentially	  expressed	  at	  6	  hours	  from	  the	  microarray	  between	  BS194,	  BS181,	  ICEC942	  and	  flavopiridol	  treatment	  during	  a	  24	  hour	  time-­‐treatment	  experiment,	  it	  is	  clear	  that	  a	  degree	  of	  concordance	  exists	  between	  BS194	  and	  flavopiridol	  over	  long	  time-­‐periods;	  although	  in	  this	  comparison,	  there	  was	  a	  striking	  resemblance	  between	  BS194	  and	  ICEC0942,	  which	  is	  surprising	  given	  that	  ICEC0942	  has	  an	  inhibitory	  profile	  similar	  to	  BS181.	  	  In	  summary,	  the	  gene	  expression	  analysis	  undertaken	  on	  HCT116	  cells	  treated	  with	  either	  BS181	  or	  BS194	  revealed	  that	  at	  the	  time-­‐points	  used,	  expression	  is	  affected	  mostly	  at	  6	  hours	  post-­‐treatment	  and	  in	  this	  regard,	  BS194	  elicits	  a	  more	  profound	  change,	  with	  the	  majority	  of	  the	  significantly	  altered	  genes	  becoming	  downregulated;	  BS181	  had	  a	  similar	  effect,	  albeit	  on	  a	  smaller	  number	  of	  genes	  but	  crucially,	  its	  molecular	  signature	  was	  defined	  by	  an	  enrichment	  of	  upregulated	  IEGs,	  indicating	  that	  at	  the	  concentrations	  used,	  BS181	  did	  not	  potentiate	  a	  complete	  block	  on	  transcription.	  Both	  inhibitors	  appear	  to	  exert	  their	  affect	  over	  long	  time	  periods	  as	  evidenced	  by	  extended	  time-­‐course	  experiments	  that	  assessed	  the	  expression	  of	  several	  proteins	  whose	  genes	  were	  shown	  to	  be	  altered	  in	  the	  microarray;	  interestingly,	  BS194	  appears	  to	  exert	  its	  effects	  later	  than	  BS181	  with	  the	  majority	  of	  proteins	  being	  maximally	  altered	  at	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12	  and	  24	  hours	  post	  treatment	  and	  BS181	  exerting	  maximal	  effect	  at	  6	  and	  12	  hours	  post-­‐treatment.	  This	  was	  also	  true	  of	  p53	  expression,	  indicating	  that	  the	  resulting	  cellular	  phenotype	  of	  these	  inhibitors	  may	  well	  be	  mediated	  through	  p53	  activation,	  however	  the	  precise	  mechanisms	  underlying	  this	  remains	  unknown	  at	  present,	  though	  it	  is	  likely	  that	  at	  the	  concentration	  used	  BS181	  may	  induce	  p53	  expression	  through	  effects	  on	  transcription.	  	  	  Further	  interrogation	  of	  the	  genes	  that	  were	  significantly	  altered	  by	  these	  two	  inhibitors	  revealed	  that	  a	  number	  of	  functional	  groups	  and	  pathways	  were	  perturbed.	  In	  general,	  where	  BS194	  treatment	  decreased	  the	  expression	  of	  genes	  involved	  with	  mitosis	  and	  apoptosis,	  BS181	  was	  associated	  with	  an	  increased	  and	  decreased	  expression	  of	  genes	  involved	  with	  transcription	  and	  a	  decreased	  expression	  of	  genes	  involved	  with	  mitosis.	  Pathway	  analyses	  highlighted	  that	  BS181	  was	  associated	  with	  an	  up	  regulation	  of	  P53	  signalling,	  whereas	  this	  was	  not	  found	  with	  BS194	  treatment.	  	  Finally,	  global	  expression	  highlighted	  further	  subtle	  differences	  between	  BS181	  and	  BS194,	  namely	  that	  there	  was	  a	  more	  generalised	  downregulation	  of	  gene	  expression	  with	  BS194.	  Furthermore,	  subsequent	  meta-­‐analyses	  of	  BS194	  and	  BS181	  with	  another	  CDK	  inhibitor,	  flavopiridol,	  highlighted	  that	  there	  may	  be	  some	  degree	  of	  overlap	  in	  the	  mode	  of	  action	  between	  BS194	  and	  flavopiridol.	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Conclusions	  
	  Disruption	  to	  the	  CAK	  complex	  through	  RNA	  interference	  produces	  a	  cellular	  phonotype	  similar	  to	  that	  observed	  following	  treatment	  with	  lethal	  doses	  of	  BS181	  and	  BS194,	  although	  there	  were	  marked	  differences	  at	  the	  molecular	  level.	  In	  retrospect,	  the	  two	  methods	  are	  not	  comparable	  owing	  to	  the	  mechanism	  of	  action	  by	  which	  they	  assert	  their	  effect:	  siRNA,	  whilst	  highly	  specific,	  does	  not	  replicate	  the	  type	  of	  functional	  inhibition	  (kinase	  activity	  repression)	  that	  is	  required	  of	  a	  selective	  CDK7	  inhibitor,	  owing	  to	  the	  almost	  complete	  physical	  abrogation	  of	  CDK7	  as	  opposed	  to	  merely	  preventing	  its	  activity.	  Therefore	  siRNA	  does	  not	  embody	  a	  suitable	  method	  by	  which	  to	  recapitulate	  (and	  validate)	  CDK7	  inhibitors.	  	  	  However,	  siRNA	  experiments	  did	  highlight	  a	  previously	  unappreciated	  co-­‐dependency	  of	  each	  CAK	  sub-­‐unit	  being	  present	  for	  the	  structural	  integrity	  of	  the	  complex,	  although	  in	  agreement	  with	  previous	  reports,	  CDK7	  appeared	  to	  continue	  to	  function	  at	  sub-­‐optimal	  capacity	  without	  cyclin	  H	  and	  MAT1.	  It	  is	  likely,	  but	  as	  yet	  unproven	  that	  the	  concomitant	  decrease	  in	  each	  CAK	  sub-­‐unit	  is	  mediated	  through	  the	  proteasome.	  	  From	  the	  microarray	  analysis,	  it	  is	  clear	  that	  BS181	  and	  BS194	  display	  subtle	  differences	  in	  their	  mode	  of	  action:	  BS194	  uniquely	  perturbs	  mitotic	  genes	  (explaining	  our	  previous	  observations	  of	  BS194-­‐mediated	  arrest	  at	  the	  G2/M	  phases	  of	  the	  cell	  cycle)	  whereas	  BS181	  was	  associated	  with	  transcription,	  p53	  signalling	  and	  the	  cell	  cycle.	  Interestingly,	  BS194	  has	  a	  broader	  inhibitory	  profile	  than	  BS181,	  as	  evidenced	  by	  the	  number	  of	  genes	  that	  were	  significantly	  changed	  at	  6	  hours,	  most	  probably	  due	  to	  the	  fact	  that	  BS194	  acts	  as	  a	  pan-­‐CDK	  inhibitor.	  In	  this	  respect	  BS194	  acts	  in	  a	  similar	  way	  to	  flavopiridol,	  which	  targets	  many	  of	  the	  same	  CDKs,	  although	  there	  were	  noticeable	  differences	  when	  transcription	  profiles	  were	  compared.	  By	  comparison,	  BS181	  significantly	  altered	  a	  smaller	  number	  of	  genes,	  presumably	  because	  of	  its	  higher	  selectivity	  for	  CDK7	  over	  other	  CDKs.	  BS181	  also	  appears	  to	  readily	  induce	  p53-­‐mediated	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apoptosis	  which	  peaked	  at	  6-­‐12	  hours	  at	  the	  concentration	  used;	  BS194	  also	  induces	  p53	  expression,	  although	  this	  occurred	  later,	  peaking	  between	  12-­‐24	  hours,	  which	  explains	  why	  analysis	  of	  the	  microarray	  data	  did	  not	  highlight	  p53	  as	  a	  significant	  pathway.	  	  	  As	  for	  whether	  CDK7	  is	  a	  good	  target	  for	  anti-­‐cancer	  therapy,	  pre-­‐clinical	  evidence	  and	  observation	  gained	  from	  the	  siRNA	  screen	  suggests	  it	  is	  a	  valid	  target	  as	  it	  induces	  apoptosis.	  Moreover,	  the	  selective	  inhibitor	  BS181	  does	  not	  appear	  to	  be	  a	  substrate	  for	  the	  drug	  efflux	  pumps	  that	  were	  tested	  for	  in	  the	  initial	  screen,	  however	  there	  is	  undoubtedly	  some	  degree	  of	  functional	  redundancy	  from	  CDK9	  or	  CDK8,	  questioning	  the	  utility	  of	  selective	  CDK7	  inhibition	  in	  cancer	  therapy.	  Judging	  from	  the	  evidence	  presented	  in	  this	  study,	  a	  more	  successful	  approach	  may	  be	  with	  a	  pan-­‐inhibitor	  that	  inhibits	  CDK7	  and	  CDK9,	  in	  order	  to	  limit	  functional	  redundancy.	  To	  this	  end,	  BS194	  could	  offer	  a	  better	  strategy.	  BS194	  also	  demonstrates	  bioavailability	  (unlike	  BS181)	  and	  had	  lower	  GI50	  concentrations	  in	  all	  cell	  lines	  it	  was	  tested	  in.	  Indeed,	  pre-­‐clinical	  evidence	  also	  highlights	  activity	  in	  mouse	  models.	  	  	  In	  summary,	  this	  work	  has	  demonstrated	  that	  CAK	  is	  rendered	  relatively	  unstable	  following	  loss	  of	  any	  of	  its	  subunits.	  This	  leads	  to	  apoptosis	  in	  HCT116	  cells,	  demonstrating	  that	  CDK7	  is	  a	  worthy	  target	  for	  anti-­‐cancer	  therapy	  however,	  it	  is	  likely	  that	  CDK9	  readily	  substitutes	  for	  CDK7	  when	  its	  activity	  is	  perturbed.	  Meanwhile,	  gene	  expression	  analysis	  of	  HCT116	  cells	  treated	  with	  the	  small	  molecule	  inhibitors	  BS181	  and	  BS194	  suggests	  that	  inhibition	  with	  a	  pan-­‐CDK	  selectivity	  may	  offer	  a	  more	  effective	  means	  to	  circumvent	  this	  functional	  redundancy	  and	  differences	  in	  global	  expression	  profiles	  between	  BS194	  and	  BS181	  indicate	  that	  BS194	  may	  have	  a	  more	  wide-­‐reaching	  effect,	  which	  is	  possibly	  due	  to	  multi-­‐CDK	  inhibition.	  Future	  work	  should	  continue	  to	  focus	  on	  validating	  some	  of	  the	  genes	  that	  are	  changed	  in	  response	  to	  these	  inhibitors	  so	  that	  potential	  biomarkers	  of	  activity	  can	  be	  followed.	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  This	  work	  has	  further	  characterized	  the	  experimental	  CDK	  inhibitors	  BS181	  and	  BS194;	  future	  work	  should	  focus	  on	  developing	  these	  insights	  further	  to	  help	  facilitate	  potential	  clinical	  use.	  Specifically,	  regarding	  the	  relationship	  between	  each	  CAK	  complex	  member,	  the	  apparent	  interdependency	  could	  be	  delineated	  by	  focusing	  on	  the	  mode	  by	  which	  the	  CAK	  members	  are	  degraded;	  treatment	  with	  proteasome	  inhibitors	  such	  as	  MG132	  is	  perhaps	  the	  most	  established	  way	  of	  doing	  this.	  Preliminary	  analysis	  suggests	  this	  is	  the	  mode	  by	  which	  these	  sub-­‐units	  are	  degraded	  and	  thus	  these	  experiments	  should	  be	  repeated	  using	  appropriate	  controls	  (PPAR/cleaved	  PPAR)	  with	  and	  without	  the	  addition	  of	  cyclohexamide,	  an	  inhibitor	  of	  protein	  translation.	  	  	  In	  agreement	  with	  previous	  observations,	  this	  study	  suggests	  that	  CAK	  activity	  is	  optimal	  when	  all	  three	  sub-­‐units	  are	  present.	  There	  is	  some	  indication	  that	  MAT1	  knockdown	  does	  not	  lead	  to	  the	  same	  level	  of	  apoptosis	  that	  CDK7	  or	  cyclin	  H	  knockdown	  does;	  therefore	  siRNA	  experiments	  should	  be	  repeated	  to	  further	  elucidate	  whether	  this	  is	  the	  case.	  To	  this	  end,	  double	  and	  triple	  transfection	  experiments	  where	  all	  three	  sub-­‐units	  are	  knocked-­‐down	  alone	  and	  simultaneously	  would	  indicate	  whether	  there	  is	  an	  additive	  effect	  when	  all	  three	  are	  absent	  (whether	  apoptosis	  is	  enhanced).	  In	  light	  of	  combined	  siRNA	  knockdown	  experiments,	  the	  role	  of	  CDK9	  (and	  CDK8)	  could	  also	  be	  confirmed	  in	  this	  way.	  This	  knowledge	  will	  be	  useful	  should	  CDK7	  inhibitors	  be	  considered	  for	  therapeutic	  use.	  	  Regarding	  the	  resistance	  data,	  BS194	  was	  shown	  to	  be	  a	  substrate	  for	  one	  or	  more	  drug	  efflux	  pumps;	  further	  experiments	  with	  efflux	  pump	  inhibitors	  such	  as	  verapamil	  and	  BS194	  treatment	  and	  or/siRNA	  against	  the	  respective	  efflux	  pump	  followed	  by	  BS194	  treatment	  could	  be	  coupled	  to	  a	  dye	  exclusion	  assay	  in	  order	  to	  confirm	  which	  pumps	  the	  compound	  is	  a	  substrate	  for.	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  Finally,	  the	  microarray	  highlighted	  several	  sets	  of	  genes	  that	  are	  differentially	  regulated	  by	  each	  respective	  inhibitor.	  Although	  it	  is	  impossible	  to	  ascertain	  if	  any	  of	  these	  would	  suffice	  as	  effective	  biomarkers	  for	  BS194	  and	  BS181,	  future	  work	  should	  concentrate	  on	  following	  the	  expression	  of	  these	  genes	  in	  (i)	  a	  panel	  of	  different	  cancer	  cell	  lines	  and	  normal	  tissue	  and	  (ii)	  in	  animal/xenograft	  models	  over	  a	  range	  of	  doses.	  Most	  of	  the	  genes	  whose	  expression	  were	  altered	  in	  these	  experiments	  did	  not	  show	  clear,	  inducible	  responses	  –	  many	  of	  them	  exhibited	  only	  transient	  changes,	  calling	  into	  question	  their	  potential	  as	  biomarkers.	  In	  addition,	  a	  valid	  biomarker	  needs	  to	  be	  easily	  assayable,	  either	  from	  biopsied	  tissue	  or	  from	  blood	  or	  urine	  and	  currently,	  we	  have	  no	  idea	  whether	  the	  products	  of	  these	  genes	  could	  be	  detected	  like	  this.	  Nevertheless,	  it	  is	  important	  to	  have	  this	  information	  to	  identify	  which	  genes	  are	  clinically	  relevant.	  For	  instance,	  genes	  that	  were	  altered	  in	  HCT116	  cells	  may	  be	  by	  virtue	  of	  the	  cell	  type	  this	  is,	  so	  it	  would	  be	  useful	  to	  know	  how	  these	  genes	  behave	  in	  other	  cell	  types	  and	  in	  in	  vivo	  models.	  	  Efforts	  should	  also	  focus	  on	  identifying	  transcription	  signatures	  that	  are	  predictive	  of	  successful	  BS194	  and	  BS181	  activity	  by	  pairing	  expression	  profiles	  of	  the	  NCI-­‐60	  cancer	  cell	  panel	  (available	  from	  the	  NCI	  CellMiner	  database)	  with	  the	  toxicity	  profile	  (LC50)	  information	  obtained	  from	  the	  NCIs	  developmental	  therapeutics	  program	  (DTP).	  Promising	  compounds	  from	  our	  laboratory	  are	  routinely	  submitted	  to	  the	  DTP	  screening	  program	  and	  toxicity	  profiles	  have	  already	  been	  obtained	  for	  several	  candidates	  including	  BS181,	  BS194	  and	  ICEC0942.	  These	  illustrate	  varying	  degrees	  of	  toxicity	  across	  different	  cancer	  cell	  lines.	  	  	  The	  array	  data	  also	  highlighted	  several	  pathways	  and	  functional	  groups	  of	  genes	  that	  were	  distinctly	  modified	  by	  each	  inhibitor.	  Further	  functional	  analysis	  could	  be	  carried	  out	  to	  try	  to	  recapitulate	  the	  phenotype	  potentiated	  by	  the	  inhibitors,	  thus	  helping	  to	  validate	  the	  effect	  of	  BS181	  and	  BS194	  and	  galvanize	  the	  link	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between	  CDK7.	  One	  of	  the	  problems	  with	  the	  wealth	  of	  data	  generated	  from	  microarray	  studies	  is	  trying	  to	  decide	  which	  genes	  genuinely	  make	  a	  contribution	  to	  the	  observed	  phenotype,	  thus	  the	  functional	  groups	  and	  signalling	  pathways	  that	  were	  perturbed	  can	  be	  used	  as	  a	  starting	  point	  for	  further	  functional	  characterization;	  protein	  arrays	  would	  be	  of	  some	  use	  to	  ascertain	  whether	  the	  altered	  genetic	  material	  is	  translated	  to	  the	  protein	  level	  and	  thus	  provide	  a	  platform	  on	  which	  to	  assay	  large	  numbers	  of	  related	  genes	  at	  the	  functional	  level.	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